id	sid	tid	token	lemma	pos
dpc-4595	1	1	dermatology	dermatology	NOUN
dpc-4595	1	2	:	:	PUNCT
dpc-4595	1	3	practical	practical	ADJ
dpc-4595	1	4	and	and	CCONJ
dpc-4595	1	5	conceptual	conceptual	ADJ
dpc-4595	1	6	original	original	ADJ
dpc-4595	1	7	article	article	NOUN
dpc-4595	1	8	|	|	ADV
dpc-4595	1	9	dermatol	dermatol	ADJ
dpc-4595	1	10	pract	pract	NOUN
dpc-4595	1	11	concept	concept	NOUN
dpc-4595	1	12	.	.	PUNCT
dpc-4595	2	1	2024;14(4):e2024267	2024;14(4):e2024267	NUM
dpc-4595	2	2	1	1	NUM
dpc-4595	2	3	serum	serum	NOUN
dpc-4595	2	4	biomarkers	biomarker	NOUN
dpc-4595	2	5	il-6	il-6	NOUN
dpc-4595	2	6	and	and	CCONJ
dpc-4595	2	7	hif-1α	hif-1α	NOUN
dpc-4595	2	8	in	in	ADP
dpc-4595	2	9	rosacea	rosacea	NOUN
dpc-4595	2	10	:	:	PUNCT
dpc-4595	2	11	assessing	assess	VERB
dpc-4595	2	12	their	their	PRON
dpc-4595	2	13	significance	significance	NOUN
dpc-4595	2	14	in	in	ADP
dpc-4595	2	15	disease	disease	NOUN
dpc-4595	2	16	pathogenesis	pathogenesis	NOUN
dpc-4595	2	17	and	and	CCONJ
dpc-4595	2	18	telangiectasia	telangiectasia	VERB
dpc-4595	2	19	formation	formation	NOUN
dpc-4595	2	20	gamze	gamze	NOUN
dpc-4595	2	21	taş	taş	NOUN
dpc-4595	2	22	-	-	PUNCT
dpc-4595	2	23	aygar1	aygar1	PROPN
dpc-4595	2	24	,	,	PUNCT
dpc-4595	2	25	bengü	bengü	PROPN
dpc-4595	2	26	çevirgen	çevirgen	PROPN
dpc-4595	2	27	cemil1	cemil1	PROPN
dpc-4595	2	28	,	,	PUNCT
dpc-4595	2	29	fevzi	fevzi	PROPN
dpc-4595	2	30	nuri	nuri	PROPN
dpc-4595	2	31	aydın2	aydın2	PROPN
dpc-4595	2	32	,	,	PUNCT
dpc-4595	2	33	volkan	volkan	PROPN
dpc-4595	2	34	buran3	buran3	PROPN
dpc-4595	2	35	,	,	PUNCT
dpc-4595	2	36	selda	selda	PROPN
dpc-4595	2	37	pelin	pelin	PROPN
dpc-4595	2	38	kartal1	kartal1	NOUN
dpc-4595	2	39	1	1	NUM
dpc-4595	2	40	dermatology	dermatology	NOUN
dpc-4595	2	41	clinic	clinic	NOUN
dpc-4595	2	42	,	,	PUNCT
dpc-4595	2	43	university	university	PROPN
dpc-4595	2	44	of	of	ADP
dpc-4595	2	45	health	health	PROPN
dpc-4595	2	46	sciences	sciences	PROPN
dpc-4595	2	47	,	,	PUNCT
dpc-4595	2	48	etlik	etlik	ADJ
dpc-4595	2	49	city	city	NOUN
dpc-4595	2	50	hospital	hospital	NOUN
dpc-4595	2	51	,	,	PUNCT
dpc-4595	2	52	ankara	ankara	PROPN
dpc-4595	2	53	,	,	PUNCT
dpc-4595	2	54	turkey	turkey	PROPN
dpc-4595	2	55	2	2	NUM
dpc-4595	2	56	biochemistry	biochemistry	NOUN
dpc-4595	2	57	clinic	clinic	NOUN
dpc-4595	2	58	,	,	PUNCT
dpc-4595	2	59	university	university	PROPN
dpc-4595	2	60	of	of	ADP
dpc-4595	2	61	health	health	PROPN
dpc-4595	2	62	sciences	sciences	PROPN
dpc-4595	2	63	,	,	PUNCT
dpc-4595	2	64	diskapi	diskapi	PROPN
dpc-4595	2	65	yildirim	yildirim	NOUN
dpc-4595	2	66	beyazit	beyazit	NOUN
dpc-4595	2	67	training	training	NOUN
dpc-4595	2	68	and	and	CCONJ
dpc-4595	2	69	research	research	NOUN
dpc-4595	2	70	hospital	hospital	NOUN
dpc-4595	2	71	,	,	PUNCT
dpc-4595	2	72	ankara	ankara	PROPN
dpc-4595	2	73	,	,	PUNCT
dpc-4595	2	74	turkey	turkey	PROPN
dpc-4595	2	75	3	3	NUM
dpc-4595	2	76	turkish	turkish	PROPN
dpc-4595	2	77	ministry	ministry	PROPN
dpc-4595	2	78	of	of	ADP
dpc-4595	2	79	health	health	PROPN
dpc-4595	2	80	29	29	NUM
dpc-4595	2	81	mayis	mayis	NOUN
dpc-4595	2	82	state	state	NOUN
dpc-4595	2	83	hospital	hospital	NOUN
dpc-4595	2	84	,	,	PUNCT
dpc-4595	2	85	ankara	ankara	PROPN
dpc-4595	2	86	,	,	PUNCT
dpc-4595	2	87	turkey	turkey	PROPN
dpc-4595	2	88	key	key	ADJ
dpc-4595	2	89	words	word	NOUN
dpc-4595	2	90	:	:	PUNCT
dpc-4595	2	91	rosacea	rosacea	NOUN
dpc-4595	2	92	,	,	PUNCT
dpc-4595	2	93	il-6	il-6	PRON
dpc-4595	2	94	,	,	PUNCT
dpc-4595	2	95	hif-1α	hif-1α	PROPN
dpc-4595	2	96	,	,	PUNCT
dpc-4595	2	97	telangiectasia	telangiectasia	PROPN
dpc-4595	2	98	citation	citation	PROPN
dpc-4595	2	99	:	:	PUNCT
dpc-4595	2	100	taş	taş	NOUN
dpc-4595	2	101	-	-	PUNCT
dpc-4595	2	102	aygar	aygar	NOUN
dpc-4595	2	103	g	g	NOUN
dpc-4595	2	104	,	,	PUNCT
dpc-4595	2	105	çevirgen	çevirgen	PROPN
dpc-4595	2	106	cemil	cemil	PROPN
dpc-4595	2	107	b	b	PROPN
dpc-4595	2	108	,	,	PUNCT
dpc-4595	2	109	nuri	nuri	PROPN
dpc-4595	2	110	aydın	aydın	PROPN
dpc-4595	2	111	f	f	PROPN
dpc-4595	2	112	,	,	PUNCT
dpc-4595	2	113	buran	buran	PROPN
dpc-4595	2	114	v	v	PROPN
dpc-4595	2	115	,	,	PUNCT
dpc-4595	2	116	pelin	pelin	PROPN
dpc-4595	2	117	kartal	kartal	PROPN
dpc-4595	2	118	s.	s.	PROPN
dpc-4595	2	119	serum	serum	PROPN
dpc-4595	2	120	biomarkers	biomarkers	PROPN
dpc-4595	2	121	il-6	il-6	NOUN
dpc-4595	2	122	and	and	CCONJ
dpc-4595	2	123	hif-1α	hif-1α	NOUN
dpc-4595	2	124	in	in	ADP
dpc-4595	2	125	rosacea	rosacea	NOUN
dpc-4595	2	126	:	:	PUNCT
dpc-4595	2	127	assessing	assess	VERB
dpc-4595	2	128	their	their	PRON
dpc-4595	2	129	significance	significance	NOUN
dpc-4595	2	130	in	in	ADP
dpc-4595	2	131	disease	disease	NOUN
dpc-4595	2	132	pathogenesis	pathogenesis	NOUN
dpc-4595	2	133	and	and	CCONJ
dpc-4595	2	134	telangiectasia	telangiectasia	NOUN
dpc-4595	2	135	formation	formation	NOUN
dpc-4595	2	136	.	.	PUNCT
dpc-4595	3	1	dermatol	dermatol	NOUN
dpc-4595	3	2	pract	pract	PROPN
dpc-4595	3	3	concept	concept	NOUN
dpc-4595	3	4	.	.	PUNCT
dpc-4595	4	1	2024;14(4):e2024267	2024;14(4):e2024267	X
dpc-4595	4	2	.	.	PUNCT
dpc-4595	4	3	doi	doi	NOUN
dpc-4595	4	4	:	:	PUNCT
dpc-4595	4	5	https://	https://	PROPN
dpc-4595	4	6	doi.org/10.5826/dpc.1404a267	doi.org/10.5826/dpc.1404a267	NOUN
dpc-4595	4	7	accepted	accept	VERB
dpc-4595	4	8	:	:	PUNCT
dpc-4595	4	9	july	july	PROPN
dpc-4595	4	10	26	26	NUM
dpc-4595	4	11	,	,	PUNCT
dpc-4595	4	12	2024	2024	NUM
dpc-4595	4	13	;	;	PUNCT
dpc-4595	4	14	published	publish	VERB
dpc-4595	4	15	:	:	PUNCT
dpc-4595	5	1	october	october	PROPN
dpc-4595	5	2	2024	2024	NUM
dpc-4595	5	3	copyright	copyright	NOUN
dpc-4595	5	4	:	:	PUNCT
dpc-4595	5	5	©	©	PROPN
dpc-4595	5	6	2024	2024	NUM
dpc-4595	5	7	taş	taş	NOUN
dpc-4595	5	8	-	-	PUNCT
dpc-4595	5	9	aygar	aygar	NOUN
dpc-4595	5	10	et	et	PROPN
dpc-4595	5	11	al	al	PROPN
dpc-4595	5	12	.	.	PUNCT
dpc-4595	6	1	this	this	PRON
dpc-4595	6	2	is	be	AUX
dpc-4595	6	3	an	an	DET
dpc-4595	6	4	open	open	ADJ
dpc-4595	6	5	-	-	PUNCT
dpc-4595	6	6	access	access	NOUN
dpc-4595	6	7	article	article	NOUN
dpc-4595	6	8	distributed	distribute	VERB
dpc-4595	6	9	under	under	ADP
dpc-4595	6	10	the	the	DET
dpc-4595	6	11	terms	term	NOUN
dpc-4595	6	12	of	of	ADP
dpc-4595	6	13	the	the	DET
dpc-4595	6	14	creative	creative	ADJ
dpc-4595	6	15	commons	common	NOUN
dpc-4595	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4595	6	17	license	license	NOUN
dpc-4595	6	18	(	(	PUNCT
dpc-4595	6	19	by	by	ADP
dpc-4595	6	20	-	-	PUNCT
dpc-4595	6	21	nc-4.0	nc-4.0	NOUN
dpc-4595	6	22	)	)	PUNCT
dpc-4595	6	23	,	,	PUNCT
dpc-4595	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4595	6	25	,	,	PUNCT
dpc-4595	6	26	which	which	PRON
dpc-4595	6	27	permits	permit	VERB
dpc-4595	6	28	unrestricted	unrestricted	ADJ
dpc-4595	6	29	noncommercial	noncommercial	ADJ
dpc-4595	6	30	use	use	NOUN
dpc-4595	6	31	,	,	PUNCT
dpc-4595	6	32	distribution	distribution	NOUN
dpc-4595	6	33	,	,	PUNCT
dpc-4595	6	34	and	and	CCONJ
dpc-4595	6	35	reproduction	reproduction	NOUN
dpc-4595	6	36	in	in	ADP
dpc-4595	6	37	any	any	DET
dpc-4595	6	38	medium	medium	NOUN
dpc-4595	6	39	,	,	PUNCT
dpc-4595	6	40	provided	provide	VERB
dpc-4595	6	41	the	the	DET
dpc-4595	6	42	original	original	ADJ
dpc-4595	6	43	authors	author	NOUN
dpc-4595	6	44	and	and	CCONJ
dpc-4595	6	45	source	source	NOUN
dpc-4595	6	46	are	be	AUX
dpc-4595	6	47	credited	credit	VERB
dpc-4595	6	48	.	.	PUNCT
dpc-4595	7	1	funding	funding	NOUN
dpc-4595	7	2	:	:	PUNCT
dpc-4595	7	3	our	our	PRON
dpc-4595	7	4	study	study	NOUN
dpc-4595	7	5	was	be	AUX
dpc-4595	7	6	supported	support	VERB
dpc-4595	7	7	by	by	ADP
dpc-4595	7	8	the	the	DET
dpc-4595	7	9	scientific	scientific	ADJ
dpc-4595	7	10	research	research	NOUN
dpc-4595	7	11	support	support	NOUN
dpc-4595	7	12	board	board	NOUN
dpc-4595	7	13	of	of	ADP
dpc-4595	7	14	dışkapı	dışkapı	PROPN
dpc-4595	7	15	yıldırım	yıldırım	PROPN
dpc-4595	7	16	beyazıt	beyazıt	PROPN
dpc-4595	7	17	training	training	NOUN
dpc-4595	7	18	and	and	CCONJ
dpc-4595	7	19	research	research	NOUN
dpc-4595	7	20	hospital	hospital	NOUN
dpc-4595	7	21	.	.	PUNCT
dpc-4595	8	1	competing	compete	VERB
dpc-4595	8	2	interests	interest	NOUN
dpc-4595	8	3	:	:	PUNCT
dpc-4595	8	4	none	none	NOUN
dpc-4595	8	5	.	.	PUNCT
dpc-4595	9	1	authorship	authorship	NOUN
dpc-4595	9	2	:	:	PUNCT
dpc-4595	9	3	all	all	DET
dpc-4595	9	4	authors	author	NOUN
dpc-4595	9	5	have	have	AUX
dpc-4595	9	6	contributed	contribute	VERB
dpc-4595	9	7	significantly	significantly	ADV
dpc-4595	9	8	to	to	ADP
dpc-4595	9	9	this	this	DET
dpc-4595	9	10	publication	publication	NOUN
dpc-4595	9	11	.	.	PUNCT
dpc-4595	10	1	corresponding	correspond	VERB
dpc-4595	10	2	author	author	NOUN
dpc-4595	10	3	:	:	PUNCT
dpc-4595	10	4	taş	taş	NOUN
dpc-4595	10	5	-	-	PUNCT
dpc-4595	10	6	aygar	aygar	NOUN
dpc-4595	10	7	gamze	gamze	NOUN
dpc-4595	10	8	,	,	PUNCT
dpc-4595	10	9	universty	universty	PROPN
dpc-4595	10	10	of	of	ADP
dpc-4595	10	11	health	health	NOUN
dpc-4595	10	12	sciences	sciences	PROPN
dpc-4595	10	13	,	,	PUNCT
dpc-4595	10	14	etlik	etlik	ADJ
dpc-4595	10	15	city	city	NOUN
dpc-4595	10	16	hospital	hospital	NOUN
dpc-4595	10	17	,	,	PUNCT
dpc-4595	10	18	dermatology	dermatology	NOUN
dpc-4595	10	19	clinic	clinic	NOUN
dpc-4595	10	20	,	,	PUNCT
dpc-4595	10	21	ankara	ankara	PROPN
dpc-4595	10	22	,	,	PUNCT
dpc-4595	10	23	turkey	turkey	PROPN
dpc-4595	10	24	.	.	PUNCT
dpc-4595	11	1	tel	tel	ADP
dpc-4595	11	2	:	:	PUNCT
dpc-4595	11	3	+903127970000	+903127970000	NUM
dpc-4595	11	4	email	email	NOUN
dpc-4595	11	5	:	:	PUNCT
dpc-4595	11	6	gamze_0890@hotmail.com	gamze_0890@hotmail.com	X
dpc-4595	11	7	introduction	introduction	NOUN
dpc-4595	11	8	:	:	PUNCT
dpc-4595	11	9	rosacea	rosacea	NOUN
dpc-4595	11	10	,	,	PUNCT
dpc-4595	11	11	a	a	DET
dpc-4595	11	12	chronic	chronic	ADJ
dpc-4595	11	13	inflammatory	inflammatory	ADJ
dpc-4595	11	14	disease	disease	NOUN
dpc-4595	11	15	primarily	primarily	ADV
dpc-4595	11	16	affecting	affect	VERB
dpc-4595	11	17	the	the	DET
dpc-4595	11	18	central	central	ADJ
dpc-4595	11	19	area	area	NOUN
dpc-4595	11	20	of	of	ADP
dpc-4595	11	21	the	the	DET
dpc-4595	11	22	face	face	NOUN
dpc-4595	11	23	,	,	PUNCT
dpc-4595	11	24	is	be	AUX
dpc-4595	11	25	a	a	DET
dpc-4595	11	26	complex	complex	ADJ
dpc-4595	11	27	condition	condition	NOUN
dpc-4595	11	28	whose	whose	DET
dpc-4595	11	29	mechanisms	mechanism	NOUN
dpc-4595	11	30	are	be	AUX
dpc-4595	11	31	still	still	ADV
dpc-4595	11	32	not	not	PART
dpc-4595	11	33	fully	fully	ADV
dpc-4595	11	34	understood	understand	VERB
dpc-4595	11	35	.	.	PUNCT
dpc-4595	12	1	however	however	ADV
dpc-4595	12	2	,	,	PUNCT
dpc-4595	12	3	research	research	NOUN
dpc-4595	12	4	has	have	AUX
dpc-4595	12	5	indicated	indicate	VERB
dpc-4595	12	6	a	a	DET
dpc-4595	12	7	positive	positive	ADJ
dpc-4595	12	8	correlation	correlation	NOUN
dpc-4595	12	9	between	between	ADP
dpc-4595	12	10	two	two	NUM
dpc-4595	12	11	molecules	molecule	NOUN
dpc-4595	12	12	:	:	PUNCT
dpc-4595	12	13	hypoxia	hypoxia	NOUN
dpc-4595	12	14	-	-	PUNCT
dpc-4595	12	15	inducible	inducible	ADJ
dpc-4595	12	16	factor-1α	factor-1α	PROPN
dpc-4595	12	17	(	(	PUNCT
dpc-4595	12	18	hif-1α	hif-1α	NOUN
dpc-4595	12	19	)	)	PUNCT
dpc-4595	12	20	and	and	CCONJ
dpc-4595	12	21	interleukin-6	interleukin-6	NUM
dpc-4595	12	22	(	(	PUNCT
dpc-4595	12	23	il-6	il-6	NUM
dpc-4595	12	24	)	)	PUNCT
dpc-4595	12	25	.	.	PUNCT
dpc-4595	13	1	the	the	DET
dpc-4595	13	2	levels	level	NOUN
dpc-4595	13	3	of	of	ADP
dpc-4595	13	4	hif-1α	hif-1α	NOUN
dpc-4595	13	5	in	in	ADP
dpc-4595	13	6	rosacea	rosacea	NOUN
dpc-4595	13	7	patients	patient	NOUN
dpc-4595	13	8	have	have	VERB
dpc-4595	13	9	yet	yet	ADV
dpc-4595	13	10	to	to	PART
dpc-4595	13	11	be	be	AUX
dpc-4595	13	12	assessed	assess	VERB
dpc-4595	13	13	.	.	PUNCT
dpc-4595	14	1	objectives	objective	NOUN
dpc-4595	14	2	:	:	PUNCT
dpc-4595	14	3	the	the	DET
dpc-4595	14	4	aim	aim	NOUN
dpc-4595	14	5	of	of	ADP
dpc-4595	14	6	this	this	DET
dpc-4595	14	7	study	study	NOUN
dpc-4595	14	8	was	be	AUX
dpc-4595	14	9	to	to	PART
dpc-4595	14	10	assess	assess	VERB
dpc-4595	14	11	the	the	DET
dpc-4595	14	12	levels	level	NOUN
dpc-4595	14	13	of	of	ADP
dpc-4595	14	14	hif-1α	hif-1α	NOUN
dpc-4595	14	15	and	and	CCONJ
dpc-4595	14	16	il-6	il-6	NOUN
dpc-4595	14	17	in	in	ADP
dpc-4595	14	18	patients	patient	NOUN
dpc-4595	14	19	with	with	ADP
dpc-4595	14	20	rosacea	rosacea	NOUN
dpc-4595	14	21	in	in	ADP
dpc-4595	14	22	relation	relation	NOUN
dpc-4595	14	23	to	to	ADP
dpc-4595	14	24	both	both	DET
dpc-4595	14	25	the	the	DET
dpc-4595	14	26	severity	severity	NOUN
dpc-4595	14	27	of	of	ADP
dpc-4595	14	28	the	the	DET
dpc-4595	14	29	disease	disease	NOUN
dpc-4595	14	30	and	and	CCONJ
dpc-4595	14	31	the	the	DET
dpc-4595	14	32	primary	primary	ADJ
dpc-4595	14	33	and	and	CCONJ
dpc-4595	14	34	secondary	secondary	ADJ
dpc-4595	14	35	clinical	clinical	ADJ
dpc-4595	14	36	manifestations	manifestation	NOUN
dpc-4595	14	37	of	of	ADP
dpc-4595	14	38	the	the	DET
dpc-4595	14	39	condition	condition	NOUN
dpc-4595	14	40	.	.	PUNCT
dpc-4595	15	1	methods	method	NOUN
dpc-4595	15	2	:	:	PUNCT
dpc-4595	15	3	the	the	DET
dpc-4595	15	4	study	study	NOUN
dpc-4595	15	5	included	include	VERB
dpc-4595	15	6	patients	patient	NOUN
dpc-4595	15	7	diagnosed	diagnose	VERB
dpc-4595	15	8	with	with	ADP
dpc-4595	15	9	rosacea	rosacea	NOUN
dpc-4595	15	10	and	and	CCONJ
dpc-4595	15	11	sex	sex	NOUN
dpc-4595	15	12	-	-	PUNCT
dpc-4595	15	13	and	and	CCONJ
dpc-4595	15	14	age	age	NOUN
dpc-4595	15	15	-	-	PUNCT
dpc-4595	15	16	matched	match	VERB
dpc-4595	15	17	healthy	healthy	ADJ
dpc-4595	15	18	controls	control	NOUN
dpc-4595	15	19	(	(	PUNCT
dpc-4595	15	20	n=40	n=40	ADJ
dpc-4595	15	21	,	,	PUNCT
dpc-4595	15	22	n=40	n=40	ADJ
dpc-4595	15	23	)	)	PUNCT
dpc-4595	15	24	.	.	PUNCT
dpc-4595	16	1	serum	serum	PROPN
dpc-4595	16	2	hif-1α	hif-1α	PROPN
dpc-4595	16	3	and	and	CCONJ
dpc-4595	16	4	il-6	il-6	NOUN
dpc-4595	16	5	levels	level	NOUN
dpc-4595	16	6	were	be	AUX
dpc-4595	16	7	quantified	quantify	VERB
dpc-4595	16	8	using	use	VERB
dpc-4595	16	9	enzyme	enzyme	NOUN
dpc-4595	16	10	-	-	PUNCT
dpc-4595	16	11	linked	link	VERB
dpc-4595	16	12	immunosorbent	immunosorbent	NOUN
dpc-4595	16	13	assay	assay	PROPN
dpc-4595	16	14	(	(	PUNCT
dpc-4595	16	15	elisa	elisa	NOUN
dpc-4595	16	16	)	)	PUNCT
dpc-4595	16	17	.	.	PUNCT
dpc-4595	17	1	results	result	NOUN
dpc-4595	17	2	:	:	PUNCT
dpc-4595	17	3	compared	compare	VERB
dpc-4595	17	4	to	to	ADP
dpc-4595	17	5	the	the	DET
dpc-4595	17	6	control	control	NOUN
dpc-4595	17	7	group	group	NOUN
dpc-4595	17	8	,	,	PUNCT
dpc-4595	17	9	the	the	DET
dpc-4595	17	10	patient	patient	ADJ
dpc-4595	17	11	group	group	NOUN
dpc-4595	17	12	had	have	AUX
dpc-4595	17	13	significantly	significantly	ADV
dpc-4595	17	14	elevated	elevate	VERB
dpc-4595	17	15	serum	serum	NOUN
dpc-4595	17	16	levels	level	NOUN
dpc-4595	17	17	of	of	ADP
dpc-4595	17	18	hif-1α	hif-1α	NOUN
dpc-4595	17	19	and	and	CCONJ
dpc-4595	17	20	il-6	il-6	NOUN
dpc-4595	17	21	.	.	PUNCT
dpc-4595	18	1	a	a	DET
dpc-4595	18	2	positive	positive	ADJ
dpc-4595	18	3	correlation	correlation	NOUN
dpc-4595	18	4	was	be	AUX
dpc-4595	18	5	found	find	VERB
dpc-4595	18	6	between	between	ADP
dpc-4595	18	7	the	the	DET
dpc-4595	18	8	level	level	NOUN
dpc-4595	18	9	of	of	ADP
dpc-4595	18	10	hif-1α	hif-1α	NOUN
dpc-4595	18	11	and	and	CCONJ
dpc-4595	18	12	the	the	DET
dpc-4595	18	13	severity	severity	NOUN
dpc-4595	18	14	of	of	ADP
dpc-4595	18	15	the	the	DET
dpc-4595	18	16	disease	disease	NOUN
dpc-4595	18	17	(	(	PUNCT
dpc-4595	18	18	r=0.374	r=0.374	NOUN
dpc-4595	18	19	,	,	PUNCT
dpc-4595	18	20	p=0.017	p=0.017	PRON
dpc-4595	18	21	)	)	PUNCT
dpc-4595	18	22	;	;	PUNCT
dpc-4595	18	23	furthermore	furthermore	ADV
dpc-4595	18	24	,	,	PUNCT
dpc-4595	18	25	a	a	DET
dpc-4595	18	26	significant	significant	ADJ
dpc-4595	18	27	association	association	NOUN
dpc-4595	18	28	was	be	AUX
dpc-4595	18	29	observed	observe	VERB
dpc-4595	18	30	between	between	ADP
dpc-4595	18	31	the	the	DET
dpc-4595	18	32	presence	presence	NOUN
dpc-4595	18	33	of	of	ADP
dpc-4595	18	34	telangiectasia	telangiectasia	NOUN
dpc-4595	18	35	,	,	PUNCT
dpc-4595	18	36	one	one	NUM
dpc-4595	18	37	of	of	ADP
dpc-4595	18	38	the	the	DET
dpc-4595	18	39	primary	primary	ADJ
dpc-4595	18	40	manifestations	manifestation	NOUN
dpc-4595	18	41	,	,	PUNCT
dpc-4595	18	42	and	and	CCONJ
dpc-4595	18	43	hif-1α	hif-1α	NOUN
dpc-4595	18	44	(	(	PUNCT
dpc-4595	18	45	z=2.401	z=2.401	PROPN
dpc-4595	18	46	,	,	PUNCT
dpc-4595	18	47	p=0.016	p=0.016	NUM
dpc-4595	18	48	)	)	PUNCT
dpc-4595	18	49	.	.	PUNCT
dpc-4595	19	1	abstract	abstract	ADJ
dpc-4595	19	2	2	2	NUM
dpc-4595	19	3	original	original	ADJ
dpc-4595	19	4	article	article	NOUN
dpc-4595	19	5	|	|	ADV
dpc-4595	19	6	dermatol	dermatol	ADJ
dpc-4595	19	7	pract	pract	NOUN
dpc-4595	19	8	concept	concept	NOUN
dpc-4595	19	9	.	.	PUNCT
dpc-4595	20	1	2024;14(4):e2024267	2024;14(4):e2024267	NUM
dpc-4595	20	2	introduction	introduction	NOUN
dpc-4595	20	3	rosacea	rosacea	NOUN
dpc-4595	20	4	is	be	AUX
dpc-4595	20	5	a	a	DET
dpc-4595	20	6	chronic	chronic	ADJ
dpc-4595	20	7	inflammatory	inflammatory	ADJ
dpc-4595	20	8	disease	disease	NOUN
dpc-4595	20	9	that	that	PRON
dpc-4595	20	10	predominantly	predominantly	ADV
dpc-4595	20	11	affects	affect	VERB
dpc-4595	20	12	the	the	DET
dpc-4595	20	13	central	central	ADJ
dpc-4595	20	14	area	area	NOUN
dpc-4595	20	15	of	of	ADP
dpc-4595	20	16	the	the	DET
dpc-4595	20	17	face	face	NOUN
dpc-4595	20	18	,	,	PUNCT
dpc-4595	20	19	including	include	VERB
dpc-4595	20	20	the	the	DET
dpc-4595	20	21	cheeks	cheek	NOUN
dpc-4595	20	22	,	,	PUNCT
dpc-4595	20	23	chin	chin	NOUN
dpc-4595	20	24	,	,	PUNCT
dpc-4595	20	25	nose	nose	NOUN
dpc-4595	20	26	,	,	PUNCT
dpc-4595	20	27	forehead	forehead	NOUN
dpc-4595	20	28	,	,	PUNCT
dpc-4595	20	29	and	and	CCONJ
dpc-4595	20	30	eyes	eye	NOUN
dpc-4595	21	1	[	[	X
dpc-4595	21	2	1	1	NUM
dpc-4595	21	3	]	]	PUNCT
dpc-4595	21	4	.	.	PUNCT
dpc-4595	22	1	rosacea	rosacea	NOUN
dpc-4595	22	2	is	be	AUX
dpc-4595	22	3	seen	see	VERB
dpc-4595	22	4	in	in	ADP
dpc-4595	22	5	5.46	5.46	NUM
dpc-4595	22	6	%	%	NOUN
dpc-4595	22	7	of	of	ADP
dpc-4595	22	8	the	the	DET
dpc-4595	22	9	adult	adult	NOUN
dpc-4595	22	10	population	population	NOUN
dpc-4595	22	11	:	:	PUNCT
dpc-4595	22	12	it	it	PRON
dpc-4595	22	13	is	be	AUX
dpc-4595	22	14	found	find	VERB
dpc-4595	22	15	in	in	ADP
dpc-4595	22	16	both	both	DET
dpc-4595	22	17	sexes	sex	NOUN
dpc-4595	22	18	,	,	PUNCT
dpc-4595	22	19	although	although	SCONJ
dpc-4595	22	20	it	it	PRON
dpc-4595	22	21	is	be	AUX
dpc-4595	22	22	more	more	ADV
dpc-4595	22	23	common	common	ADJ
dpc-4595	22	24	in	in	ADP
dpc-4595	22	25	women	woman	NOUN
dpc-4595	22	26	over	over	ADP
dpc-4595	22	27	the	the	DET
dpc-4595	22	28	age	age	NOUN
dpc-4595	22	29	of	of	ADP
dpc-4595	22	30	30	30	NUM
dpc-4595	22	31	,	,	PUNCT
dpc-4595	22	32	and	and	CCONJ
dpc-4595	22	33	its	its	PRON
dpc-4595	22	34	incidence	incidence	NOUN
dpc-4595	22	35	increases	increase	VERB
dpc-4595	22	36	with	with	ADP
dpc-4595	22	37	age	age	NOUN
dpc-4595	22	38	,	,	PUNCT
dpc-4595	22	39	becoming	become	VERB
dpc-4595	22	40	more	more	ADV
dpc-4595	22	41	common	common	ADJ
dpc-4595	22	42	at	at	ADP
dpc-4595	22	43	the	the	DET
dpc-4595	22	44	ages	age	NOUN
dpc-4595	22	45	of	of	ADP
dpc-4595	22	46	45–60	45–60	NUM
dpc-4595	22	47	years	year	NOUN
dpc-4595	23	1	[	[	X
dpc-4595	23	2	2	2	NUM
dpc-4595	23	3	]	]	PUNCT
dpc-4595	23	4	.	.	PUNCT
dpc-4595	24	1	despite	despite	SCONJ
dpc-4595	24	2	ongoing	ongoing	ADJ
dpc-4595	24	3	research	research	NOUN
dpc-4595	24	4	,	,	PUNCT
dpc-4595	24	5	the	the	DET
dpc-4595	24	6	understanding	understanding	NOUN
dpc-4595	24	7	of	of	ADP
dpc-4595	24	8	the	the	DET
dpc-4595	24	9	etiology	etiology	NOUN
dpc-4595	24	10	and	and	CCONJ
dpc-4595	24	11	pathophysiology	pathophysiology	NOUN
dpc-4595	24	12	of	of	ADP
dpc-4595	24	13	rosacea	rosacea	NOUN
dpc-4595	24	14	remains	remain	VERB
dpc-4595	24	15	incomplete	incomplete	ADJ
dpc-4595	24	16	.	.	PUNCT
dpc-4595	25	1	however	however	ADV
dpc-4595	25	2	,	,	PUNCT
dpc-4595	25	3	recent	recent	ADJ
dpc-4595	25	4	findings	finding	NOUN
dpc-4595	25	5	indicate	indicate	VERB
dpc-4595	25	6	that	that	SCONJ
dpc-4595	25	7	a	a	DET
dpc-4595	25	8	combination	combination	NOUN
dpc-4595	25	9	of	of	ADP
dpc-4595	25	10	genetic	genetic	ADJ
dpc-4595	25	11	and	and	CCONJ
dpc-4595	25	12	environmental	environmental	ADJ
dpc-4595	25	13	factors	factor	NOUN
dpc-4595	25	14	contributes	contribute	VERB
dpc-4595	25	15	to	to	ADP
dpc-4595	25	16	the	the	DET
dpc-4595	25	17	onset	onset	NOUN
dpc-4595	25	18	and/or	and/or	CCONJ
dpc-4595	25	19	exacerbation	exacerbation	NOUN
dpc-4595	25	20	of	of	ADP
dpc-4595	25	21	rosacea	rosacea	NOUN
dpc-4595	25	22	by	by	ADP
dpc-4595	25	23	influencing	influence	VERB
dpc-4595	25	24	both	both	CCONJ
dpc-4595	25	25	the	the	DET
dpc-4595	25	26	innate	innate	NOUN
dpc-4595	25	27	and	and	CCONJ
dpc-4595	25	28	the	the	DET
dpc-4595	25	29	adaptive	adaptive	ADJ
dpc-4595	25	30	immune	immune	ADJ
dpc-4595	25	31	systems	system	NOUN
dpc-4595	25	32	as	as	ADV
dpc-4595	25	33	well	well	ADV
dpc-4595	25	34	as	as	ADP
dpc-4595	25	35	neurovascular	neurovascular	ADJ
dpc-4595	25	36	dysfunction	dysfunction	NOUN
dpc-4595	25	37	[	[	X
dpc-4595	25	38	3,4	3,4	NUM
dpc-4595	25	39	]	]	PUNCT
dpc-4595	25	40	.	.	PUNCT
dpc-4595	26	1	various	various	ADJ
dpc-4595	26	2	trigger	trigger	NOUN
dpc-4595	26	3	factors	factor	NOUN
dpc-4595	26	4	—	—	PUNCT
dpc-4595	26	5	such	such	ADJ
dpc-4595	26	6	as	as	ADP
dpc-4595	26	7	sun	sun	NOUN
dpc-4595	26	8	exposure	exposure	NOUN
dpc-4595	26	9	,	,	PUNCT
dpc-4595	26	10	temperature	temperature	NOUN
dpc-4595	26	11	extremes	extreme	NOUN
dpc-4595	26	12	(	(	PUNCT
dpc-4595	26	13	hot	hot	ADJ
dpc-4595	26	14	and	and	CCONJ
dpc-4595	26	15	cold	cold	ADJ
dpc-4595	26	16	)	)	PUNCT
dpc-4595	26	17	,	,	PUNCT
dpc-4595	26	18	hot	hot	ADJ
dpc-4595	26	19	beverages	beverage	NOUN
dpc-4595	26	20	,	,	PUNCT
dpc-4595	26	21	spicy	spicy	ADJ
dpc-4595	26	22	foods	food	NOUN
dpc-4595	26	23	,	,	PUNCT
dpc-4595	26	24	and	and	CCONJ
dpc-4595	26	25	physical	physical	ADJ
dpc-4595	26	26	activity	activity	NOUN
dpc-4595	26	27	—	—	PUNCT
dpc-4595	26	28	have	have	AUX
dpc-4595	26	29	been	be	AUX
dpc-4595	26	30	identified	identify	VERB
dpc-4595	26	31	,	,	PUNCT
dpc-4595	26	32	although	although	SCONJ
dpc-4595	26	33	they	they	PRON
dpc-4595	26	34	can	can	AUX
dpc-4595	26	35	vary	vary	VERB
dpc-4595	26	36	across	across	ADP
dpc-4595	26	37	individuals	individual	NOUN
dpc-4595	26	38	;	;	PUNCT
dpc-4595	26	39	these	these	DET
dpc-4595	26	40	factors	factor	NOUN
dpc-4595	26	41	may	may	AUX
dpc-4595	26	42	worsen	worsen	VERB
dpc-4595	26	43	the	the	DET
dpc-4595	26	44	disease	disease	NOUN
dpc-4595	26	45	,	,	PUNCT
dpc-4595	26	46	both	both	CCONJ
dpc-4595	26	47	through	through	ADP
dpc-4595	26	48	the	the	DET
dpc-4595	26	49	release	release	NOUN
dpc-4595	26	50	of	of	ADP
dpc-4595	26	51	mediators	mediator	NOUN
dpc-4595	26	52	from	from	ADP
dpc-4595	26	53	cells	cell	NOUN
dpc-4595	26	54	and	and	CCONJ
dpc-4595	26	55	by	by	ADP
dpc-4595	26	56	directly	directly	ADV
dpc-4595	26	57	activating	activate	VERB
dpc-4595	26	58	the	the	DET
dpc-4595	26	59	cutaneous	cutaneous	ADJ
dpc-4595	26	60	nervous	nervous	ADJ
dpc-4595	26	61	system	system	NOUN
dpc-4595	27	1	[	[	X
dpc-4595	27	2	2,4	2,4	NUM
dpc-4595	27	3	]	]	PUNCT
dpc-4595	27	4	.	.	PUNCT
dpc-4595	28	1	hypoxia	hypoxia	NOUN
dpc-4595	28	2	-	-	PUNCT
dpc-4595	28	3	inducible	inducible	ADJ
dpc-4595	28	4	factor-1	factor-1	PROPN
dpc-4595	28	5	(	(	PUNCT
dpc-4595	28	6	hif-1	hif-1	NUM
dpc-4595	28	7	)	)	PUNCT
dpc-4595	28	8	is	be	AUX
dpc-4595	28	9	a	a	DET
dpc-4595	28	10	heterodimeric	heterodimeric	ADJ
dpc-4595	28	11	transcription	transcription	NOUN
dpc-4595	28	12	factor	factor	NOUN
dpc-4595	28	13	regulated	regulate	VERB
dpc-4595	28	14	by	by	ADP
dpc-4595	28	15	oxygen	oxygen	NOUN
dpc-4595	28	16	,	,	PUNCT
dpc-4595	28	17	and	and	CCONJ
dpc-4595	28	18	it	it	PRON
dpc-4595	28	19	comprises	comprise	VERB
dpc-4595	28	20	the	the	DET
dpc-4595	28	21	subunits	subunit	NOUN
dpc-4595	28	22	hif-1α	hif-1α	NOUN
dpc-4595	28	23	and	and	CCONJ
dpc-4595	28	24	hif-1β	hif-1β	VERB
dpc-4595	28	25	[	[	X
dpc-4595	28	26	5	5	NUM
dpc-4595	28	27	]	]	PUNCT
dpc-4595	28	28	.	.	PUNCT
dpc-4595	29	1	in	in	ADP
dpc-4595	29	2	normal	normal	ADJ
dpc-4595	29	3	skin	skin	NOUN
dpc-4595	29	4	,	,	PUNCT
dpc-4595	29	5	hif-1α	hif-1α	NOUN
dpc-4595	29	6	is	be	AUX
dpc-4595	29	7	expressed	express	VERB
dpc-4595	29	8	in	in	ADP
dpc-4595	29	9	epidermal	epidermal	ADJ
dpc-4595	29	10	cells	cell	NOUN
dpc-4595	29	11	,	,	PUNCT
dpc-4595	29	12	and	and	CCONJ
dpc-4595	29	13	its	its	PRON
dpc-4595	29	14	expression	expression	NOUN
dpc-4595	29	15	has	have	AUX
dpc-4595	29	16	been	be	AUX
dpc-4595	29	17	demonstrated	demonstrate	VERB
dpc-4595	29	18	as	as	ADP
dpc-4595	29	19	higher	high	ADJ
dpc-4595	29	20	in	in	ADP
dpc-4595	29	21	psoriatic	psoriatic	ADJ
dpc-4595	29	22	lesions	lesion	NOUN
dpc-4595	29	23	[	[	X
dpc-4595	29	24	6	6	NUM
dpc-4595	29	25	]	]	PUNCT
dpc-4595	29	26	.	.	PUNCT
dpc-4595	30	1	selective	selective	ADJ
dpc-4595	30	2	upregulation	upregulation	NOUN
dpc-4595	30	3	of	of	ADP
dpc-4595	30	4	hif-1α	hif-1α	NOUN
dpc-4595	30	5	has	have	AUX
dpc-4595	30	6	been	be	AUX
dpc-4595	30	7	observed	observe	VERB
dpc-4595	30	8	in	in	ADP
dpc-4595	30	9	the	the	DET
dpc-4595	30	10	differentiation	differentiation	NOUN
dpc-4595	30	11	of	of	ADP
dpc-4595	30	12	t	t	NOUN
dpc-4595	30	13	cells	cell	NOUN
dpc-4595	30	14	toward	toward	ADP
dpc-4595	30	15	t	t	PROPN
dpc-4595	30	16	helper	helper	NOUN
dpc-4595	30	17	(	(	PUNCT
dpc-4595	30	18	th)-17	th)-17	NOUN
dpc-4595	30	19	polarization	polarization	NOUN
dpc-4595	30	20	;	;	PUNCT
dpc-4595	30	21	however	however	ADV
dpc-4595	30	22	,	,	PUNCT
dpc-4595	30	23	hif-1α	hif-1α	NOUN
dpc-4595	30	24	is	be	AUX
dpc-4595	30	25	necessary	necessary	ADJ
dpc-4595	30	26	to	to	PART
dpc-4595	30	27	inhibit	inhibit	VERB
dpc-4595	30	28	regulatory	regulatory	ADJ
dpc-4595	30	29	t	t	PROPN
dpc-4595	30	30	(	(	PUNCT
dpc-4595	30	31	t	t	NOUN
dpc-4595	30	32	-	-	PUNCT
dpc-4595	30	33	reg	reg	NOUN
dpc-4595	30	34	)	)	PUNCT
dpc-4595	30	35	cell	cell	NOUN
dpc-4595	30	36	differentiation	differentiation	NOUN
dpc-4595	30	37	.	.	PUNCT
dpc-4595	31	1	the	the	DET
dpc-4595	31	2	cell	cell	NOUN
dpc-4595	31	3	decision	decision	NOUN
dpc-4595	31	4	of	of	ADP
dpc-4595	31	5	polarization	polarization	NOUN
dpc-4595	31	6	from	from	ADP
dpc-4595	31	7	precursor	precursor	NOUN
dpc-4595	31	8	cells	cell	NOUN
dpc-4595	31	9	toward	toward	ADP
dpc-4595	31	10	th-17	th-17	NOUN
dpc-4595	31	11	and	and	CCONJ
dpc-4595	31	12	t	t	PROPN
dpc-4595	31	13	-	-	PUNCT
dpc-4595	31	14	reg	reg	NOUN
dpc-4595	31	15	cells	cell	NOUN
dpc-4595	31	16	is	be	AUX
dpc-4595	31	17	critically	critically	ADV
dpc-4595	31	18	dependent	dependent	ADJ
dpc-4595	31	19	on	on	ADP
dpc-4595	31	20	interleukin	interleukin	NOUN
dpc-4595	31	21	(	(	PUNCT
dpc-4595	31	22	il)-6	il)-6	NOUN
dpc-4595	31	23	.	.	NOUN
dpc-4595	32	1	under	under	ADP
dpc-4595	32	2	hypoxic	hypoxic	ADJ
dpc-4595	32	3	conditions	condition	NOUN
dpc-4595	32	4	,	,	PUNCT
dpc-4595	32	5	il-6	il-6	NOUN
dpc-4595	32	6	expression	expression	NOUN
dpc-4595	32	7	,	,	PUNCT
dpc-4595	32	8	like	like	ADP
dpc-4595	32	9	hif-1α	hif-1α	NOUN
dpc-4595	32	10	,	,	PUNCT
dpc-4595	32	11	increases	increase	VERB
dpc-4595	32	12	.	.	PUNCT
dpc-4595	33	1	a	a	DET
dpc-4595	33	2	positive	positive	ADJ
dpc-4595	33	3	relationship	relationship	NOUN
dpc-4595	33	4	exists	exist	VERB
dpc-4595	33	5	between	between	ADP
dpc-4595	33	6	hif-1α	hif-1α	NOUN
dpc-4595	33	7	and	and	CCONJ
dpc-4595	33	8	il-6	il-6	NOUN
dpc-4595	33	9	,	,	PUNCT
dpc-4595	33	10	wherein	wherein	SCONJ
dpc-4595	33	11	elevated	elevated	ADJ
dpc-4595	33	12	il-6	il-6	NUM
dpc-4595	33	13	is	be	AUX
dpc-4595	33	14	accompanied	accompany	VERB
dpc-4595	33	15	by	by	ADP
dpc-4595	33	16	higher	high	ADJ
dpc-4595	33	17	hif-1α	hif-1α	NOUN
dpc-4595	33	18	levels	level	NOUN
dpc-4595	33	19	.	.	PUNCT
dpc-4595	34	1	this	this	PRON
dpc-4595	34	2	suggests	suggest	VERB
dpc-4595	34	3	a	a	DET
dpc-4595	34	4	significant	significant	ADJ
dpc-4595	34	5	role	role	NOUN
dpc-4595	34	6	for	for	ADP
dpc-4595	34	7	il-6	il-6	NOUN
dpc-4595	34	8	signaling	signal	VERB
dpc-4595	34	9	in	in	ADP
dpc-4595	34	10	hif-1α	hif-1α	NOUN
dpc-4595	34	11	induction	induction	NOUN
dpc-4595	34	12	[	[	X
dpc-4595	34	13	5,7	5,7	NUM
dpc-4595	34	14	]	]	PUNCT
dpc-4595	34	15	.	.	PUNCT
dpc-4595	35	1	objectives	objective	VERB
dpc-4595	35	2	the	the	DET
dpc-4595	35	3	purpose	purpose	NOUN
dpc-4595	35	4	of	of	ADP
dpc-4595	35	5	our	our	PRON
dpc-4595	35	6	study	study	NOUN
dpc-4595	35	7	was	be	AUX
dpc-4595	35	8	to	to	PART
dpc-4595	35	9	investigate	investigate	VERB
dpc-4595	35	10	serum	serum	NOUN
dpc-4595	35	11	hif-1α	hif-1α	PROPN
dpc-4595	35	12	and	and	CCONJ
dpc-4595	35	13	il6	il6	NOUN
dpc-4595	35	14	levels	level	NOUN
dpc-4595	35	15	in	in	ADP
dpc-4595	35	16	rosacea	rosacea	NOUN
dpc-4595	35	17	patients	patient	NOUN
dpc-4595	35	18	and	and	CCONJ
dpc-4595	35	19	their	their	PRON
dpc-4595	35	20	relationship	relationship	NOUN
dpc-4595	35	21	with	with	ADP
dpc-4595	35	22	patients	patient	NOUN
dpc-4595	35	23	’	'	PUNCT
dpc-4595	35	24	demographic	demographic	ADJ
dpc-4595	35	25	and	and	CCONJ
dpc-4595	35	26	clinical	clinical	ADJ
dpc-4595	35	27	characteristics	characteristic	NOUN
dpc-4595	35	28	.	.	PUNCT
dpc-4595	36	1	methods	method	NOUN
dpc-4595	36	2	the	the	DET
dpc-4595	36	3	study	study	NOUN
dpc-4595	36	4	protocol	protocol	NOUN
dpc-4595	36	5	was	be	AUX
dpc-4595	36	6	approved	approve	VERB
dpc-4595	36	7	by	by	ADP
dpc-4595	36	8	the	the	DET
dpc-4595	36	9	university	university	PROPN
dpc-4595	36	10	of	of	ADP
dpc-4595	36	11	health	health	PROPN
dpc-4595	36	12	sciences	sciences	PROPN
dpc-4595	36	13	,	,	PUNCT
dpc-4595	36	14	diskapi	diskapi	PROPN
dpc-4595	36	15	yildirim	yildirim	NOUN
dpc-4595	36	16	beyazit	beyazit	NOUN
dpc-4595	36	17	training	training	NOUN
dpc-4595	36	18	and	and	CCONJ
dpc-4595	36	19	research	research	NOUN
dpc-4595	36	20	hospital	hospital	NOUN
dpc-4595	36	21	ethics	ethic	NOUN
dpc-4595	36	22	committee	committee	NOUN
dpc-4595	36	23	,	,	PUNCT
dpc-4595	36	24	and	and	CCONJ
dpc-4595	36	25	it	it	PRON
dpc-4595	36	26	followed	follow	VERB
dpc-4595	36	27	the	the	DET
dpc-4595	36	28	international	international	ADJ
dpc-4595	36	29	ethical	ethical	ADJ
dpc-4595	36	30	guidelines	guideline	NOUN
dpc-4595	36	31	of	of	ADP
dpc-4595	36	32	the	the	DET
dpc-4595	36	33	declaration	declaration	NOUN
dpc-4595	36	34	of	of	ADP
dpc-4595	36	35	helsinki	helsinki	PROPN
dpc-4595	36	36	.	.	PUNCT
dpc-4595	37	1	informed	inform	VERB
dpc-4595	37	2	consent	consent	NOUN
dpc-4595	37	3	was	be	AUX
dpc-4595	37	4	obtained	obtain	VERB
dpc-4595	37	5	from	from	ADP
dpc-4595	37	6	all	all	DET
dpc-4595	37	7	participants	participant	NOUN
dpc-4595	37	8	prior	prior	ADV
dpc-4595	37	9	to	to	ADP
dpc-4595	37	10	initiation	initiation	NOUN
dpc-4595	37	11	of	of	ADP
dpc-4595	37	12	the	the	DET
dpc-4595	37	13	study	study	NOUN
dpc-4595	37	14	.	.	PUNCT
dpc-4595	38	1	forty	forty	NUM
dpc-4595	38	2	adult	adult	NOUN
dpc-4595	38	3	patients	patient	NOUN
dpc-4595	38	4	diagnosed	diagnose	VERB
dpc-4595	38	5	with	with	ADP
dpc-4595	38	6	rosacea	rosacea	NOUN
dpc-4595	38	7	visiting	visit	VERB
dpc-4595	38	8	the	the	DET
dpc-4595	38	9	department	department	NOUN
dpc-4595	38	10	of	of	ADP
dpc-4595	38	11	dermatology	dermatology	NOUN
dpc-4595	38	12	at	at	ADP
dpc-4595	38	13	the	the	DET
dpc-4595	38	14	university	university	PROPN
dpc-4595	38	15	of	of	ADP
dpc-4595	38	16	health	health	PROPN
dpc-4595	38	17	sciences	sciences	PROPN
dpc-4595	38	18	,	,	PUNCT
dpc-4595	38	19	diskapi	diskapi	PROPN
dpc-4595	38	20	yildirim	yildirim	NOUN
dpc-4595	38	21	beyazit	beyazit	NOUN
dpc-4595	38	22	training	training	NOUN
dpc-4595	38	23	and	and	CCONJ
dpc-4595	38	24	research	research	NOUN
dpc-4595	38	25	hospital	hospital	NOUN
dpc-4595	38	26	from	from	ADP
dpc-4595	38	27	may	may	PROPN
dpc-4595	38	28	2022	2022	NUM
dpc-4595	38	29	to	to	ADP
dpc-4595	38	30	december	december	PROPN
dpc-4595	38	31	2022	2022	NUM
dpc-4595	38	32	were	be	AUX
dpc-4595	38	33	enrolled	enrol	VERB
dpc-4595	38	34	in	in	ADP
dpc-4595	38	35	the	the	DET
dpc-4595	38	36	study	study	NOUN
dpc-4595	38	37	.	.	PUNCT
dpc-4595	39	1	the	the	DET
dpc-4595	39	2	inclusion	inclusion	NOUN
dpc-4595	39	3	criterion	criterion	NOUN
dpc-4595	39	4	was	be	AUX
dpc-4595	39	5	having	have	VERB
dpc-4595	39	6	a	a	DET
dpc-4595	39	7	diagnosis	diagnosis	NOUN
dpc-4595	39	8	of	of	ADP
dpc-4595	39	9	rosacea	rosacea	NOUN
dpc-4595	39	10	according	accord	VERB
dpc-4595	39	11	to	to	ADP
dpc-4595	39	12	the	the	DET
dpc-4595	39	13	american	american	PROPN
dpc-4595	39	14	national	national	PROPN
dpc-4595	39	15	rosacea	rosacea	PROPN
dpc-4595	39	16	society	society	PROPN
dpc-4595	39	17	expert	expert	PROPN
dpc-4595	39	18	committee	committee	PROPN
dpc-4595	39	19	(	(	PUNCT
dpc-4595	39	20	nrsec	nrsec	PROPN
dpc-4595	39	21	)	)	PUNCT
dpc-4595	39	22	criteria	criterion	NOUN
dpc-4595	39	23	[	[	X
dpc-4595	39	24	8	8	NUM
dpc-4595	39	25	]	]	PUNCT
dpc-4595	39	26	;	;	PUNCT
dpc-4595	39	27	exclusion	exclusion	NOUN
dpc-4595	39	28	criteria	criterion	NOUN
dpc-4595	39	29	included	include	VERB
dpc-4595	39	30	patients	patient	NOUN
dpc-4595	39	31	younger	young	ADJ
dpc-4595	39	32	than	than	ADP
dpc-4595	39	33	18	18	NUM
dpc-4595	39	34	or	or	CCONJ
dpc-4595	39	35	older	old	ADJ
dpc-4595	39	36	than	than	ADP
dpc-4595	39	37	65	65	NUM
dpc-4595	39	38	years	year	NOUN
dpc-4595	39	39	,	,	PUNCT
dpc-4595	39	40	pregnant	pregnant	ADJ
dpc-4595	39	41	or	or	CCONJ
dpc-4595	39	42	lactating	lactate	VERB
dpc-4595	39	43	patients	patient	NOUN
dpc-4595	39	44	,	,	PUNCT
dpc-4595	39	45	and	and	CCONJ
dpc-4595	39	46	patients	patient	NOUN
dpc-4595	39	47	with	with	ADP
dpc-4595	39	48	diabetes	diabetes	NOUN
dpc-4595	39	49	mellitus	mellitus	NOUN
dpc-4595	39	50	,	,	PUNCT
dpc-4595	39	51	chronic	chronic	ADJ
dpc-4595	39	52	inflammatory	inflammatory	ADJ
dpc-4595	39	53	disorders	disorder	NOUN
dpc-4595	39	54	,	,	PUNCT
dpc-4595	39	55	immunological	immunological	ADJ
dpc-4595	39	56	disorders	disorder	NOUN
dpc-4595	39	57	,	,	PUNCT
dpc-4595	39	58	infections	infection	NOUN
dpc-4595	39	59	,	,	PUNCT
dpc-4595	39	60	obesity	obesity	NOUN
dpc-4595	39	61	(	(	PUNCT
dpc-4595	39	62	bmi	bmi	X
dpc-4595	39	63	>	>	X
dpc-4595	39	64	30	30	NUM
dpc-4595	39	65	)	)	PUNCT
dpc-4595	39	66	,	,	PUNCT
dpc-4595	39	67	or	or	CCONJ
dpc-4595	39	68	malignant	malignant	ADJ
dpc-4595	39	69	cancer	cancer	NOUN
dpc-4595	39	70	.	.	PUNCT
dpc-4595	40	1	the	the	DET
dpc-4595	40	2	control	control	PROPN
dpc-4595	40	3	group	group	NOUN
dpc-4595	40	4	comprised	comprise	VERB
dpc-4595	40	5	healthy	healthy	ADJ
dpc-4595	40	6	volunteers	volunteer	NOUN
dpc-4595	40	7	with	with	ADP
dpc-4595	40	8	no	no	DET
dpc-4595	40	9	known	know	VERB
dpc-4595	40	10	diseases	disease	NOUN
dpc-4595	40	11	who	who	PRON
dpc-4595	40	12	sought	seek	VERB
dpc-4595	40	13	routine	routine	ADJ
dpc-4595	40	14	physical	physical	ADJ
dpc-4595	40	15	examinations	examination	NOUN
dpc-4595	40	16	at	at	ADP
dpc-4595	40	17	our	our	PRON
dpc-4595	40	18	hospital	hospital	NOUN
dpc-4595	40	19	;	;	PUNCT
dpc-4595	40	20	age	age	NOUN
dpc-4595	40	21	and	and	CCONJ
dpc-4595	40	22	sex	sex	NOUN
dpc-4595	40	23	compatibility	compatibility	NOUN
dpc-4595	40	24	with	with	ADP
dpc-4595	40	25	the	the	DET
dpc-4595	40	26	patient	patient	NOUN
dpc-4595	40	27	group	group	NOUN
dpc-4595	40	28	was	be	AUX
dpc-4595	40	29	ensured	ensure	VERB
dpc-4595	40	30	.	.	PUNCT
dpc-4595	41	1	neither	neither	CCONJ
dpc-4595	41	2	the	the	DET
dpc-4595	41	3	patients	patient	NOUN
dpc-4595	41	4	nor	nor	CCONJ
dpc-4595	41	5	the	the	DET
dpc-4595	41	6	control	control	NOUN
dpc-4595	41	7	group	group	NOUN
dpc-4595	41	8	members	member	NOUN
dpc-4595	41	9	were	be	AUX
dpc-4595	41	10	subjected	subject	VERB
dpc-4595	41	11	to	to	ADP
dpc-4595	41	12	any	any	DET
dpc-4595	41	13	dietary	dietary	ADJ
dpc-4595	41	14	restrictions	restriction	NOUN
dpc-4595	41	15	.	.	PUNCT
dpc-4595	42	1	blood	blood	NOUN
dpc-4595	42	2	samples	sample	NOUN
dpc-4595	42	3	were	be	AUX
dpc-4595	42	4	taken	take	VERB
dpc-4595	42	5	from	from	ADP
dpc-4595	42	6	all	all	DET
dpc-4595	42	7	participants	participant	NOUN
dpc-4595	42	8	under	under	ADP
dpc-4595	42	9	the	the	DET
dpc-4595	42	10	same	same	ADJ
dpc-4595	42	11	conditions	condition	NOUN
dpc-4595	42	12	in	in	ADP
dpc-4595	42	13	our	our	PRON
dpc-4595	42	14	hospital	hospital	NOUN
dpc-4595	42	15	laboratory	laboratory	NOUN
dpc-4595	42	16	.	.	PUNCT
dpc-4595	43	1	all	all	DET
dpc-4595	43	2	patients	patient	NOUN
dpc-4595	43	3	were	be	AUX
dpc-4595	43	4	asked	ask	VERB
dpc-4595	43	5	for	for	ADP
dpc-4595	43	6	a	a	DET
dpc-4595	43	7	detailed	detailed	ADJ
dpc-4595	43	8	anamnesis	anamnesis	NOUN
dpc-4595	43	9	,	,	PUNCT
dpc-4595	43	10	and	and	CCONJ
dpc-4595	43	11	physical	physical	ADJ
dpc-4595	43	12	examinations	examination	NOUN
dpc-4595	43	13	were	be	AUX
dpc-4595	43	14	performed	perform	VERB
dpc-4595	43	15	.	.	PUNCT
dpc-4595	44	1	patients	patient	NOUN
dpc-4595	44	2	were	be	AUX
dpc-4595	44	3	also	also	ADV
dpc-4595	44	4	asked	ask	VERB
dpc-4595	44	5	about	about	ADP
dpc-4595	44	6	disease	disease	NOUN
dpc-4595	44	7	duration	duration	NOUN
dpc-4595	44	8	and	and	CCONJ
dpc-4595	44	9	treatments	treatment	NOUN
dpc-4595	44	10	;	;	PUNCT
dpc-4595	44	11	rosacea	rosacea	NOUN
dpc-4595	44	12	type	type	NOUN
dpc-4595	44	13	was	be	AUX
dpc-4595	44	14	determined	determine	VERB
dpc-4595	44	15	using	use	VERB
dpc-4595	44	16	the	the	DET
dpc-4595	44	17	nrsec	nrsec	ADJ
dpc-4595	44	18	classification	classification	NOUN
dpc-4595	44	19	system	system	NOUN
dpc-4595	44	20	for	for	ADP
dpc-4595	44	21	the	the	DET
dpc-4595	44	22	categorization	categorization	NOUN
dpc-4595	44	23	of	of	ADP
dpc-4595	44	24	rosacea	rosacea	NOUN
dpc-4595	44	25	cases	case	NOUN
dpc-4595	44	26	,	,	PUNCT
dpc-4595	44	27	and	and	CCONJ
dpc-4595	44	28	severity	severity	NOUN
dpc-4595	44	29	scores	score	NOUN
dpc-4595	44	30	were	be	AUX
dpc-4595	44	31	determined	determine	VERB
dpc-4595	44	32	in	in	ADP
dpc-4595	44	33	accordance	accordance	NOUN
dpc-4595	44	34	with	with	ADP
dpc-4595	44	35	this	this	DET
dpc-4595	44	36	classification	classification	NOUN
dpc-4595	45	1	[	[	X
dpc-4595	45	2	8	8	NUM
dpc-4595	45	3	]	]	PUNCT
dpc-4595	45	4	.	.	PUNCT
dpc-4595	46	1	with	with	ADP
dpc-4595	46	2	this	this	DET
dpc-4595	46	3	scoring	scoring	NOUN
dpc-4595	46	4	system	system	NOUN
dpc-4595	46	5	,	,	PUNCT
dpc-4595	46	6	patients	patient	NOUN
dpc-4595	46	7	’	'	PUNCT
dpc-4595	46	8	symptoms	symptom	NOUN
dpc-4595	46	9	were	be	AUX
dpc-4595	46	10	scored	score	VERB
dpc-4595	46	11	as	as	ADP
dpc-4595	46	12	one	one	NUM
dpc-4595	46	13	,	,	PUNCT
dpc-4595	46	14	two	two	NUM
dpc-4595	46	15	,	,	PUNCT
dpc-4595	46	16	or	or	CCONJ
dpc-4595	46	17	three	three	NUM
dpc-4595	46	18	,	,	PUNCT
dpc-4595	46	19	with	with	ADP
dpc-4595	46	20	assessments	assessment	NOUN
dpc-4595	46	21	of	of	ADP
dpc-4595	46	22	mild	mild	ADJ
dpc-4595	46	23	,	,	PUNCT
dpc-4595	46	24	moderate	moderate	ADJ
dpc-4595	46	25	,	,	PUNCT
dpc-4595	46	26	or	or	CCONJ
dpc-4595	46	27	severe	severe	ADJ
dpc-4595	46	28	,	,	PUNCT
dpc-4595	46	29	respectively	respectively	ADV
dpc-4595	46	30	.	.	PUNCT
dpc-4595	47	1	non	non	ADJ
dpc-4595	47	2	-	-	ADJ
dpc-4595	47	3	existent	existent	ADJ
dpc-4595	47	4	symptoms	symptom	NOUN
dpc-4595	47	5	received	receive	VERB
dpc-4595	47	6	a	a	DET
dpc-4595	47	7	score	score	NOUN
dpc-4595	47	8	of	of	ADP
dpc-4595	47	9	zero	zero	NUM
dpc-4595	47	10	.	.	PUNCT
dpc-4595	48	1	in	in	ADP
dpc-4595	48	2	the	the	DET
dpc-4595	48	3	final	final	ADJ
dpc-4595	48	4	step	step	NOUN
dpc-4595	48	5	,	,	PUNCT
dpc-4595	48	6	the	the	DET
dpc-4595	48	7	type	type	NOUN
dpc-4595	48	8	of	of	ADP
dpc-4595	48	9	disease	disease	NOUN
dpc-4595	48	10	was	be	AUX
dpc-4595	48	11	determined	determine	VERB
dpc-4595	48	12	,	,	PUNCT
dpc-4595	48	13	and	and	CCONJ
dpc-4595	48	14	the	the	DET
dpc-4595	48	15	severity	severity	NOUN
dpc-4595	48	16	score	score	NOUN
dpc-4595	48	17	was	be	AUX
dpc-4595	48	18	again	again	ADV
dpc-4595	48	19	assessed	assess	VERB
dpc-4595	48	20	by	by	ADP
dpc-4595	48	21	the	the	DET
dpc-4595	48	22	physician	physician	NOUN
dpc-4595	48	23	in	in	ADP
dpc-4595	48	24	the	the	DET
dpc-4595	48	25	same	same	ADJ
dpc-4595	48	26	manner	manner	NOUN
dpc-4595	48	27	.	.	PUNCT
dpc-4595	49	1	after	after	SCONJ
dpc-4595	49	2	the	the	DET
dpc-4595	49	3	overall	overall	ADJ
dpc-4595	49	4	severity	severity	NOUN
dpc-4595	49	5	of	of	ADP
dpc-4595	49	6	the	the	DET
dpc-4595	49	7	disease	disease	NOUN
dpc-4595	49	8	was	be	AUX
dpc-4595	49	9	evaluated	evaluate	VERB
dpc-4595	49	10	by	by	ADP
dpc-4595	49	11	the	the	DET
dpc-4595	49	12	physician	physician	NOUN
dpc-4595	49	13	,	,	PUNCT
dpc-4595	49	14	the	the	DET
dpc-4595	49	15	total	total	NOUN
dpc-4595	49	16	obtained	obtain	VERB
dpc-4595	49	17	score	score	NOUN
dpc-4595	49	18	provided	provide	VERB
dpc-4595	49	19	the	the	DET
dpc-4595	49	20	rosacea	rosacea	NOUN
dpc-4595	49	21	severity	severity	NOUN
dpc-4595	49	22	score	score	NOUN
dpc-4595	49	23	.	.	PUNCT
dpc-4595	50	1	following	follow	VERB
dpc-4595	50	2	an	an	DET
dpc-4595	50	3	8	8	NUM
dpc-4595	50	4	-	-	PUNCT
dpc-4595	50	5	hour	hour	NOUN
dpc-4595	50	6	fasting	fasting	NOUN
dpc-4595	50	7	period	period	NOUN
dpc-4595	50	8	,	,	PUNCT
dpc-4595	50	9	patients	patient	NOUN
dpc-4595	50	10	had	have	VERB
dpc-4595	50	11	their	their	PRON
dpc-4595	50	12	blood	blood	NOUN
dpc-4595	50	13	drawn	draw	VERB
dpc-4595	50	14	;	;	PUNCT
dpc-4595	50	15	these	these	DET
dpc-4595	50	16	non	non	ADJ
dpc-4595	50	17	-	-	ADJ
dpc-4595	50	18	stimulated	stimulated	ADJ
dpc-4595	50	19	blood	blood	NOUN
dpc-4595	50	20	samples	sample	NOUN
dpc-4595	50	21	were	be	AUX
dpc-4595	50	22	then	then	ADV
dpc-4595	50	23	conclusion	conclusion	NOUN
dpc-4595	50	24	:	:	PUNCT
dpc-4595	50	25	the	the	DET
dpc-4595	50	26	significantly	significantly	ADV
dpc-4595	50	27	elevated	elevated	ADJ
dpc-4595	50	28	levels	level	NOUN
dpc-4595	50	29	of	of	ADP
dpc-4595	50	30	il-6	il-6	NUM
dpc-4595	50	31	and	and	CCONJ
dpc-4595	50	32	hif-1α	hif-1α	NOUN
dpc-4595	50	33	in	in	ADP
dpc-4595	50	34	patients	patient	NOUN
dpc-4595	50	35	with	with	ADP
dpc-4595	50	36	rosacea	rosacea	NOUN
dpc-4595	50	37	compared	compare	VERB
dpc-4595	50	38	to	to	ADP
dpc-4595	50	39	the	the	DET
dpc-4595	50	40	control	control	NOUN
dpc-4595	50	41	group	group	NOUN
dpc-4595	50	42	support	support	VERB
dpc-4595	50	43	the	the	DET
dpc-4595	50	44	hypothesis	hypothesis	NOUN
dpc-4595	50	45	that	that	PRON
dpc-4595	50	46	these	these	DET
dpc-4595	50	47	molecules	molecule	NOUN
dpc-4595	50	48	play	play	VERB
dpc-4595	50	49	a	a	DET
dpc-4595	50	50	role	role	NOUN
dpc-4595	50	51	in	in	ADP
dpc-4595	50	52	the	the	DET
dpc-4595	50	53	pathogenesis	pathogenesis	NOUN
dpc-4595	50	54	of	of	ADP
dpc-4595	50	55	the	the	DET
dpc-4595	50	56	disease	disease	NOUN
dpc-4595	50	57	.	.	PUNCT
dpc-4595	51	1	the	the	DET
dpc-4595	51	2	correlation	correlation	NOUN
dpc-4595	51	3	between	between	ADP
dpc-4595	51	4	hif-1α	hif-1α	NOUN
dpc-4595	51	5	and	and	CCONJ
dpc-4595	51	6	the	the	DET
dpc-4595	51	7	severity	severity	NOUN
dpc-4595	51	8	of	of	ADP
dpc-4595	51	9	the	the	DET
dpc-4595	51	10	disease	disease	NOUN
dpc-4595	51	11	,	,	PUNCT
dpc-4595	51	12	and	and	CCONJ
dpc-4595	51	13	its	its	PRON
dpc-4595	51	14	significant	significant	ADJ
dpc-4595	51	15	elevation	elevation	NOUN
dpc-4595	51	16	in	in	ADP
dpc-4595	51	17	patients	patient	NOUN
dpc-4595	51	18	with	with	ADP
dpc-4595	51	19	telangiectasia	telangiectasia	NOUN
dpc-4595	51	20	,	,	PUNCT
dpc-4595	51	21	suggest	suggest	VERB
dpc-4595	51	22	its	its	PRON
dpc-4595	51	23	potential	potential	ADJ
dpc-4595	51	24	involvement	involvement	NOUN
dpc-4595	51	25	in	in	ADP
dpc-4595	51	26	the	the	DET
dpc-4595	51	27	pathogenesis	pathogenesis	NOUN
dpc-4595	51	28	of	of	ADP
dpc-4595	51	29	the	the	DET
dpc-4595	51	30	disease	disease	NOUN
dpc-4595	51	31	,	,	PUNCT
dpc-4595	51	32	particularly	particularly	ADV
dpc-4595	51	33	in	in	ADP
dpc-4595	51	34	the	the	DET
dpc-4595	51	35	formation	formation	NOUN
dpc-4595	51	36	of	of	ADP
dpc-4595	51	37	telangiectasia	telangiectasia	NOUN
dpc-4595	51	38	.	.	PUNCT
dpc-4595	52	1	original	original	ADJ
dpc-4595	52	2	article	article	NOUN
dpc-4595	52	3	|	|	ADV
dpc-4595	52	4	dermatol	dermatol	ADJ
dpc-4595	52	5	pract	pract	NOUN
dpc-4595	52	6	concept	concept	NOUN
dpc-4595	52	7	.	.	PUNCT
dpc-4595	53	1	2024;14(4):e2024267	2024;14(4):e2024267	NUM
dpc-4595	53	2	3	3	NUM
dpc-4595	53	3	centrifuged	centrifuge	VERB
dpc-4595	53	4	at	at	ADP
dpc-4595	53	5	1000	1000	NUM
dpc-4595	53	6	x	x	SYM
dpc-4595	53	7	g	g	NOUN
dpc-4595	53	8	for	for	ADP
dpc-4595	53	9	20	20	NUM
dpc-4595	53	10	minutes	minute	NOUN
dpc-4595	53	11	at	at	ADP
dpc-4595	53	12	4	4	NUM
dpc-4595	53	13	°	°	NOUN
dpc-4595	53	14	c	c	NOUN
dpc-4595	53	15	.	.	PUNCT
dpc-4595	54	1	the	the	DET
dpc-4595	54	2	serum	serum	NOUN
dpc-4595	54	3	was	be	AUX
dpc-4595	54	4	subsequently	subsequently	ADV
dpc-4595	54	5	stored	store	VERB
dpc-4595	54	6	at	at	ADP
dpc-4595	54	7	−20	−20	PROPN
dpc-4595	54	8	°	°	ADP
dpc-4595	54	9	c	c	NOUN
dpc-4595	54	10	in	in	ADP
dpc-4595	54	11	the	the	DET
dpc-4595	54	12	biochemistry	biochemistry	NOUN
dpc-4595	54	13	department	department	PROPN
dpc-4595	54	14	until	until	ADP
dpc-4595	54	15	analysis	analysis	NOUN
dpc-4595	54	16	.	.	PUNCT
dpc-4595	55	1	serum	serum	PROPN
dpc-4595	55	2	hif-1α	hif-1α	PROPN
dpc-4595	55	3	and	and	CCONJ
dpc-4595	55	4	il-6	il-6	NOUN
dpc-4595	55	5	levels	level	NOUN
dpc-4595	55	6	were	be	AUX
dpc-4595	55	7	measured	measure	VERB
dpc-4595	55	8	through	through	ADP
dpc-4595	55	9	enzyme	enzyme	NOUN
dpc-4595	55	10	-	-	PUNCT
dpc-4595	55	11	linked	link	VERB
dpc-4595	55	12	immunosorbent	immunosorbent	NOUN
dpc-4595	55	13	assay	assay	PROPN
dpc-4595	55	14	(	(	PUNCT
dpc-4595	55	15	elisa	elisa	NOUN
dpc-4595	55	16	)	)	PUNCT
dpc-4595	55	17	using	use	VERB
dpc-4595	55	18	commercial	commercial	ADJ
dpc-4595	55	19	kits	kit	NOUN
dpc-4595	55	20	(	(	PUNCT
dpc-4595	55	21	sandwich	sandwich	NOUN
dpc-4595	55	22	-	-	PUNCT
dpc-4595	55	23	elisa	elisa	NOUN
dpc-4595	55	24	,	,	PUNCT
dpc-4595	55	25	cloudclone	cloudclone	PROPN
dpc-4595	55	26	corp	corp	PROPN
dpc-4595	55	27	.	.	PROPN
dpc-4595	55	28	,	,	PUNCT
dpc-4595	55	29	sea079hu	sea079hu	NOUN
dpc-4595	55	30	(	(	PUNCT
dpc-4595	55	31	hif-1α	hif-1α	NOUN
dpc-4595	55	32	)	)	PUNCT
dpc-4595	55	33	,	,	PUNCT
dpc-4595	55	34	sea798hu	sea798hu	X
dpc-4595	55	35	(	(	PUNCT
dpc-4595	55	36	il-6	il-6	NUM
dpc-4595	55	37	)	)	PUNCT
dpc-4595	55	38	,	,	PUNCT
dpc-4595	55	39	usa	usa	PROPN
dpc-4595	55	40	)	)	PUNCT
dpc-4595	55	41	at	at	ADP
dpc-4595	55	42	diskapi	diskapi	PROPN
dpc-4595	55	43	yildirim	yildirim	PROPN
dpc-4595	55	44	beyazit	beyazit	PROPN
dpc-4595	55	45	training	training	NOUN
dpc-4595	55	46	and	and	CCONJ
dpc-4595	55	47	research	research	NOUN
dpc-4595	55	48	hospital	hospital	NOUN
dpc-4595	55	49	laboratories	laboratory	NOUN
dpc-4595	55	50	.	.	PUNCT
dpc-4595	56	1	hif-1α	hif-1α	NOUN
dpc-4595	56	2	and	and	CCONJ
dpc-4595	56	3	il-6	il-6	NOUN
dpc-4595	56	4	concentration	concentration	NOUN
dpc-4595	56	5	of	of	ADP
dpc-4595	56	6	the	the	DET
dpc-4595	56	7	samples	sample	NOUN
dpc-4595	56	8	were	be	AUX
dpc-4595	56	9	interpolated	interpolate	VERB
dpc-4595	56	10	from	from	ADP
dpc-4595	56	11	the	the	DET
dpc-4595	56	12	standard	standard	ADJ
dpc-4595	56	13	curve	curve	NOUN
dpc-4595	56	14	.	.	PUNCT
dpc-4595	57	1	the	the	DET
dpc-4595	57	2	detection	detection	NOUN
dpc-4595	57	3	ranges	range	VERB
dpc-4595	57	4	for	for	SCONJ
dpc-4595	57	5	the	the	DET
dpc-4595	57	6	assay	assay	NOUN
dpc-4595	57	7	were	be	AUX
dpc-4595	57	8	0.156–10	0.156–10	NOUN
dpc-4595	57	9	ng	ng	PROPN
dpc-4595	57	10	/	/	SYM
dpc-4595	57	11	ml	ml	NOUN
dpc-4595	57	12	for	for	ADP
dpc-4595	57	13	hif-1α	hif-1α	NOUN
dpc-4595	57	14	and	and	CCONJ
dpc-4595	57	15	7.8–500	7.8–500	NUM
dpc-4595	57	16	pg	pg	NOUN
dpc-4595	57	17	/	/	SYM
dpc-4595	57	18	ml	ml	X
dpc-4595	57	19	for	for	ADP
dpc-4595	57	20	il-6	il-6	PRON
dpc-4595	57	21	.	.	PUNCT
dpc-4595	58	1	the	the	DET
dpc-4595	58	2	obtained	obtain	VERB
dpc-4595	58	3	data	datum	NOUN
dpc-4595	58	4	were	be	AUX
dpc-4595	58	5	transferred	transfer	VERB
dpc-4595	58	6	to	to	ADP
dpc-4595	58	7	a	a	DET
dpc-4595	58	8	computer	computer	NOUN
dpc-4595	58	9	environment	environment	NOUN
dpc-4595	58	10	and	and	CCONJ
dpc-4595	58	11	evaluated	evaluate	VERB
dpc-4595	58	12	using	use	VERB
dpc-4595	58	13	the	the	DET
dpc-4595	58	14	statistics	statistic	NOUN
dpc-4595	58	15	program	program	NOUN
dpc-4595	58	16	spss	spss	PROPN
dpc-4595	58	17	(	(	PUNCT
dpc-4595	58	18	v.15.0	v.15.0	NUM
dpc-4595	58	19	)	)	PUNCT
dpc-4595	58	20	.	.	PUNCT
dpc-4595	59	1	the	the	DET
dpc-4595	59	2	conformity	conformity	NOUN
dpc-4595	59	3	of	of	ADP
dpc-4595	59	4	the	the	DET
dpc-4595	59	5	data	datum	NOUN
dpc-4595	59	6	to	to	ADP
dpc-4595	59	7	normal	normal	ADJ
dpc-4595	59	8	distribution	distribution	NOUN
dpc-4595	59	9	was	be	AUX
dpc-4595	59	10	evaluated	evaluate	VERB
dpc-4595	59	11	using	use	VERB
dpc-4595	59	12	the	the	DET
dpc-4595	59	13	kolmogrov	kolmogrov	ADJ
dpc-4595	59	14	–	–	PUNCT
dpc-4595	59	15	smirnov	smirnov	ADJ
dpc-4595	59	16	test	test	NOUN
dpc-4595	59	17	:	:	PUNCT
dpc-4595	59	18	analysis	analysis	NOUN
dpc-4595	59	19	of	of	ADP
dpc-4595	59	20	data	datum	NOUN
dpc-4595	59	21	inappropriate	inappropriate	ADJ
dpc-4595	59	22	to	to	ADP
dpc-4595	59	23	normal	normal	ADJ
dpc-4595	59	24	distribution	distribution	NOUN
dpc-4595	59	25	was	be	AUX
dpc-4595	59	26	conducted	conduct	VERB
dpc-4595	59	27	using	use	VERB
dpc-4595	59	28	the	the	DET
dpc-4595	59	29	mann	mann	PROPN
dpc-4595	59	30	–	–	PUNCT
dpc-4595	59	31	whitney	whitney	PROPN
dpc-4595	59	32	u	u	PROPN
dpc-4595	59	33	,	,	PUNCT
dpc-4595	59	34	kruskal	kruskal	PROPN
dpc-4595	59	35	–	–	PUNCT
dpc-4595	59	36	wallis	wallis	PROPN
dpc-4595	59	37	,	,	PUNCT
dpc-4595	59	38	and	and	CCONJ
dpc-4595	59	39	spearman	spearman	NOUN
dpc-4595	59	40	correlation	correlation	NOUN
dpc-4595	59	41	tests	test	NOUN
dpc-4595	59	42	,	,	PUNCT
dpc-4595	59	43	while	while	SCONJ
dpc-4595	59	44	analysis	analysis	NOUN
dpc-4595	59	45	of	of	ADP
dpc-4595	59	46	data	datum	NOUN
dpc-4595	59	47	appropriate	appropriate	ADJ
dpc-4595	59	48	to	to	ADP
dpc-4595	59	49	normal	normal	ADJ
dpc-4595	59	50	distribution	distribution	NOUN
dpc-4595	59	51	was	be	AUX
dpc-4595	59	52	conducted	conduct	VERB
dpc-4595	59	53	using	use	VERB
dpc-4595	59	54	student	student	NOUN
dpc-4595	59	55	’s	’s	PART
dpc-4595	59	56	t	t	PROPN
dpc-4595	59	57	-	-	PUNCT
dpc-4595	59	58	test	test	NOUN
dpc-4595	59	59	.	.	PUNCT
dpc-4595	60	1	chisquare	chisquare	NOUN
dpc-4595	60	2	analysis	analysis	NOUN
dpc-4595	60	3	was	be	AUX
dpc-4595	60	4	employed	employ	VERB
dpc-4595	60	5	to	to	PART
dpc-4595	60	6	assess	assess	VERB
dpc-4595	60	7	categorical	categorical	ADJ
dpc-4595	60	8	variables	variable	NOUN
dpc-4595	60	9	in	in	ADP
dpc-4595	60	10	the	the	DET
dpc-4595	60	11	study	study	NOUN
dpc-4595	60	12	.	.	PUNCT
dpc-4595	61	1	results	result	VERB
dpc-4595	61	2	the	the	DET
dpc-4595	61	3	study	study	NOUN
dpc-4595	61	4	included	include	VERB
dpc-4595	61	5	40	40	NUM
dpc-4595	61	6	(	(	PUNCT
dpc-4595	61	7	30	30	NUM
dpc-4595	61	8	female	female	NOUN
dpc-4595	61	9	,	,	PUNCT
dpc-4595	61	10	10	10	NUM
dpc-4595	61	11	male	male	NOUN
dpc-4595	61	12	)	)	PUNCT
dpc-4595	61	13	patients	patient	NOUN
dpc-4595	61	14	diagnosed	diagnose	VERB
dpc-4595	61	15	with	with	ADP
dpc-4595	61	16	rosacea	rosacea	NOUN
dpc-4595	61	17	and	and	CCONJ
dpc-4595	61	18	40	40	NUM
dpc-4595	61	19	(	(	PUNCT
dpc-4595	61	20	27	27	NUM
dpc-4595	61	21	female	female	NOUN
dpc-4595	61	22	,	,	PUNCT
dpc-4595	61	23	13	13	NUM
dpc-4595	61	24	male	male	NOUN
dpc-4595	61	25	)	)	PUNCT
dpc-4595	61	26	healthy	healthy	ADJ
dpc-4595	61	27	controls	control	NOUN
dpc-4595	61	28	.	.	PUNCT
dpc-4595	62	1	no	no	DET
dpc-4595	62	2	significant	significant	ADJ
dpc-4595	62	3	differences	difference	NOUN
dpc-4595	62	4	were	be	AUX
dpc-4595	62	5	observed	observe	VERB
dpc-4595	62	6	between	between	ADP
dpc-4595	62	7	the	the	DET
dpc-4595	62	8	patient	patient	ADJ
dpc-4595	62	9	and	and	CCONJ
dpc-4595	62	10	control	control	NOUN
dpc-4595	62	11	groups	group	NOUN
dpc-4595	62	12	in	in	ADP
dpc-4595	62	13	terms	term	NOUN
dpc-4595	62	14	of	of	ADP
dpc-4595	62	15	sex	sex	NOUN
dpc-4595	62	16	.	.	PUNCT
dpc-4595	63	1	the	the	DET
dpc-4595	63	2	participants	participant	NOUN
dpc-4595	63	3	in	in	ADP
dpc-4595	63	4	the	the	DET
dpc-4595	63	5	study	study	NOUN
dpc-4595	63	6	group	group	NOUN
dpc-4595	63	7	were	be	AUX
dpc-4595	63	8	aged	age	VERB
dpc-4595	63	9	18–62	18–62	NUM
dpc-4595	63	10	years	year	NOUN
dpc-4595	63	11	,	,	PUNCT
dpc-4595	63	12	with	with	ADP
dpc-4595	63	13	a	a	DET
dpc-4595	63	14	mean	mean	ADJ
dpc-4595	63	15	age	age	NOUN
dpc-4595	63	16	of	of	ADP
dpc-4595	63	17	39.97±10.26	39.97±10.26	NUM
dpc-4595	63	18	:	:	PUNCT
dpc-4595	63	19	participants	participant	NOUN
dpc-4595	63	20	in	in	ADP
dpc-4595	63	21	the	the	DET
dpc-4595	63	22	patient	patient	NOUN
dpc-4595	63	23	group	group	NOUN
dpc-4595	63	24	were	be	AUX
dpc-4595	63	25	aged	age	VERB
dpc-4595	63	26	23–61	23–61	NUM
dpc-4595	63	27	years	year	NOUN
dpc-4595	63	28	,	,	PUNCT
dpc-4595	63	29	with	with	ADP
dpc-4595	63	30	a	a	DET
dpc-4595	63	31	mean	mean	ADJ
dpc-4595	63	32	age	age	NOUN
dpc-4595	63	33	of	of	ADP
dpc-4595	63	34	40.25±10.86	40.25±10.86	NOUN
dpc-4595	63	35	,	,	PUNCT
dpc-4595	63	36	while	while	SCONJ
dpc-4595	63	37	those	those	PRON
dpc-4595	63	38	in	in	ADP
dpc-4595	63	39	the	the	DET
dpc-4595	63	40	control	control	NOUN
dpc-4595	63	41	group	group	NOUN
dpc-4595	63	42	were	be	AUX
dpc-4595	63	43	aged	age	VERB
dpc-4595	63	44	18–62	18–62	NUM
dpc-4595	63	45	years	year	NOUN
dpc-4595	63	46	,	,	PUNCT
dpc-4595	63	47	with	with	ADP
dpc-4595	63	48	a	a	DET
dpc-4595	63	49	mean	mean	ADJ
dpc-4595	63	50	age	age	NOUN
dpc-4595	63	51	of	of	ADP
dpc-4595	63	52	39.7±9.74	39.7±9.74	NUM
dpc-4595	63	53	.	.	PUNCT
dpc-4595	64	1	there	there	PRON
dpc-4595	64	2	was	be	VERB
dpc-4595	64	3	no	no	DET
dpc-4595	64	4	statistically	statistically	ADV
dpc-4595	64	5	significant	significant	ADJ
dpc-4595	64	6	difference	difference	NOUN
dpc-4595	64	7	in	in	ADP
dpc-4595	64	8	the	the	DET
dpc-4595	64	9	mean	mean	ADJ
dpc-4595	64	10	ages	age	NOUN
dpc-4595	64	11	between	between	ADP
dpc-4595	64	12	the	the	DET
dpc-4595	64	13	patient	patient	ADJ
dpc-4595	64	14	and	and	CCONJ
dpc-4595	64	15	control	control	NOUN
dpc-4595	64	16	groups	group	NOUN
dpc-4595	64	17	(	(	PUNCT
dpc-4595	64	18	p	p	X
dpc-4595	64	19	=	=	PUNCT
dpc-4595	64	20	0.264	0.264	NUM
dpc-4595	64	21	)	)	PUNCT
dpc-4595	64	22	.	.	PUNCT
dpc-4595	65	1	our	our	PRON
dpc-4595	65	2	study	study	NOUN
dpc-4595	65	3	group	group	NOUN
dpc-4595	65	4	consists	consist	VERB
dpc-4595	65	5	of	of	ADP
dpc-4595	65	6	patients	patient	NOUN
dpc-4595	65	7	diagnosed	diagnose	VERB
dpc-4595	65	8	with	with	ADP
dpc-4595	65	9	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-4595	65	10	and	and	CCONJ
dpc-4595	65	11	papulopustular	papulopustular	ADJ
dpc-4595	65	12	rosacea	rosacea	NOUN
dpc-4595	65	13	;	;	PUNCT
dpc-4595	65	14	there	there	PRON
dpc-4595	65	15	were	be	VERB
dpc-4595	65	16	no	no	DET
dpc-4595	65	17	patients	patient	NOUN
dpc-4595	65	18	with	with	ADP
dpc-4595	65	19	ocular	ocular	ADJ
dpc-4595	65	20	rosacea	rosacea	NOUN
dpc-4595	65	21	or	or	CCONJ
dpc-4595	65	22	phymatous	phymatous	ADJ
dpc-4595	65	23	rosacea	rosacea	NOUN
dpc-4595	65	24	.	.	PUNCT
dpc-4595	66	1	all	all	DET
dpc-4595	66	2	patients	patient	NOUN
dpc-4595	66	3	had	have	VERB
dpc-4595	66	4	at	at	ADV
dpc-4595	66	5	least	least	ADJ
dpc-4595	66	6	one	one	NUM
dpc-4595	66	7	triggering	trigger	VERB
dpc-4595	66	8	factor	factor	NOUN
dpc-4595	66	9	.	.	PUNCT
dpc-4595	67	1	the	the	DET
dpc-4595	67	2	fitzpatrick	fitzpatrick	PROPN
dpc-4595	67	3	skin	skin	NOUN
dpc-4595	67	4	types	type	NOUN
dpc-4595	67	5	included	include	VERB
dpc-4595	67	6	in	in	ADP
dpc-4595	67	7	the	the	DET
dpc-4595	67	8	study	study	NOUN
dpc-4595	67	9	were	be	AUX
dpc-4595	67	10	2	2	NUM
dpc-4595	67	11	,	,	PUNCT
dpc-4595	67	12	3	3	NUM
dpc-4595	67	13	,	,	PUNCT
dpc-4595	67	14	and	and	CCONJ
dpc-4595	67	15	4	4	NUM
dpc-4595	67	16	;	;	PUNCT
dpc-4595	67	17	there	there	PRON
dpc-4595	67	18	were	be	VERB
dpc-4595	67	19	no	no	DET
dpc-4595	67	20	patients	patient	NOUN
dpc-4595	67	21	with	with	ADP
dpc-4595	67	22	other	other	ADJ
dpc-4595	67	23	skin	skin	NOUN
dpc-4595	67	24	types	type	NOUN
dpc-4595	67	25	.	.	PUNCT
dpc-4595	68	1	patient	patient	ADJ
dpc-4595	68	2	characteristics	characteristic	NOUN
dpc-4595	68	3	—	—	PUNCT
dpc-4595	68	4	including	include	VERB
dpc-4595	68	5	age	age	NOUN
dpc-4595	68	6	at	at	ADP
dpc-4595	68	7	onset	onset	NOUN
dpc-4595	68	8	of	of	ADP
dpc-4595	68	9	disease	disease	NOUN
dpc-4595	68	10	,	,	PUNCT
dpc-4595	68	11	duration	duration	NOUN
dpc-4595	68	12	of	of	ADP
dpc-4595	68	13	disease	disease	NOUN
dpc-4595	68	14	,	,	PUNCT
dpc-4595	68	15	disease	disease	NOUN
dpc-4595	68	16	subtype	subtype	NOUN
dpc-4595	68	17	,	,	PUNCT
dpc-4595	68	18	triggering	trigger	VERB
dpc-4595	68	19	factors	factor	NOUN
dpc-4595	68	20	,	,	PUNCT
dpc-4595	68	21	skin	skin	NOUN
dpc-4595	68	22	phototype	phototype	NOUN
dpc-4595	68	23	,	,	PUNCT
dpc-4595	68	24	and	and	CCONJ
dpc-4595	68	25	family	family	NOUN
dpc-4595	68	26	history	history	NOUN
dpc-4595	68	27	—	—	PUNCT
dpc-4595	68	28	are	be	AUX
dpc-4595	68	29	presented	present	VERB
dpc-4595	68	30	in	in	ADP
dpc-4595	68	31	table	table	NOUN
dpc-4595	68	32	1	1	NUM
dpc-4595	68	33	.	.	PUNCT
dpc-4595	69	1	the	the	DET
dpc-4595	69	2	clinical	clinical	ADJ
dpc-4595	69	3	findings	finding	NOUN
dpc-4595	69	4	used	use	VERB
dpc-4595	69	5	in	in	ADP
dpc-4595	69	6	calculating	calculate	VERB
dpc-4595	69	7	patients	patient	NOUN
dpc-4595	69	8	’	’	PART
dpc-4595	69	9	severity	severity	NOUN
dpc-4595	69	10	scores	score	NOUN
dpc-4595	69	11	,	,	PUNCT
dpc-4595	69	12	along	along	ADP
dpc-4595	69	13	with	with	ADP
dpc-4595	69	14	their	their	PRON
dpc-4595	69	15	distribution	distribution	NOUN
dpc-4595	69	16	in	in	ADP
dpc-4595	69	17	terms	term	NOUN
dpc-4595	69	18	of	of	ADP
dpc-4595	69	19	severity	severity	NOUN
dpc-4595	69	20	and	and	CCONJ
dpc-4595	69	21	number	number	NOUN
dpc-4595	69	22	of	of	ADP
dpc-4595	69	23	patients	patient	NOUN
dpc-4595	69	24	,	,	PUNCT
dpc-4595	69	25	are	be	AUX
dpc-4595	69	26	detailed	detail	VERB
dpc-4595	69	27	in	in	ADP
dpc-4595	69	28	table	table	NOUN
dpc-4595	69	29	2	2	NUM
dpc-4595	69	30	.	.	PUNCT
dpc-4595	70	1	a	a	DET
dpc-4595	70	2	significant	significant	ADJ
dpc-4595	70	3	difference	difference	NOUN
dpc-4595	70	4	was	be	AUX
dpc-4595	70	5	observed	observe	VERB
dpc-4595	70	6	between	between	ADP
dpc-4595	70	7	the	the	DET
dpc-4595	70	8	patient	patient	ADJ
dpc-4595	70	9	and	and	CCONJ
dpc-4595	70	10	control	control	NOUN
dpc-4595	70	11	groups	group	NOUN
dpc-4595	70	12	in	in	ADP
dpc-4595	70	13	terms	term	NOUN
dpc-4595	70	14	of	of	ADP
dpc-4595	70	15	hif-1α	hif-1α	NOUN
dpc-4595	70	16	and	and	CCONJ
dpc-4595	70	17	il-6	il-6	NOUN
dpc-4595	70	18	levels	level	NOUN
dpc-4595	70	19	(	(	PUNCT
dpc-4595	70	20	p	p	X
dpc-4595	70	21	<	<	X
dpc-4595	70	22	0.001	0.001	NUM
dpc-4595	70	23	for	for	ADP
dpc-4595	70	24	each	each	PRON
dpc-4595	70	25	)	)	PUNCT
dpc-4595	70	26	(	(	PUNCT
dpc-4595	70	27	table	table	NOUN
dpc-4595	70	28	3	3	NUM
dpc-4595	70	29	)	)	PUNCT
dpc-4595	70	30	.	.	PUNCT
dpc-4595	71	1	when	when	SCONJ
dpc-4595	71	2	patients	patient	NOUN
dpc-4595	71	3	were	be	AUX
dpc-4595	71	4	grouped	group	VERB
dpc-4595	71	5	according	accord	VERB
dpc-4595	71	6	to	to	ADP
dpc-4595	71	7	severity	severity	NOUN
dpc-4595	71	8	score	score	NOUN
dpc-4595	71	9	,	,	PUNCT
dpc-4595	71	10	we	we	PRON
dpc-4595	71	11	observed	observe	VERB
dpc-4595	71	12	that	that	SCONJ
dpc-4595	71	13	eight	eight	NUM
dpc-4595	71	14	(	(	PUNCT
dpc-4595	71	15	20	20	NUM
dpc-4595	71	16	%	%	NOUN
dpc-4595	71	17	)	)	PUNCT
dpc-4595	71	18	patients	patient	NOUN
dpc-4595	71	19	had	have	VERB
dpc-4595	71	20	mild	mild	ADJ
dpc-4595	71	21	severity	severity	NOUN
dpc-4595	71	22	,	,	PUNCT
dpc-4595	71	23	while	while	SCONJ
dpc-4595	71	24	32	32	NUM
dpc-4595	71	25	(	(	PUNCT
dpc-4595	71	26	80	80	NUM
dpc-4595	71	27	%	%	NOUN
dpc-4595	71	28	)	)	PUNCT
dpc-4595	71	29	patients	patient	NOUN
dpc-4595	71	30	had	have	VERB
dpc-4595	71	31	moderate	moderate	ADJ
dpc-4595	71	32	severity	severity	NOUN
dpc-4595	71	33	.	.	PUNCT
dpc-4595	72	1	although	although	SCONJ
dpc-4595	72	2	there	there	PRON
dpc-4595	72	3	were	be	VERB
dpc-4595	72	4	severe	severe	ADJ
dpc-4595	72	5	symptoms	symptom	NOUN
dpc-4595	72	6	in	in	ADP
dpc-4595	72	7	some	some	DET
dpc-4595	72	8	specific	specific	ADJ
dpc-4595	72	9	aspects	aspect	NOUN
dpc-4595	72	10	,	,	PUNCT
dpc-4595	72	11	the	the	DET
dpc-4595	72	12	overall	overall	ADJ
dpc-4595	72	13	severity	severity	NOUN
dpc-4595	72	14	scores	score	NOUN
dpc-4595	72	15	placed	place	VERB
dpc-4595	72	16	our	our	PRON
dpc-4595	72	17	patients	patient	NOUN
dpc-4595	72	18	in	in	ADP
dpc-4595	72	19	the	the	DET
dpc-4595	72	20	‘	'	PUNCT
dpc-4595	72	21	mild	mild	ADJ
dpc-4595	72	22	’	'	PUNCT
dpc-4595	72	23	and	and	CCONJ
dpc-4595	72	24	‘	'	PUNCT
dpc-4595	72	25	moderate	moderate	ADJ
dpc-4595	72	26	’	'	PUNCT
dpc-4595	72	27	severity	severity	NOUN
dpc-4595	72	28	groups	group	NOUN
dpc-4595	72	29	,	,	PUNCT
dpc-4595	72	30	and	and	CCONJ
dpc-4595	72	31	thus	thus	ADV
dpc-4595	72	32	there	there	PRON
dpc-4595	72	33	were	be	VERB
dpc-4595	72	34	no	no	DET
dpc-4595	72	35	patients	patient	NOUN
dpc-4595	72	36	classified	classify	VERB
dpc-4595	72	37	as	as	ADP
dpc-4595	72	38	‘	'	PUNCT
dpc-4595	72	39	severe	severe	ADJ
dpc-4595	72	40	’	'	PUNCT
dpc-4595	72	41	.	.	PUNCT
dpc-4595	73	1	a	a	DET
dpc-4595	73	2	positive	positive	ADJ
dpc-4595	73	3	correlation	correlation	NOUN
dpc-4595	73	4	was	be	AUX
dpc-4595	73	5	found	find	VERB
dpc-4595	73	6	between	between	ADP
dpc-4595	73	7	the	the	DET
dpc-4595	73	8	rosacea	rosacea	NOUN
dpc-4595	73	9	severity	severity	NOUN
dpc-4595	73	10	score	score	NOUN
dpc-4595	73	11	and	and	CCONJ
dpc-4595	73	12	serum	serum	NOUN
dpc-4595	73	13	hif-1α	hif-1α	PROPN
dpc-4595	73	14	(	(	PUNCT
dpc-4595	73	15	r=0.374	r=0.374	PROPN
dpc-4595	73	16	,	,	PUNCT
dpc-4595	73	17	p	p	X
dpc-4595	73	18	=	=	NOUN
dpc-4595	73	19	0.017	0.017	NUM
dpc-4595	73	20	)	)	PUNCT
dpc-4595	73	21	.	.	PUNCT
dpc-4595	74	1	no	no	DET
dpc-4595	74	2	relationship	relationship	NOUN
dpc-4595	74	3	was	be	AUX
dpc-4595	74	4	found	find	VERB
dpc-4595	74	5	between	between	ADP
dpc-4595	74	6	serum	serum	NOUN
dpc-4595	74	7	il-6	il-6	NOUN
dpc-4595	74	8	and	and	CCONJ
dpc-4595	74	9	the	the	DET
dpc-4595	74	10	severity	severity	NOUN
dpc-4595	74	11	score	score	NOUN
dpc-4595	74	12	of	of	ADP
dpc-4595	74	13	the	the	DET
dpc-4595	74	14	disease	disease	NOUN
dpc-4595	74	15	(	(	PUNCT
dpc-4595	74	16	z=0.032	z=0.032	X
dpc-4595	74	17	,	,	PUNCT
dpc-4595	74	18	p	p	X
dpc-4595	74	19	=	=	NOUN
dpc-4595	74	20	0.844	0.844	NUM
dpc-4595	74	21	)	)	PUNCT
dpc-4595	74	22	.	.	PUNCT
dpc-4595	75	1	there	there	PRON
dpc-4595	75	2	was	be	VERB
dpc-4595	75	3	no	no	DET
dpc-4595	75	4	observed	observed	ADJ
dpc-4595	75	5	correlation	correlation	NOUN
dpc-4595	75	6	between	between	ADP
dpc-4595	75	7	serum	serum	NOUN
dpc-4595	75	8	hif-1α	hif-1α	PROPN
dpc-4595	75	9	and	and	CCONJ
dpc-4595	75	10	il-6	il-6	NOUN
dpc-4595	75	11	(	(	PUNCT
dpc-4595	75	12	r=0.104	r=0.104	X
dpc-4595	75	13	,	,	PUNCT
dpc-4595	75	14	p	p	X
dpc-4595	75	15	=	=	NOUN
dpc-4595	75	16	0.523	0.523	NUM
dpc-4595	75	17	)	)	PUNCT
dpc-4595	75	18	.	.	PUNCT
dpc-4595	76	1	in	in	ADP
dpc-4595	76	2	an	an	DET
dpc-4595	76	3	examination	examination	NOUN
dpc-4595	76	4	of	of	ADP
dpc-4595	76	5	associations	association	NOUN
dpc-4595	76	6	between	between	ADP
dpc-4595	76	7	the	the	DET
dpc-4595	76	8	presence	presence	NOUN
dpc-4595	76	9	of	of	ADP
dpc-4595	76	10	primary	primary	ADJ
dpc-4595	76	11	and	and	CCONJ
dpc-4595	76	12	secondary	secondary	ADJ
dpc-4595	76	13	manifestations	manifestation	NOUN
dpc-4595	76	14	of	of	ADP
dpc-4595	76	15	the	the	DET
dpc-4595	76	16	disease	disease	NOUN
dpc-4595	76	17	and	and	CCONJ
dpc-4595	76	18	hif-1α	hif-1α	NOUN
dpc-4595	76	19	and	and	CCONJ
dpc-4595	76	20	il-6	il-6	NOUN
dpc-4595	76	21	levels	level	NOUN
dpc-4595	76	22	,	,	PUNCT
dpc-4595	76	23	it	it	PRON
dpc-4595	76	24	was	be	AUX
dpc-4595	76	25	determined	determine	VERB
dpc-4595	76	26	that	that	SCONJ
dpc-4595	76	27	the	the	DET
dpc-4595	76	28	level	level	NOUN
dpc-4595	76	29	of	of	ADP
dpc-4595	76	30	hif-1α	hif-1α	NOUN
dpc-4595	76	31	was	be	AUX
dpc-4595	76	32	table	table	NOUN
dpc-4595	76	33	1	1	NUM
dpc-4595	76	34	.	.	PUNCT
dpc-4595	76	35	general	general	ADJ
dpc-4595	76	36	characteristics	characteristic	NOUN
dpc-4595	76	37	of	of	ADP
dpc-4595	76	38	rosacea	rosacea	NOUN
dpc-4595	76	39	patients	patient	NOUN
dpc-4595	76	40	.	.	PUNCT
dpc-4595	77	1	characteristics	characteristic	NOUN
dpc-4595	77	2	n(%	n(%	PROPN
dpc-4595	77	3	)	)	PUNCT
dpc-4595	77	4	age	age	NOUN
dpc-4595	77	5	,	,	PUNCT
dpc-4595	77	6	years	year	NOUN
dpc-4595	77	7	40.25(±10.86	40.25(±10.86	NUM
dpc-4595	77	8	)	)	PUNCT
dpc-4595	77	9	sex	sex	NOUN
dpc-4595	77	10	•	•	NUM
dpc-4595	77	11	female	female	ADJ
dpc-4595	77	12	30	30	NUM
dpc-4595	77	13	(	(	PUNCT
dpc-4595	77	14	75	75	NUM
dpc-4595	77	15	%	%	NOUN
dpc-4595	77	16	)	)	PUNCT
dpc-4595	77	17	•	•	NOUN
dpc-4595	77	18	male	male	NOUN
dpc-4595	77	19	10	10	NUM
dpc-4595	77	20	(	(	PUNCT
dpc-4595	77	21	25	25	NUM
dpc-4595	77	22	%	%	NOUN
dpc-4595	77	23	)	)	PUNCT
dpc-4595	77	24	age	age	NOUN
dpc-4595	77	25	at	at	ADP
dpc-4595	77	26	disease	disease	NOUN
dpc-4595	77	27	onset	onset	NOUN
dpc-4595	77	28	(	(	PUNCT
dpc-4595	77	29	mean	mean	NOUN
dpc-4595	77	30	)	)	PUNCT
dpc-4595	77	31	35.75	35.75	NUM
dpc-4595	77	32	±	±	NUM
dpc-4595	77	33	10.82	10.82	NUM
dpc-4595	77	34	(	(	PUNCT
dpc-4595	77	35	19.0	19.0	NUM
dpc-4595	77	36	-	-	SYM
dpc-4595	77	37	59.0	59.0	NUM
dpc-4595	77	38	)	)	PUNCT
dpc-4595	77	39	disease	disease	NOUN
dpc-4595	77	40	duration	duration	NOUN
dpc-4595	77	41	,	,	PUNCT
dpc-4595	77	42	months	month	NOUN
dpc-4595	77	43	(	(	PUNCT
dpc-4595	77	44	mean	mean	NOUN
dpc-4595	77	45	)	)	PUNCT
dpc-4595	77	46	51.73	51.73	NUM
dpc-4595	77	47	±	±	NUM
dpc-4595	77	48	46.02	46.02	NUM
dpc-4595	77	49	(	(	PUNCT
dpc-4595	77	50	1	1	NUM
dpc-4595	77	51	-	-	SYM
dpc-4595	77	52	180	180	NUM
dpc-4595	77	53	)	)	PUNCT
dpc-4595	77	54	rosacea	rosacea	NOUN
dpc-4595	77	55	subtype	subtype	NOUN
dpc-4595	77	56	•	•	ADP
dpc-4595	77	57	et	et	NOUN
dpc-4595	77	58	21	21	NUM
dpc-4595	77	59	(	(	PUNCT
dpc-4595	77	60	52	52	NUM
dpc-4595	77	61	%	%	NOUN
dpc-4595	77	62	)	)	PUNCT
dpc-4595	77	63	•	•	NOUN
dpc-4595	77	64	pp	pp	ADV
dpc-4595	77	65	19	19	NUM
dpc-4595	77	66	(	(	PUNCT
dpc-4595	77	67	48	48	NUM
dpc-4595	77	68	%	%	NOUN
dpc-4595	77	69	)	)	PUNCT
dpc-4595	77	70	aggravating	aggravate	VERB
dpc-4595	77	71	factors	factor	NOUN
dpc-4595	77	72	•	•	ADP
dpc-4595	77	73	sun	sun	NOUN
dpc-4595	77	74	exposure	exposure	NOUN
dpc-4595	77	75	38	38	NUM
dpc-4595	77	76	(	(	PUNCT
dpc-4595	77	77	95	95	NUM
dpc-4595	77	78	%	%	NOUN
dpc-4595	77	79	)	)	PUNCT
dpc-4595	77	80	•	•	NOUN
dpc-4595	77	81	stress	stress	NOUN
dpc-4595	77	82	28	28	NUM
dpc-4595	77	83	(	(	PUNCT
dpc-4595	77	84	70	70	NUM
dpc-4595	77	85	%	%	NOUN
dpc-4595	77	86	)	)	PUNCT
dpc-4595	77	87	•	•	NUM
dpc-4595	77	88	heat	heat	NOUN
dpc-4595	77	89	38	38	NUM
dpc-4595	77	90	(	(	PUNCT
dpc-4595	77	91	95	95	NUM
dpc-4595	77	92	%	%	NOUN
dpc-4595	77	93	)	)	PUNCT
dpc-4595	77	94	•	•	NOUN
dpc-4595	77	95	cold	cold	ADJ
dpc-4595	77	96	21	21	NUM
dpc-4595	77	97	(	(	PUNCT
dpc-4595	77	98	52.5	52.5	NUM
dpc-4595	77	99	%	%	NOUN
dpc-4595	77	100	)	)	PUNCT
dpc-4595	77	101	•	•	NUM
dpc-4595	77	102	wind	wind	NOUN
dpc-4595	77	103	20	20	NUM
dpc-4595	77	104	(	(	PUNCT
dpc-4595	77	105	50	50	NUM
dpc-4595	77	106	%	%	NOUN
dpc-4595	77	107	)	)	PUNCT
dpc-4595	77	108	•	•	NUM
dpc-4595	77	109	exercise	exercise	NOUN
dpc-4595	77	110	9	9	NUM
dpc-4595	77	111	(	(	PUNCT
dpc-4595	77	112	22.5	22.5	NUM
dpc-4595	77	113	%	%	NOUN
dpc-4595	77	114	)	)	PUNCT
dpc-4595	77	115	•	•	NUM
dpc-4595	77	116	spice	spice	NOUN
dpc-4595	77	117	16	16	NUM
dpc-4595	77	118	(	(	PUNCT
dpc-4595	77	119	40	40	NUM
dpc-4595	77	120	%	%	NOUN
dpc-4595	77	121	)	)	PUNCT
dpc-4595	77	122	skin	skin	NOUN
dpc-4595	77	123	phototype	phototype	NOUN
dpc-4595	78	1	•	•	ADP
dpc-4595	78	2	phototype	phototype	NOUN
dpc-4595	78	3	1	1	NUM
dpc-4595	78	4	•	•	NOUN
dpc-4595	78	5	phototype	phototype	NOUN
dpc-4595	78	6	2	2	NUM
dpc-4595	78	7	5	5	NUM
dpc-4595	78	8	(	(	PUNCT
dpc-4595	78	9	12.5	12.5	NUM
dpc-4595	78	10	%	%	NOUN
dpc-4595	78	11	)	)	PUNCT
dpc-4595	78	12	•	•	NOUN
dpc-4595	78	13	phototype	phototype	VERB
dpc-4595	78	14	3	3	NUM
dpc-4595	78	15	26	26	NUM
dpc-4595	78	16	(	(	PUNCT
dpc-4595	78	17	65.0	65.0	NUM
dpc-4595	78	18	%	%	NOUN
dpc-4595	78	19	)	)	PUNCT
dpc-4595	78	20	•	•	NOUN
dpc-4595	78	21	phototype	phototype	NOUN
dpc-4595	78	22	4	4	NUM
dpc-4595	78	23	9	9	NUM
dpc-4595	78	24	(	(	PUNCT
dpc-4595	78	25	22.5	22.5	NUM
dpc-4595	78	26	%	%	NOUN
dpc-4595	78	27	)	)	PUNCT
dpc-4595	78	28	•	•	NOUN
dpc-4595	78	29	phototype	phototype	NOUN
dpc-4595	78	30	5	5	NUM
dpc-4595	78	31	•	•	NOUN
dpc-4595	78	32	phototype	phototype	NOUN
dpc-4595	78	33	6	6	NUM
dpc-4595	78	34	family	family	NOUN
dpc-4595	78	35	history	history	NOUN
dpc-4595	78	36	•	•	ADP
dpc-4595	78	37	present	present	ADJ
dpc-4595	78	38	13	13	NUM
dpc-4595	78	39	(	(	PUNCT
dpc-4595	78	40	32.5	32.5	NUM
dpc-4595	78	41	%	%	NOUN
dpc-4595	78	42	)	)	PUNCT
dpc-4595	78	43	•	•	NOUN
dpc-4595	78	44	absent	absent	ADJ
dpc-4595	78	45	27	27	NUM
dpc-4595	78	46	(	(	PUNCT
dpc-4595	78	47	67.5	67.5	NUM
dpc-4595	78	48	%	%	NOUN
dpc-4595	78	49	)	)	PUNCT
dpc-4595	78	50	abbreviations	abbreviation	NOUN
dpc-4595	78	51	:	:	PUNCT
dpc-4595	78	52	et	et	NOUN
dpc-4595	78	53	:	:	PUNCT
dpc-4595	78	54	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-4595	78	55	;	;	PUNCT
dpc-4595	78	56	pp	pp	ADV
dpc-4595	78	57	:	:	PUNCT
dpc-4595	78	58	papulopustular	papulopustular	ADJ
dpc-4595	78	59	.	.	PUNCT
dpc-4595	79	1	4	4	NUM
dpc-4595	79	2	original	original	ADJ
dpc-4595	79	3	article	article	NOUN
dpc-4595	79	4	|	|	ADV
dpc-4595	79	5	dermatol	dermatol	ADJ
dpc-4595	79	6	pract	pract	NOUN
dpc-4595	79	7	concept	concept	NOUN
dpc-4595	79	8	.	.	PUNCT
dpc-4595	80	1	2024;14(4):e2024267	2024;14(4):e2024267	NUM
dpc-4595	80	2	table	table	NOUN
dpc-4595	80	3	2	2	NUM
dpc-4595	80	4	.	.	PUNCT
dpc-4595	80	5	distribution	distribution	NOUN
dpc-4595	80	6	of	of	ADP
dpc-4595	80	7	rosacea	rosacea	NOUN
dpc-4595	80	8	symptoms	symptom	NOUN
dpc-4595	80	9	and	and	CCONJ
dpc-4595	80	10	severity	severity	NOUN
dpc-4595	80	11	scores	score	NOUN
dpc-4595	80	12	among	among	ADP
dpc-4595	80	13	patients	patient	NOUN
dpc-4595	80	14	.	.	PUNCT
dpc-4595	81	1	absent	absent	ADJ
dpc-4595	81	2	n(%	n(%	NOUN
dpc-4595	81	3	)	)	PUNCT
dpc-4595	81	4	mild	mild	ADJ
dpc-4595	81	5	n(%	n(%	PROPN
dpc-4595	81	6	)	)	PUNCT
dpc-4595	81	7	moderate	moderate	ADJ
dpc-4595	81	8	n(%	n(%	PROPN
dpc-4595	81	9	)	)	PUNCT
dpc-4595	81	10	severe	severe	ADJ
dpc-4595	81	11	n(%	n(%	PROPN
dpc-4595	81	12	)	)	PUNCT
dpc-4595	81	13	primary	primary	ADJ
dpc-4595	81	14	features	feature	NOUN
dpc-4595	81	15	•	•	ADV
dpc-4595	81	16	flushing	flush	VERB
dpc-4595	81	17	14	14	NUM
dpc-4595	81	18	(	(	PUNCT
dpc-4595	81	19	35.0	35.0	NUM
dpc-4595	81	20	)	)	PUNCT
dpc-4595	81	21	21	21	NUM
dpc-4595	81	22	(	(	PUNCT
dpc-4595	81	23	52.5	52.5	NUM
dpc-4595	81	24	)	)	PUNCT
dpc-4595	81	25	3	3	NUM
dpc-4595	81	26	(	(	PUNCT
dpc-4595	81	27	7.5	7.5	NUM
dpc-4595	81	28	)	)	SYM
dpc-4595	81	29	2	2	NUM
dpc-4595	81	30	(	(	PUNCT
dpc-4595	81	31	5	5	NUM
dpc-4595	81	32	)	)	PUNCT
dpc-4595	81	33	•	•	NUM
dpc-4595	81	34	nontransient	nontransient	NOUN
dpc-4595	81	35	erythema	erythema	VERB
dpc-4595	81	36	0	0	NUM
dpc-4595	81	37	18	18	NUM
dpc-4595	81	38	(	(	PUNCT
dpc-4595	81	39	45.09	45.09	NUM
dpc-4595	81	40	)	)	PUNCT
dpc-4595	81	41	19	19	NUM
dpc-4595	81	42	(	(	PUNCT
dpc-4595	81	43	47.5	47.5	NUM
dpc-4595	81	44	)	)	PUNCT
dpc-4595	81	45	3	3	NUM
dpc-4595	81	46	(	(	PUNCT
dpc-4595	81	47	7.5	7.5	NUM
dpc-4595	81	48	)	)	PUNCT
dpc-4595	81	49	•	•	NUM
dpc-4595	81	50	papules	papule	NOUN
dpc-4595	81	51	and	and	CCONJ
dpc-4595	81	52	pustules	pustule	NOUN
dpc-4595	81	53	18	18	NUM
dpc-4595	81	54	(	(	PUNCT
dpc-4595	81	55	45.0	45.0	NUM
dpc-4595	81	56	)	)	PUNCT
dpc-4595	81	57	10	10	NUM
dpc-4595	81	58	(	(	PUNCT
dpc-4595	81	59	25.0	25.0	NUM
dpc-4595	81	60	)	)	PUNCT
dpc-4595	81	61	7	7	NUM
dpc-4595	81	62	(	(	PUNCT
dpc-4595	81	63	17.5	17.5	NUM
dpc-4595	81	64	)	)	SYM
dpc-4595	81	65	5	5	NUM
dpc-4595	81	66	(	(	PUNCT
dpc-4595	81	67	12.5	12.5	NUM
dpc-4595	81	68	)	)	PUNCT
dpc-4595	81	69	•	•	NOUN
dpc-4595	81	70	telangiectasia	telangiectasia	NOUN
dpc-4595	81	71	8	8	NUM
dpc-4595	81	72	(	(	PUNCT
dpc-4595	81	73	20	20	NUM
dpc-4595	81	74	)	)	SYM
dpc-4595	81	75	18	18	NUM
dpc-4595	81	76	(	(	PUNCT
dpc-4595	81	77	45	45	NUM
dpc-4595	81	78	)	)	PUNCT
dpc-4595	81	79	13	13	NUM
dpc-4595	81	80	(	(	PUNCT
dpc-4595	81	81	32.5	32.5	NUM
dpc-4595	81	82	)	)	PUNCT
dpc-4595	81	83	1	1	NUM
dpc-4595	81	84	(	(	PUNCT
dpc-4595	81	85	2.5	2.5	NUM
dpc-4595	81	86	)	)	PUNCT
dpc-4595	81	87	secondary	secondary	ADJ
dpc-4595	81	88	features	feature	NOUN
dpc-4595	81	89	•	•	ADV
dpc-4595	81	90	burning	burn	VERB
dpc-4595	81	91	10	10	NUM
dpc-4595	81	92	(	(	PUNCT
dpc-4595	81	93	25.0	25.0	NUM
dpc-4595	81	94	)	)	PUNCT
dpc-4595	81	95	21	21	NUM
dpc-4595	81	96	(	(	PUNCT
dpc-4595	81	97	52.5	52.5	NUM
dpc-4595	81	98	)	)	SYM
dpc-4595	81	99	8	8	NUM
dpc-4595	81	100	(	(	PUNCT
dpc-4595	81	101	20.0	20.0	NUM
dpc-4595	81	102	)	)	SYM
dpc-4595	81	103	1	1	NUM
dpc-4595	81	104	(	(	PUNCT
dpc-4595	81	105	2.5	2.5	NUM
dpc-4595	81	106	)	)	PUNCT
dpc-4595	81	107	•	•	NOUN
dpc-4595	81	108	plaques	plaque	NOUN
dpc-4595	81	109	27(67.5	27(67.5	NUM
dpc-4595	81	110	)	)	PUNCT
dpc-4595	81	111	11	11	NUM
dpc-4595	81	112	(	(	PUNCT
dpc-4595	81	113	27.5	27.5	NUM
dpc-4595	81	114	)	)	SYM
dpc-4595	81	115	2	2	NUM
dpc-4595	81	116	(	(	PUNCT
dpc-4595	81	117	5	5	NUM
dpc-4595	81	118	)	)	PUNCT
dpc-4595	81	119	0	0	NUM
dpc-4595	81	120	•	•	NUM
dpc-4595	81	121	dry	dry	ADJ
dpc-4595	81	122	appearance	appearance	NOUN
dpc-4595	81	123	6	6	NUM
dpc-4595	81	124	(	(	PUNCT
dpc-4595	81	125	15.0	15.0	NUM
dpc-4595	81	126	)	)	PUNCT
dpc-4595	81	127	27	27	NUM
dpc-4595	81	128	(	(	PUNCT
dpc-4595	81	129	67.5	67.5	NUM
dpc-4595	81	130	)	)	PUNCT
dpc-4595	81	131	6	6	NUM
dpc-4595	81	132	(	(	PUNCT
dpc-4595	81	133	15.0	15.0	NUM
dpc-4595	81	134	)	)	PUNCT
dpc-4595	81	135	1	1	NUM
dpc-4595	81	136	(	(	PUNCT
dpc-4595	81	137	2.5	2.5	NUM
dpc-4595	81	138	)	)	PUNCT
dpc-4595	81	139	•	•	NUM
dpc-4595	81	140	edema	edema	NOUN
dpc-4595	81	141	27	27	NUM
dpc-4595	81	142	(	(	PUNCT
dpc-4595	81	143	67.5	67.5	NUM
dpc-4595	81	144	)	)	SYM
dpc-4595	81	145	8	8	NUM
dpc-4595	81	146	(	(	PUNCT
dpc-4595	81	147	20.0	20.0	NUM
dpc-4595	81	148	)	)	SYM
dpc-4595	81	149	5	5	NUM
dpc-4595	81	150	(	(	PUNCT
dpc-4595	81	151	12.5	12.5	NUM
dpc-4595	81	152	)	)	PUNCT
dpc-4595	81	153	0	0	NUM
dpc-4595	81	154	•	•	NUM
dpc-4595	81	155	ocular	ocular	ADJ
dpc-4595	81	156	manifestations	manifestation	NOUN
dpc-4595	81	157	39	39	NUM
dpc-4595	81	158	(	(	PUNCT
dpc-4595	81	159	97.5	97.5	NUM
dpc-4595	81	160	)	)	SYM
dpc-4595	81	161	1	1	NUM
dpc-4595	81	162	(	(	PUNCT
dpc-4595	81	163	2.5	2.5	NUM
dpc-4595	81	164	)	)	PUNCT
dpc-4595	81	165	0	0	NUM
dpc-4595	81	166	0	0	NUM
dpc-4595	81	167	•	•	NOUN
dpc-4595	81	168	phymatous	phymatous	ADJ
dpc-4595	81	169	change	change	NOUN
dpc-4595	81	170	36	36	NUM
dpc-4595	81	171	(	(	PUNCT
dpc-4595	81	172	90.0	90.0	NUM
dpc-4595	81	173	)	)	SYM
dpc-4595	81	174	4	4	NUM
dpc-4595	81	175	(	(	PUNCT
dpc-4595	81	176	10.0	10.0	NUM
dpc-4595	81	177	)	)	PUNCT
dpc-4595	81	178	0	0	NUM
dpc-4595	81	179	0	0	NUM
dpc-4595	81	180	physician	physician	NOUN
dpc-4595	81	181	ratings	rating	NOUN
dpc-4595	81	182	by	by	ADP
dpc-4595	81	183	subtype	subtype	NOUN
dpc-4595	81	184	•	•	NOUN
dpc-4595	81	185	et	et	NOUN
dpc-4595	81	186	10	10	NUM
dpc-4595	81	187	(	(	PUNCT
dpc-4595	81	188	25	25	NUM
dpc-4595	81	189	)	)	PUNCT
dpc-4595	81	190	9	9	NUM
dpc-4595	81	191	(	(	PUNCT
dpc-4595	81	192	22.5	22.5	NUM
dpc-4595	81	193	)	)	SYM
dpc-4595	81	194	2	2	NUM
dpc-4595	81	195	(	(	PUNCT
dpc-4595	81	196	5	5	NUM
dpc-4595	81	197	)	)	PUNCT
dpc-4595	81	198	•	•	NOUN
dpc-4595	81	199	pp	pp	ADP
dpc-4595	81	200	7	7	NUM
dpc-4595	81	201	(	(	PUNCT
dpc-4595	81	202	17.5	17.5	NUM
dpc-4595	81	203	)	)	PUNCT
dpc-4595	81	204	6	6	NUM
dpc-4595	81	205	(	(	PUNCT
dpc-4595	81	206	15	15	NUM
dpc-4595	81	207	)	)	PUNCT
dpc-4595	81	208	6	6	NUM
dpc-4595	81	209	(	(	PUNCT
dpc-4595	81	210	15	15	NUM
dpc-4595	81	211	)	)	PUNCT
dpc-4595	81	212	•	•	NOUN
dpc-4595	81	213	phymatous	phymatous	ADJ
dpc-4595	81	214	0	0	NUM
dpc-4595	81	215	•	•	NOUN
dpc-4595	81	216	ocular	ocular	ADJ
dpc-4595	81	217	0	0	NUM
dpc-4595	81	218	patient	patient	NOUN
dpc-4595	81	219	’s	’s	PART
dpc-4595	81	220	global	global	ADJ
dpc-4595	81	221	assessment	assessment	NOUN
dpc-4595	81	222	17	17	NUM
dpc-4595	81	223	(	(	PUNCT
dpc-4595	81	224	42.5	42.5	NUM
dpc-4595	81	225	)	)	SYM
dpc-4595	81	226	15	15	NUM
dpc-4595	81	227	(	(	PUNCT
dpc-4595	81	228	37.5	37.5	NUM
dpc-4595	81	229	)	)	SYM
dpc-4595	81	230	8	8	NUM
dpc-4595	81	231	(	(	PUNCT
dpc-4595	81	232	20	20	NUM
dpc-4595	81	233	)	)	PUNCT
dpc-4595	81	234	abbreviations	abbreviation	NOUN
dpc-4595	81	235	:	:	PUNCT
dpc-4595	81	236	et	et	NOUN
dpc-4595	81	237	:	:	PUNCT
dpc-4595	81	238	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-4595	81	239	;	;	PUNCT
dpc-4595	81	240	pp	pp	ADV
dpc-4595	81	241	:	:	PUNCT
dpc-4595	81	242	papulopustular	papulopustular	ADJ
dpc-4595	81	243	.	.	PUNCT
dpc-4595	81	244	table	table	NOUN
dpc-4595	82	1	3	3	NUM
dpc-4595	82	2	.	.	PUNCT
dpc-4595	82	3	evaluation	evaluation	NOUN
dpc-4595	82	4	of	of	ADP
dpc-4595	82	5	hif-1α	hif-1α	NOUN
dpc-4595	82	6	and	and	CCONJ
dpc-4595	82	7	il-6	il-6	NOUN
dpc-4595	82	8	levels	level	NOUN
dpc-4595	82	9	in	in	ADP
dpc-4595	82	10	patient	patient	ADJ
dpc-4595	82	11	and	and	CCONJ
dpc-4595	82	12	control	control	NOUN
dpc-4595	82	13	groups	group	NOUN
dpc-4595	82	14	.	.	PUNCT
dpc-4595	83	1	patient	patient	NOUN
dpc-4595	83	2	(	(	PUNCT
dpc-4595	83	3	mean±sd	mean±sd	PROPN
dpc-4595	83	4	(	(	PUNCT
dpc-4595	83	5	min	min	NOUN
dpc-4595	83	6	-	-	PUNCT
dpc-4595	83	7	max	max	NOUN
dpc-4595	83	8	)	)	PUNCT
dpc-4595	83	9	)	)	PUNCT
dpc-4595	83	10	control	control	NOUN
dpc-4595	83	11	(	(	PUNCT
dpc-4595	83	12	mean±sd	mean±sd	PROPN
dpc-4595	83	13	(	(	PUNCT
dpc-4595	83	14	min	min	NOUN
dpc-4595	83	15	-	-	PUNCT
dpc-4595	83	16	max	max	NOUN
dpc-4595	83	17	)	)	PUNCT
dpc-4595	83	18	)	)	PUNCT
dpc-4595	83	19	z	z	NOUN
dpc-4595	83	20	;	;	PUNCT
dpc-4595	83	21	p	p	X
dpc-4595	83	22	-	-	PUNCT
dpc-4595	83	23	value	value	NOUN
dpc-4595	83	24	hif-1α	hif-1α	NOUN
dpc-4595	83	25	0.207±0.009	0.207±0.009	NUM
dpc-4595	83	26	(	(	PUNCT
dpc-4595	83	27	0.195	0.195	NUM
dpc-4595	83	28	-	-	SYM
dpc-4595	83	29	0.242	0.242	NUM
dpc-4595	83	30	)	)	PUNCT
dpc-4595	83	31	0.035±0.063	0.035±0.063	NOUN
dpc-4595	83	32	(	(	PUNCT
dpc-4595	83	33	0.03	0.03	NUM
dpc-4595	83	34	-	-	SYM
dpc-4595	83	35	0.317	0.317	NUM
dpc-4595	83	36	)	)	PUNCT
dpc-4595	83	37	6.983	6.983	NUM
dpc-4595	83	38	:	:	PUNCT
dpc-4595	83	39	p<0.01	p<0.01	PROPN
dpc-4595	83	40	il-6	il-6	NOUN
dpc-4595	84	1	0.359±0.184	0.359±0.184	X
dpc-4595	84	2	(	(	PUNCT
dpc-4595	84	3	0.051	0.051	NUM
dpc-4595	84	4	-	-	SYM
dpc-4595	84	5	1.204	1.204	NUM
dpc-4595	84	6	)	)	PUNCT
dpc-4595	84	7	0.072±0.109	0.072±0.109	NUM
dpc-4595	84	8	(	(	PUNCT
dpc-4595	84	9	0.046	0.046	NUM
dpc-4595	84	10	-	-	PUNCT
dpc-4595	84	11	0.742	0.742	NUM
dpc-4595	84	12	)	)	PUNCT
dpc-4595	84	13	6.639	6.639	NUM
dpc-4595	84	14	:	:	PUNCT
dpc-4595	84	15	p<0.01	p<0.01	PROPN
dpc-4595	84	16	abbreviations	abbreviation	NOUN
dpc-4595	84	17	:	:	PUNCT
dpc-4595	84	18	hif	hif	PROPN
dpc-4595	84	19	:	:	PUNCT
dpc-4595	84	20	hypoxia	hypoxia	NOUN
dpc-4595	84	21	-	-	PUNCT
dpc-4595	84	22	inducible	inducible	ADJ
dpc-4595	84	23	factor	factor	NOUN
dpc-4595	84	24	;	;	PUNCT
dpc-4595	84	25	il	il	PROPN
dpc-4595	84	26	:	:	PUNCT
dpc-4595	84	27	interleukin	interleukin	NOUN
dpc-4595	84	28	;	;	PUNCT
dpc-4595	84	29	sd	sd	X
dpc-4595	84	30	:	:	PUNCT
dpc-4595	84	31	standard	standard	ADJ
dpc-4595	84	32	deviation	deviation	NOUN
dpc-4595	84	33	.	.	PUNCT
dpc-4595	84	34	found	find	VERB
dpc-4595	84	35	to	to	PART
dpc-4595	84	36	be	be	AUX
dpc-4595	84	37	statistically	statistically	ADV
dpc-4595	84	38	significantly	significantly	ADV
dpc-4595	84	39	higher	high	ADJ
dpc-4595	84	40	in	in	ADP
dpc-4595	84	41	patients	patient	NOUN
dpc-4595	84	42	with	with	ADP
dpc-4595	84	43	telangiectasia	telangiectasia	NOUN
dpc-4595	84	44	(	(	PUNCT
dpc-4595	84	45	z=2.401	z=2.401	PROPN
dpc-4595	84	46	,	,	PUNCT
dpc-4595	84	47	p	p	X
dpc-4595	84	48	=	=	NOUN
dpc-4595	84	49	0.016	0.016	NUM
dpc-4595	84	50	)	)	PUNCT
dpc-4595	84	51	(	(	PUNCT
dpc-4595	84	52	z=2.401	z=2.401	PROPN
dpc-4595	84	53	,	,	PUNCT
dpc-4595	84	54	p	p	X
dpc-4595	84	55	=	=	PROPN
dpc-4595	84	56	0.016	0.016	NUM
dpc-4595	84	57	)	)	PUNCT
dpc-4595	84	58	,	,	PUNCT
dpc-4595	84	59	although	although	SCONJ
dpc-4595	84	60	no	no	DET
dpc-4595	84	61	correlation	correlation	NOUN
dpc-4595	84	62	was	be	AUX
dpc-4595	84	63	found	find	VERB
dpc-4595	84	64	with	with	ADP
dpc-4595	84	65	the	the	DET
dpc-4595	84	66	severity	severity	NOUN
dpc-4595	84	67	of	of	ADP
dpc-4595	84	68	telangiectasia	telangiectasia	NOUN
dpc-4595	84	69	.	.	PUNCT
dpc-4595	85	1	no	no	DET
dpc-4595	85	2	significant	significant	ADJ
dpc-4595	85	3	association	association	NOUN
dpc-4595	85	4	was	be	AUX
dpc-4595	85	5	found	find	VERB
dpc-4595	85	6	between	between	ADP
dpc-4595	85	7	hif-1α	hif-1α	NOUN
dpc-4595	85	8	and	and	CCONJ
dpc-4595	85	9	il-6	il-6	NOUN
dpc-4595	85	10	levels	level	NOUN
dpc-4595	85	11	and	and	CCONJ
dpc-4595	85	12	the	the	DET
dpc-4595	85	13	primary	primary	ADJ
dpc-4595	85	14	clinical	clinical	ADJ
dpc-4595	85	15	manifestations	manifestation	NOUN
dpc-4595	85	16	flushing	flush	VERB
dpc-4595	85	17	,	,	PUNCT
dpc-4595	85	18	non	non	ADJ
dpc-4595	85	19	-	-	ADJ
dpc-4595	85	20	transient	transient	ADJ
dpc-4595	85	21	erythema	erythema	NOUN
dpc-4595	85	22	,	,	PUNCT
dpc-4595	85	23	and	and	CCONJ
dpc-4595	85	24	papules	papule	NOUN
dpc-4595	85	25	and	and	CCONJ
dpc-4595	85	26	pustules	pustule	NOUN
dpc-4595	85	27	.	.	PUNCT
dpc-4595	86	1	additionally	additionally	ADV
dpc-4595	86	2	,	,	PUNCT
dpc-4595	86	3	no	no	DET
dpc-4595	86	4	significant	significant	ADJ
dpc-4595	86	5	relationship	relationship	NOUN
dpc-4595	86	6	was	be	AUX
dpc-4595	86	7	found	find	VERB
dpc-4595	86	8	between	between	ADP
dpc-4595	86	9	the	the	DET
dpc-4595	86	10	secondary	secondary	ADJ
dpc-4595	86	11	clinical	clinical	ADJ
dpc-4595	86	12	manifestations	manifestation	NOUN
dpc-4595	86	13	of	of	ADP
dpc-4595	86	14	rosacea	rosacea	NOUN
dpc-4595	86	15	and	and	CCONJ
dpc-4595	86	16	hif-1a	hif-1a	PROPN
dpc-4595	86	17	or	or	CCONJ
dpc-4595	86	18	il-6	il-6	NOUN
dpc-4595	86	19	levels	level	NOUN
dpc-4595	86	20	(	(	PUNCT
dpc-4595	86	21	p	p	X
dpc-4595	86	22	>	>	X
dpc-4595	86	23	0.05	0.05	NUM
dpc-4595	86	24	for	for	ADP
dpc-4595	86	25	each	each	PRON
dpc-4595	86	26	)	)	PUNCT
dpc-4595	86	27	.	.	PUNCT
dpc-4595	87	1	discussion	discussion	NOUN
dpc-4595	87	2	while	while	SCONJ
dpc-4595	87	3	greater	great	ADJ
dpc-4595	87	4	il-6	il-6	NOUN
dpc-4595	87	5	expression	expression	NOUN
dpc-4595	87	6	has	have	AUX
dpc-4595	87	7	been	be	AUX
dpc-4595	87	8	demonstrated	demonstrate	VERB
dpc-4595	87	9	multiple	multiple	ADJ
dpc-4595	87	10	times	time	NOUN
dpc-4595	87	11	in	in	ADP
dpc-4595	87	12	tissue	tissue	NOUN
dpc-4595	87	13	studies	study	NOUN
dpc-4595	87	14	,	,	PUNCT
dpc-4595	87	15	no	no	DET
dpc-4595	87	16	consensus	consensus	NOUN
dpc-4595	87	17	has	have	AUX
dpc-4595	87	18	been	be	AUX
dpc-4595	87	19	reached	reach	VERB
dpc-4595	87	20	regarding	regard	VERB
dpc-4595	87	21	serum	serum	NOUN
dpc-4595	87	22	levels	level	NOUN
dpc-4595	87	23	.	.	PUNCT
dpc-4595	88	1	specifically	specifically	ADV
dpc-4595	88	2	,	,	PUNCT
dpc-4595	88	3	in	in	ADP
dpc-4595	88	4	a	a	DET
dpc-4595	88	5	study	study	NOUN
dpc-4595	88	6	by	by	ADP
dpc-4595	88	7	ertekin	ertekin	PROPN
dpc-4595	88	8	et	et	PROPN
dpc-4595	88	9	al	al	PROPN
dpc-4595	88	10	.	.	PROPN
dpc-4595	88	11	,	,	PUNCT
dpc-4595	88	12	il-6	il-6	NUM
dpc-4595	89	1	levels	level	NOUN
dpc-4595	89	2	were	be	AUX
dpc-4595	89	3	found	find	VERB
dpc-4595	89	4	to	to	PART
dpc-4595	89	5	be	be	AUX
dpc-4595	89	6	higher	high	ADJ
dpc-4595	89	7	and	and	CCONJ
dpc-4595	89	8	associated	associate	VERB
dpc-4595	89	9	with	with	ADP
dpc-4595	89	10	disease	disease	NOUN
dpc-4595	89	11	severity	severity	NOUN
dpc-4595	89	12	in	in	ADP
dpc-4595	89	13	rosacea	rosacea	NOUN
dpc-4595	89	14	patients	patient	NOUN
dpc-4595	90	1	[	[	X
dpc-4595	90	2	9–15	9–15	PROPN
dpc-4595	90	3	]	]	PUNCT
dpc-4595	90	4	.	.	PUNCT
dpc-4595	91	1	additionally	additionally	ADV
dpc-4595	91	2	,	,	PUNCT
dpc-4595	91	3	il-6	il-6	PRON
dpc-4595	91	4	has	have	AUX
dpc-4595	91	5	been	be	AUX
dpc-4595	91	6	reported	report	VERB
dpc-4595	91	7	to	to	PART
dpc-4595	91	8	play	play	VERB
dpc-4595	91	9	a	a	DET
dpc-4595	91	10	role	role	NOUN
dpc-4595	91	11	in	in	ADP
dpc-4595	91	12	the	the	DET
dpc-4595	91	13	pathogenesis	pathogenesis	NOUN
dpc-4595	91	14	of	of	ADP
dpc-4595	91	15	rhinophyma	rhinophyma	NOUN
dpc-4595	91	16	in	in	ADP
dpc-4595	91	17	conjunction	conjunction	NOUN
dpc-4595	91	18	with	with	ADP
dpc-4595	91	19	transforming	transform	VERB
dpc-4595	91	20	growth	growth	NOUN
dpc-4595	91	21	factor	factor	NOUN
dpc-4595	91	22	-	-	PUNCT
dpc-4595	91	23	beta	beta	NOUN
dpc-4595	91	24	(	(	PUNCT
dpc-4595	91	25	tgf	tgf	PROPN
dpc-4595	91	26	-	-	PUNCT
dpc-4595	91	27	β	β	NOUN
dpc-4595	91	28	)	)	PUNCT
dpc-4595	92	1	[	[	X
dpc-4595	92	2	3	3	NUM
dpc-4595	92	3	]	]	PUNCT
dpc-4595	92	4	.	.	PUNCT
dpc-4595	93	1	furthermore	furthermore	ADV
dpc-4595	93	2	,	,	PUNCT
dpc-4595	93	3	timolol	timolol	VERB
dpc-4595	93	4	,	,	PUNCT
dpc-4595	93	5	a	a	DET
dpc-4595	93	6	non	non	ADJ
dpc-4595	93	7	-	-	ADJ
dpc-4595	93	8	selective	selective	ADJ
dpc-4595	93	9	β	β	ADJ
dpc-4595	93	10	-	-	ADJ
dpc-4595	93	11	adrenergic	adrenergic	ADJ
dpc-4595	93	12	receptor	receptor	NOUN
dpc-4595	93	13	blocker	blocker	NOUN
dpc-4595	93	14	,	,	PUNCT
dpc-4595	93	15	exhibits	exhibit	VERB
dpc-4595	93	16	vasoconstrictive	vasoconstrictive	ADJ
dpc-4595	93	17	and	and	CCONJ
dpc-4595	93	18	anti	anti	ADJ
dpc-4595	93	19	-	-	ADJ
dpc-4595	93	20	angiogenic	angiogenic	ADJ
dpc-4595	93	21	effects	effect	NOUN
dpc-4595	93	22	by	by	ADP
dpc-4595	93	23	modulating	modulate	VERB
dpc-4595	93	24	the	the	DET
dpc-4595	93	25	activity	activity	NOUN
dpc-4595	93	26	of	of	ADP
dpc-4595	93	27	matrix	matrix	NOUN
dpc-4595	93	28	metalloproteinases	metalloproteinase	NOUN
dpc-4595	93	29	  	  	SPACE
dpc-4595	93	30	(	(	PUNCT
dpc-4595	93	31	mmps	mmp	NOUN
dpc-4595	93	32	)	)	PUNCT
dpc-4595	93	33	and	and	CCONJ
dpc-4595	93	34	il-6	il-6	NOUN
dpc-4595	93	35	,	,	PUNCT
dpc-4595	93	36	and	and	CCONJ
dpc-4595	93	37	reducing	reduce	VERB
dpc-4595	93	38	vegf	vegf	NOUN
dpc-4595	93	39	expression	expression	NOUN
dpc-4595	93	40	.	.	PUNCT
dpc-4595	94	1	moreover	moreover	ADV
dpc-4595	94	2	,	,	PUNCT
dpc-4595	94	3	metronidazole	metronidazole	NOUN
dpc-4595	94	4	,	,	PUNCT
dpc-4595	94	5	an	an	DET
dpc-4595	94	6	antimicrobial	antimicrobial	ADJ
dpc-4595	94	7	agent	agent	NOUN
dpc-4595	94	8	used	use	VERB
dpc-4595	94	9	in	in	ADP
dpc-4595	94	10	treatment	treatment	NOUN
dpc-4595	94	11	for	for	ADP
dpc-4595	94	12	its	its	PRON
dpc-4595	94	13	anti	anti	ADJ
dpc-4595	94	14	-	-	ADJ
dpc-4595	94	15	demodex	demodex	ADJ
dpc-4595	94	16	and	and	CCONJ
dpc-4595	94	17	anti	anti	ADJ
dpc-4595	94	18	-	-	ADJ
dpc-4595	94	19	inflammatory	inflammatory	ADJ
dpc-4595	94	20	properties	property	NOUN
dpc-4595	94	21	,	,	PUNCT
dpc-4595	94	22	has	have	AUX
dpc-4595	94	23	been	be	AUX
dpc-4595	94	24	shown	show	VERB
dpc-4595	94	25	to	to	PART
dpc-4595	94	26	impair	impair	VERB
dpc-4595	94	27	the	the	DET
dpc-4595	94	28	induction	induction	NOUN
dpc-4595	94	29	of	of	ADP
dpc-4595	94	30	il-17	il-17	NUM
dpc-4595	94	31	both	both	PRON
dpc-4595	94	32	directly	directly	ADV
dpc-4595	94	33	and	and	CCONJ
dpc-4595	94	34	indirectly	indirectly	ADV
dpc-4595	94	35	via	via	ADP
dpc-4595	94	36	the	the	DET
dpc-4595	94	37	suppression	suppression	NOUN
dpc-4595	94	38	of	of	ADP
dpc-4595	94	39	il-6	il-6	NUM
dpc-4595	94	40	and	and	CCONJ
dpc-4595	94	41	chemokine	chemokine	ADJ
dpc-4595	94	42	(	(	PUNCT
dpc-4595	94	43	c	c	NOUN
dpc-4595	94	44	-	-	PUNCT
dpc-4595	94	45	x	x	NOUN
dpc-4595	94	46	-	-	NOUN
dpc-4595	94	47	c	c	NOUN
dpc-4595	94	48	motif	motif	NOUN
dpc-4595	94	49	)	)	PUNCT
dpc-4595	94	50	ligand-8	ligand-8	NUM
dpc-4595	94	51	(	(	PUNCT
dpc-4595	94	52	cxcl-8	cxcl-8	NOUN
dpc-4595	94	53	)	)	PUNCT
dpc-4595	95	1	[	[	X
dpc-4595	95	2	16	16	NUM
dpc-4595	95	3	]	]	PUNCT
dpc-4595	95	4	.	.	PUNCT
dpc-4595	96	1	to	to	ADP
dpc-4595	96	2	our	our	PRON
dpc-4595	96	3	knowledge	knowledge	NOUN
dpc-4595	96	4	,	,	PUNCT
dpc-4595	96	5	serum	serum	NOUN
dpc-4595	96	6	hif-1α	hif-1α	NOUN
dpc-4595	96	7	levels	level	NOUN
dpc-4595	96	8	in	in	ADP
dpc-4595	96	9	rosacea	rosacea	NOUN
dpc-4595	96	10	patients	patient	NOUN
dpc-4595	96	11	have	have	AUX
dpc-4595	96	12	not	not	PART
dpc-4595	96	13	been	be	AUX
dpc-4595	96	14	explored	explore	VERB
dpc-4595	96	15	.	.	PUNCT
dpc-4595	97	1	our	our	PRON
dpc-4595	97	2	findings	finding	NOUN
dpc-4595	97	3	revealed	reveal	VERB
dpc-4595	97	4	that	that	SCONJ
dpc-4595	97	5	,	,	PUNCT
dpc-4595	97	6	compared	compare	VERB
dpc-4595	97	7	to	to	ADP
dpc-4595	97	8	those	those	PRON
dpc-4595	97	9	in	in	ADP
dpc-4595	97	10	the	the	DET
dpc-4595	97	11	control	control	NOUN
dpc-4595	97	12	group	group	NOUN
dpc-4595	97	13	,	,	PUNCT
dpc-4595	97	14	patients	patient	NOUN
dpc-4595	97	15	with	with	ADP
dpc-4595	97	16	rosacea	rosacea	NOUN
dpc-4595	97	17	exhibited	exhibit	VERB
dpc-4595	97	18	significantly	significantly	ADV
dpc-4595	97	19	higher	high	ADJ
dpc-4595	97	20	concentrations	concentration	NOUN
dpc-4595	97	21	of	of	ADP
dpc-4595	97	22	both	both	PRON
dpc-4595	97	23	serum	serum	VERB
dpc-4595	97	24	hif-1α	hif-1α	NOUN
dpc-4595	97	25	and	and	CCONJ
dpc-4595	97	26	serum	serum	VERB
dpc-4595	97	27	il-6	il-6	NUM
dpc-4595	97	28	.	.	PUNCT
dpc-4595	98	1	we	we	PRON
dpc-4595	98	2	found	find	VERB
dpc-4595	98	3	a	a	DET
dpc-4595	98	4	significant	significant	ADJ
dpc-4595	98	5	association	association	NOUN
dpc-4595	98	6	between	between	ADP
dpc-4595	98	7	the	the	DET
dpc-4595	98	8	hif-1α	hif-1α	NOUN
dpc-4595	98	9	level	level	NOUN
dpc-4595	98	10	and	and	CCONJ
dpc-4595	98	11	the	the	DET
dpc-4595	98	12	severity	severity	NOUN
dpc-4595	98	13	of	of	ADP
dpc-4595	98	14	the	the	DET
dpc-4595	98	15	disease	disease	NOUN
dpc-4595	98	16	,	,	PUNCT
dpc-4595	98	17	but	but	CCONJ
dpc-4595	98	18	we	we	PRON
dpc-4595	98	19	did	do	AUX
dpc-4595	98	20	not	not	PART
dpc-4595	98	21	find	find	VERB
dpc-4595	98	22	an	an	DET
dpc-4595	98	23	association	association	NOUN
dpc-4595	98	24	between	between	ADP
dpc-4595	98	25	the	the	DET
dpc-4595	98	26	il-6	il-6	NUM
dpc-4595	98	27	level	level	NOUN
dpc-4595	98	28	and	and	CCONJ
dpc-4595	98	29	the	the	DET
dpc-4595	98	30	severity	severity	NOUN
dpc-4595	98	31	of	of	ADP
dpc-4595	98	32	the	the	DET
dpc-4595	98	33	disease	disease	NOUN
dpc-4595	98	34	.	.	PUNCT
dpc-4595	99	1	original	original	ADJ
dpc-4595	99	2	article	article	NOUN
dpc-4595	99	3	|	|	ADV
dpc-4595	99	4	dermatol	dermatol	ADJ
dpc-4595	99	5	pract	pract	NOUN
dpc-4595	99	6	concept	concept	NOUN
dpc-4595	99	7	.	.	PUNCT
dpc-4595	100	1	2024;14(4):e2024267	2024;14(4):e2024267	NUM
dpc-4595	100	2	5	5	NUM
dpc-4595	100	3	significant	significant	ADJ
dpc-4595	100	4	activation	activation	NOUN
dpc-4595	100	5	of	of	ADP
dpc-4595	100	6	the	the	DET
dpc-4595	100	7	immune	immune	ADJ
dpc-4595	100	8	system	system	NOUN
dpc-4595	100	9	has	have	AUX
dpc-4595	100	10	been	be	AUX
dpc-4595	100	11	shown	show	VERB
dpc-4595	100	12	in	in	ADP
dpc-4595	100	13	all	all	DET
dpc-4595	100	14	subtypes	subtype	NOUN
dpc-4595	100	15	of	of	ADP
dpc-4595	100	16	rosacea	rosacea	NOUN
dpc-4595	100	17	:	:	PUNCT
dpc-4595	100	18	the	the	DET
dpc-4595	100	19	increase	increase	NOUN
dpc-4595	100	20	in	in	ADP
dpc-4595	100	21	interferon	interferon	NOUN
dpc-4595	100	22	(	(	PUNCT
dpc-4595	100	23	ifn)-γ	ifn)-γ	NOUN
dpc-4595	100	24	and	and	CCONJ
dpc-4595	100	25	il-17	il-17	NUM
dpc-4595	100	26	cytokines	cytokine	NOUN
dpc-4595	100	27	leads	lead	VERB
dpc-4595	100	28	to	to	ADP
dpc-4595	100	29	th-1	th-1	PRON
dpc-4595	100	30	and	and	CCONJ
dpc-4595	100	31	th-17	th-17	ADP
dpc-4595	100	32	polarization	polarization	NOUN
dpc-4595	100	33	(	(	PUNCT
dpc-4595	100	34	12	12	NUM
dpc-4595	100	35	)	)	PUNCT
dpc-4595	100	36	,	,	PUNCT
dpc-4595	100	37	and	and	CCONJ
dpc-4595	100	38	the	the	DET
dpc-4595	100	39	deficiency	deficiency	NOUN
dpc-4595	100	40	in	in	ADP
dpc-4595	100	41	hif-1α	hif-1α	NOUN
dpc-4595	100	42	leads	lead	VERB
dpc-4595	100	43	to	to	ADP
dpc-4595	100	44	a	a	DET
dpc-4595	100	45	reduction	reduction	NOUN
dpc-4595	100	46	in	in	ADP
dpc-4595	100	47	th-17	th-17	NUM
dpc-4595	100	48	development	development	NOUN
dpc-4595	100	49	and	and	CCONJ
dpc-4595	100	50	an	an	DET
dpc-4595	100	51	increase	increase	NOUN
dpc-4595	100	52	in	in	ADP
dpc-4595	100	53	the	the	DET
dpc-4595	100	54	differentiation	differentiation	NOUN
dpc-4595	100	55	of	of	ADP
dpc-4595	100	56	t	t	PROPN
dpc-4595	100	57	-	-	PUNCT
dpc-4595	100	58	reg	reg	NOUN
dpc-4595	100	59	cells	cell	NOUN
dpc-4595	100	60	.	.	PUNCT
dpc-4595	101	1	earlier	early	ADJ
dpc-4595	101	2	work	work	NOUN
dpc-4595	101	3	has	have	AUX
dpc-4595	101	4	demonstrated	demonstrate	VERB
dpc-4595	101	5	that	that	SCONJ
dpc-4595	101	6	the	the	DET
dpc-4595	101	7	hif-1α	hif-1α	NOUN
dpc-4595	101	8	-	-	PUNCT
dpc-4595	101	9	dependent	dependent	ADJ
dpc-4595	101	10	glycolytic	glycolytic	ADJ
dpc-4595	101	11	pathway	pathway	NOUN
dpc-4595	101	12	serves	serve	VERB
dpc-4595	101	13	as	as	ADP
dpc-4595	101	14	a	a	DET
dpc-4595	101	15	metabolic	metabolic	NOUN
dpc-4595	101	16	control	control	NOUN
dpc-4595	101	17	point	point	NOUN
dpc-4595	101	18	that	that	PRON
dpc-4595	101	19	regulates	regulate	VERB
dpc-4595	101	20	the	the	DET
dpc-4595	101	21	differentiation	differentiation	NOUN
dpc-4595	101	22	of	of	ADP
dpc-4595	101	23	both	both	PRON
dpc-4595	101	24	th-17	th-17	NOUN
dpc-4595	101	25	and	and	CCONJ
dpc-4595	101	26	t	t	PROPN
dpc-4595	101	27	-	-	PUNCT
dpc-4595	101	28	reg	reg	NOUN
dpc-4595	101	29	cells	cell	NOUN
dpc-4595	101	30	[	[	X
dpc-4595	101	31	7	7	NUM
dpc-4595	101	32	]	]	PUNCT
dpc-4595	101	33	.	.	PUNCT
dpc-4595	102	1	furthermore	furthermore	ADV
dpc-4595	102	2	,	,	PUNCT
dpc-4595	102	3	patients	patient	NOUN
dpc-4595	102	4	with	with	ADP
dpc-4595	102	5	rosacea	rosacea	NOUN
dpc-4595	102	6	exhibit	exhibit	VERB
dpc-4595	102	7	an	an	DET
dpc-4595	102	8	increase	increase	NOUN
dpc-4595	102	9	in	in	ADP
dpc-4595	102	10	the	the	DET
dpc-4595	102	11	genes	gene	NOUN
dpc-4595	102	12	that	that	PRON
dpc-4595	102	13	provide	provide	VERB
dpc-4595	102	14	th-17	th-17	NUM
dpc-4595	102	15	polarization	polarization	NOUN
dpc-4595	102	16	in	in	ADP
dpc-4595	102	17	tissue	tissue	NOUN
dpc-4595	102	18	,	,	PUNCT
dpc-4595	102	19	and	and	CCONJ
dpc-4595	102	20	the	the	DET
dpc-4595	102	21	amount	amount	NOUN
dpc-4595	102	22	of	of	ADP
dpc-4595	102	23	il-17	il-17	PRON
dpc-4595	102	24	was	be	AUX
dpc-4595	102	25	also	also	ADV
dpc-4595	102	26	found	find	VERB
dpc-4595	102	27	to	to	PART
dpc-4595	102	28	be	be	AUX
dpc-4595	102	29	increased	increase	VERB
dpc-4595	102	30	in	in	ADP
dpc-4595	102	31	both	both	PRON
dpc-4595	102	32	tissue	tissue	NOUN
dpc-4595	102	33	and	and	CCONJ
dpc-4595	102	34	serum	serum	NOUN
dpc-4595	102	35	samples	sample	NOUN
dpc-4595	102	36	[	[	X
dpc-4595	102	37	12,17	12,17	NUM
dpc-4595	102	38	]	]	PUNCT
dpc-4595	102	39	.	.	PUNCT
dpc-4595	103	1	it	it	PRON
dpc-4595	103	2	has	have	AUX
dpc-4595	103	3	been	be	AUX
dpc-4595	103	4	suggested	suggest	VERB
dpc-4595	103	5	that	that	SCONJ
dpc-4595	103	6	serum	serum	NOUN
dpc-4595	103	7	il-17	il-17	NUM
dpc-4595	103	8	levels	level	NOUN
dpc-4595	103	9	are	be	AUX
dpc-4595	103	10	not	not	PART
dpc-4595	103	11	associated	associate	VERB
dpc-4595	103	12	with	with	ADP
dpc-4595	103	13	the	the	DET
dpc-4595	103	14	severity	severity	NOUN
dpc-4595	103	15	of	of	ADP
dpc-4595	103	16	rosacea	rosacea	NOUN
dpc-4595	103	17	,	,	PUNCT
dpc-4595	103	18	although	although	SCONJ
dpc-4595	103	19	they	they	PRON
dpc-4595	103	20	may	may	AUX
dpc-4595	103	21	play	play	VERB
dpc-4595	103	22	a	a	DET
dpc-4595	103	23	role	role	NOUN
dpc-4595	103	24	in	in	ADP
dpc-4595	103	25	its	its	PRON
dpc-4595	103	26	pathogenesis	pathogenesis	NOUN
dpc-4595	103	27	[	[	X
dpc-4595	103	28	17	17	NUM
dpc-4595	103	29	]	]	PUNCT
dpc-4595	103	30	.	.	PUNCT
dpc-4595	104	1	the	the	DET
dpc-4595	104	2	overexpression	overexpression	NOUN
dpc-4595	104	3	of	of	ADP
dpc-4595	104	4	hif-1α	hif-1α	NOUN
dpc-4595	104	5	has	have	AUX
dpc-4595	104	6	been	be	AUX
dpc-4595	104	7	demonstrated	demonstrate	VERB
dpc-4595	104	8	in	in	ADP
dpc-4595	104	9	various	various	ADJ
dpc-4595	104	10	autoimmune	autoimmune	ADJ
dpc-4595	104	11	conditions	condition	NOUN
dpc-4595	104	12	,	,	PUNCT
dpc-4595	104	13	including	include	VERB
dpc-4595	104	14	systemic	systemic	ADJ
dpc-4595	104	15	lupus	lupus	PROPN
dpc-4595	104	16	erythematosus	erythematosus	NOUN
dpc-4595	104	17	,	,	PUNCT
dpc-4595	104	18	inflammatory	inflammatory	ADJ
dpc-4595	104	19	bowel	bowel	NOUN
dpc-4595	104	20	disease	disease	NOUN
dpc-4595	104	21	,	,	PUNCT
dpc-4595	104	22	rheumatoid	rheumatoid	NOUN
dpc-4595	104	23	arthritis	arthritis	NOUN
dpc-4595	104	24	,	,	PUNCT
dpc-4595	104	25	systemic	systemic	ADJ
dpc-4595	104	26	sclerosis	sclerosis	NOUN
dpc-4595	104	27	,	,	PUNCT
dpc-4595	104	28	multiple	multiple	ADJ
dpc-4595	104	29	sclerosis	sclerosis	NOUN
dpc-4595	104	30	,	,	PUNCT
dpc-4595	104	31	and	and	CCONJ
dpc-4595	104	32	psoriasis	psoriasis	NOUN
dpc-4595	104	33	[	[	X
dpc-4595	104	34	18	18	NUM
dpc-4595	104	35	]	]	PUNCT
dpc-4595	104	36	.	.	PUNCT
dpc-4595	105	1	investigation	investigation	NOUN
dpc-4595	105	2	of	of	ADP
dpc-4595	105	3	chronic	chronic	ADJ
dpc-4595	105	4	inflammatory	inflammatory	ADJ
dpc-4595	105	5	processes	process	NOUN
dpc-4595	105	6	and	and	CCONJ
dpc-4595	105	7	comorbidities	comorbiditie	NOUN
dpc-4595	105	8	constitutes	constitute	VERB
dpc-4595	105	9	an	an	DET
dpc-4595	105	10	intriguing	intriguing	ADJ
dpc-4595	105	11	aspect	aspect	NOUN
dpc-4595	105	12	of	of	ADP
dpc-4595	105	13	the	the	DET
dpc-4595	105	14	pathogenesis	pathogenesis	NOUN
dpc-4595	105	15	of	of	ADP
dpc-4595	105	16	rosacea	rosacea	NOUN
dpc-4595	105	17	.	.	PUNCT
dpc-4595	106	1	in	in	ADP
dpc-4595	106	2	this	this	DET
dpc-4595	106	3	context	context	NOUN
dpc-4595	106	4	,	,	PUNCT
dpc-4595	106	5	numerous	numerous	ADJ
dpc-4595	106	6	studies	study	NOUN
dpc-4595	106	7	have	have	AUX
dpc-4595	106	8	been	be	AUX
dpc-4595	106	9	conducted	conduct	VERB
dpc-4595	106	10	to	to	PART
dpc-4595	106	11	elucidate	elucidate	VERB
dpc-4595	106	12	the	the	DET
dpc-4595	106	13	involvement	involvement	NOUN
dpc-4595	106	14	of	of	ADP
dpc-4595	106	15	oxidative	oxidative	ADJ
dpc-4595	106	16	stress	stress	NOUN
dpc-4595	106	17	,	,	PUNCT
dpc-4595	106	18	antioxidant	antioxidant	ADJ
dpc-4595	106	19	levels	level	NOUN
dpc-4595	106	20	,	,	PUNCT
dpc-4595	106	21	and	and	CCONJ
dpc-4595	106	22	levels	level	NOUN
dpc-4595	106	23	of	of	ADP
dpc-4595	106	24	proinflammatory	proinflammatory	ADJ
dpc-4595	106	25	/	/	SYM
dpc-4595	106	26	inflammatory	inflammatory	ADJ
dpc-4595	106	27	mediators	mediator	NOUN
dpc-4595	106	28	and	and	CCONJ
dpc-4595	106	29	markers	marker	NOUN
dpc-4595	106	30	.	.	PUNCT
dpc-4595	107	1	the	the	DET
dpc-4595	107	2	majority	majority	NOUN
dpc-4595	107	3	of	of	ADP
dpc-4595	107	4	such	such	ADJ
dpc-4595	107	5	studies	study	NOUN
dpc-4595	107	6	have	have	AUX
dpc-4595	107	7	demonstrated	demonstrate	VERB
dpc-4595	107	8	an	an	DET
dpc-4595	107	9	increase	increase	NOUN
dpc-4595	107	10	in	in	ADP
dpc-4595	107	11	these	these	DET
dpc-4595	107	12	markers	marker	NOUN
dpc-4595	107	13	compared	compare	VERB
dpc-4595	107	14	to	to	ADP
dpc-4595	107	15	the	the	DET
dpc-4595	107	16	control	control	NOUN
dpc-4595	107	17	group	group	NOUN
dpc-4595	107	18	;	;	PUNCT
dpc-4595	107	19	however	however	ADV
dpc-4595	107	20	,	,	PUNCT
dpc-4595	107	21	in	in	ADP
dpc-4595	107	22	most	most	ADJ
dpc-4595	107	23	studies	study	NOUN
dpc-4595	107	24	,	,	PUNCT
dpc-4595	107	25	these	these	DET
dpc-4595	107	26	markers	marker	NOUN
dpc-4595	107	27	have	have	AUX
dpc-4595	107	28	not	not	PART
dpc-4595	107	29	been	be	AUX
dpc-4595	107	30	found	find	VERB
dpc-4595	107	31	to	to	PART
dpc-4595	107	32	be	be	AUX
dpc-4595	107	33	associated	associate	VERB
dpc-4595	107	34	with	with	ADP
dpc-4595	107	35	disease	disease	NOUN
dpc-4595	107	36	severity	severity	NOUN
dpc-4595	107	37	but	but	CCONJ
dpc-4595	107	38	rather	rather	ADV
dpc-4595	107	39	have	have	AUX
dpc-4595	107	40	been	be	AUX
dpc-4595	107	41	more	more	ADV
dpc-4595	107	42	closely	closely	ADV
dpc-4595	107	43	linked	link	VERB
dpc-4595	107	44	to	to	ADP
dpc-4595	107	45	pathogenesis	pathogenesis	NOUN
dpc-4595	107	46	 	 	SPACE
dpc-4595	108	1	[	[	X
dpc-4595	108	2	14	14	NUM
dpc-4595	108	3	]	]	PUNCT
dpc-4595	108	4	.	.	PUNCT
dpc-4595	109	1	in	in	ADP
dpc-4595	109	2	our	our	PRON
dpc-4595	109	3	study	study	NOUN
dpc-4595	109	4	,	,	PUNCT
dpc-4595	109	5	we	we	PRON
dpc-4595	109	6	identified	identify	VERB
dpc-4595	109	7	an	an	DET
dpc-4595	109	8	association	association	NOUN
dpc-4595	109	9	between	between	ADP
dpc-4595	109	10	the	the	DET
dpc-4595	109	11	level	level	NOUN
dpc-4595	109	12	of	of	ADP
dpc-4595	109	13	hif-1α	hif-1α	NOUN
dpc-4595	109	14	and	and	CCONJ
dpc-4595	109	15	disease	disease	NOUN
dpc-4595	109	16	severity	severity	NOUN
dpc-4595	109	17	,	,	PUNCT
dpc-4595	109	18	which	which	PRON
dpc-4595	109	19	indicates	indicate	VERB
dpc-4595	109	20	both	both	DET
dpc-4595	109	21	its	its	PRON
dpc-4595	109	22	role	role	NOUN
dpc-4595	109	23	in	in	ADP
dpc-4595	109	24	pathogenesis	pathogenesis	NOUN
dpc-4595	109	25	and	and	CCONJ
dpc-4595	109	26	its	its	PRON
dpc-4595	109	27	potential	potential	ADJ
dpc-4595	109	28	use	use	NOUN
dpc-4595	109	29	as	as	ADP
dpc-4595	109	30	an	an	DET
dpc-4595	109	31	indicator	indicator	NOUN
dpc-4595	109	32	of	of	ADP
dpc-4595	109	33	severity	severity	NOUN
dpc-4595	109	34	.	.	PUNCT
dpc-4595	110	1	the	the	DET
dpc-4595	110	2	participants	participant	NOUN
dpc-4595	110	3	in	in	ADP
dpc-4595	110	4	this	this	DET
dpc-4595	110	5	study	study	NOUN
dpc-4595	110	6	included	include	VERB
dpc-4595	110	7	patients	patient	NOUN
dpc-4595	110	8	with	with	ADP
dpc-4595	110	9	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-4595	110	10	rosacea	rosacea	NOUN
dpc-4595	110	11	.	.	PUNCT
dpc-4595	111	1	although	although	SCONJ
dpc-4595	111	2	no	no	DET
dpc-4595	111	3	study	study	NOUN
dpc-4595	111	4	has	have	AUX
dpc-4595	111	5	directly	directly	ADV
dpc-4595	111	6	shown	show	VERB
dpc-4595	111	7	an	an	DET
dpc-4595	111	8	increased	increase	VERB
dpc-4595	111	9	expression	expression	NOUN
dpc-4595	111	10	of	of	ADP
dpc-4595	111	11	hif-1α	hif-1α	NOUN
dpc-4595	111	12	in	in	ADP
dpc-4595	111	13	the	the	DET
dpc-4595	111	14	tissue	tissue	NOUN
dpc-4595	111	15	of	of	ADP
dpc-4595	111	16	patients	patient	NOUN
dpc-4595	111	17	with	with	ADP
dpc-4595	111	18	rosacea	rosacea	NOUN
dpc-4595	111	19	,	,	PUNCT
dpc-4595	111	20	the	the	DET
dpc-4595	111	21	presence	presence	NOUN
dpc-4595	111	22	of	of	ADP
dpc-4595	111	23	th-17	th-17	NUM
dpc-4595	111	24	polarization	polarization	NOUN
dpc-4595	111	25	and	and	CCONJ
dpc-4595	111	26	the	the	DET
dpc-4595	111	27	elevated	elevated	ADJ
dpc-4595	111	28	expression	expression	NOUN
dpc-4595	111	29	of	of	ADP
dpc-4595	111	30	cytokines	cytokine	NOUN
dpc-4595	111	31	such	such	ADJ
dpc-4595	111	32	as	as	ADP
dpc-4595	111	33	il-6	il-6	NUM
dpc-4595	111	34	and	and	CCONJ
dpc-4595	111	35	vegf	vegf	PROPN
dpc-4595	111	36	in	in	ADP
dpc-4595	111	37	these	these	DET
dpc-4595	111	38	patients	patient	NOUN
dpc-4595	111	39	suggests	suggest	VERB
dpc-4595	111	40	a	a	DET
dpc-4595	111	41	potential	potential	ADJ
dpc-4595	111	42	increase	increase	NOUN
dpc-4595	111	43	in	in	ADP
dpc-4595	111	44	hif-1α	hif-1α	NOUN
dpc-4595	111	45	levels	level	NOUN
dpc-4595	111	46	.	.	PUNCT
dpc-4595	112	1	earlier	early	ADV
dpc-4595	112	2	observed	observe	VERB
dpc-4595	112	3	decreases	decrease	NOUN
dpc-4595	112	4	in	in	ADP
dpc-4595	112	5	hif-1α	hif-1α	NOUN
dpc-4595	112	6	expression	expression	NOUN
dpc-4595	112	7	following	follow	VERB
dpc-4595	112	8	the	the	DET
dpc-4595	112	9	application	application	NOUN
dpc-4595	112	10	of	of	ADP
dpc-4595	112	11	green	green	ADJ
dpc-4595	112	12	tea	tea	NOUN
dpc-4595	112	13	extract	extract	NOUN
dpc-4595	112	14	further	far	ADV
dpc-4595	112	15	support	support	VERB
dpc-4595	112	16	his	his	PRON
dpc-4595	112	17	hypothesis	hypothesis	NOUN
dpc-4595	112	18	[	[	X
dpc-4595	112	19	17,19,20	17,19,20	NUM
dpc-4595	112	20	]	]	X
dpc-4595	112	21	.	.	PUNCT
dpc-4595	113	1	in	in	ADP
dpc-4595	113	2	our	our	PRON
dpc-4595	113	3	study	study	NOUN
dpc-4595	113	4	,	,	PUNCT
dpc-4595	113	5	we	we	PRON
dpc-4595	113	6	found	find	VERB
dpc-4595	113	7	an	an	DET
dpc-4595	113	8	association	association	NOUN
dpc-4595	113	9	between	between	ADP
dpc-4595	113	10	the	the	DET
dpc-4595	113	11	level	level	NOUN
dpc-4595	113	12	of	of	ADP
dpc-4595	113	13	hif-1α	hif-1α	NOUN
dpc-4595	113	14	and	and	CCONJ
dpc-4595	113	15	the	the	DET
dpc-4595	113	16	presence	presence	NOUN
dpc-4595	113	17	of	of	ADP
dpc-4595	113	18	telangiectasia	telangiectasia	NOUN
dpc-4595	113	19	in	in	ADP
dpc-4595	113	20	patients	patient	NOUN
dpc-4595	113	21	.	.	PUNCT
dpc-4595	114	1	we	we	PRON
dpc-4595	114	2	hypothesize	hypothesize	VERB
dpc-4595	114	3	that	that	SCONJ
dpc-4595	114	4	hif-1α	hif-1α	NOUN
dpc-4595	114	5	may	may	AUX
dpc-4595	114	6	wield	wield	VERB
dpc-4595	114	7	its	its	PRON
dpc-4595	114	8	effects	effect	NOUN
dpc-4595	114	9	in	in	ADP
dpc-4595	114	10	individuals	individual	NOUN
dpc-4595	114	11	with	with	ADP
dpc-4595	114	12	rosacea	rosacea	NOUN
dpc-4595	114	13	through	through	ADP
dpc-4595	114	14	the	the	DET
dpc-4595	114	15	promotion	promotion	NOUN
dpc-4595	114	16	of	of	ADP
dpc-4595	114	17	neovascularization	neovascularization	NOUN
dpc-4595	114	18	via	via	ADP
dpc-4595	114	19	vegf	vegf	PROPN
dpc-4595	114	20	.	.	PUNCT
dpc-4595	115	1	compared	compare	VERB
dpc-4595	115	2	to	to	ADP
dpc-4595	115	3	participants	participant	NOUN
dpc-4595	115	4	in	in	ADP
dpc-4595	115	5	the	the	DET
dpc-4595	115	6	control	control	NOUN
dpc-4595	115	7	group	group	NOUN
dpc-4595	115	8	,	,	PUNCT
dpc-4595	115	9	il-6	il-6	NUM
dpc-4595	115	10	levels	level	NOUN
dpc-4595	115	11	were	be	AUX
dpc-4595	115	12	found	find	VERB
dpc-4595	115	13	to	to	PART
dpc-4595	115	14	be	be	AUX
dpc-4595	115	15	significantly	significantly	ADV
dpc-4595	115	16	elevated	elevate	VERB
dpc-4595	115	17	in	in	ADP
dpc-4595	115	18	patients	patient	NOUN
dpc-4595	115	19	,	,	PUNCT
dpc-4595	115	20	although	although	SCONJ
dpc-4595	115	21	they	they	PRON
dpc-4595	115	22	could	could	AUX
dpc-4595	115	23	not	not	PART
dpc-4595	115	24	be	be	AUX
dpc-4595	115	25	correlated	correlate	VERB
dpc-4595	115	26	with	with	ADP
dpc-4595	115	27	the	the	DET
dpc-4595	115	28	severity	severity	NOUN
dpc-4595	115	29	of	of	ADP
dpc-4595	115	30	the	the	DET
dpc-4595	115	31	disease	disease	NOUN
dpc-4595	115	32	or	or	CCONJ
dpc-4595	115	33	the	the	DET
dpc-4595	115	34	presence	presence	NOUN
dpc-4595	115	35	of	of	ADP
dpc-4595	115	36	clinical	clinical	ADJ
dpc-4595	115	37	symptoms	symptom	NOUN
dpc-4595	115	38	and	and	CCONJ
dpc-4595	115	39	findings	finding	NOUN
dpc-4595	115	40	.	.	PUNCT
dpc-4595	116	1	the	the	DET
dpc-4595	116	2	influence	influence	NOUN
dpc-4595	116	3	of	of	ADP
dpc-4595	116	4	il-6	il-6	NOUN
dpc-4595	116	5	on	on	ADP
dpc-4595	116	6	vegf	vegf	PROPN
dpc-4595	116	7	has	have	AUX
dpc-4595	116	8	been	be	AUX
dpc-4595	116	9	demonstrated	demonstrate	VERB
dpc-4595	116	10	as	as	ADP
dpc-4595	116	11	occurring	occur	VERB
dpc-4595	116	12	through	through	ADP
dpc-4595	116	13	hif-1α	hif-1α	NOUN
dpc-4595	116	14	in	in	ADP
dpc-4595	116	15	patients	patient	NOUN
dpc-4595	116	16	with	with	ADP
dpc-4595	116	17	psoriasis	psoriasis	NOUN
dpc-4595	116	18	.	.	PUNCT
dpc-4595	117	1	however	however	ADV
dpc-4595	117	2	,	,	PUNCT
dpc-4595	117	3	the	the	DET
dpc-4595	117	4	lack	lack	NOUN
dpc-4595	117	5	of	of	ADP
dpc-4595	117	6	association	association	NOUN
dpc-4595	117	7	between	between	ADP
dpc-4595	117	8	the	the	DET
dpc-4595	117	9	il-6	il-6	NUM
dpc-4595	117	10	level	level	NOUN
dpc-4595	117	11	and	and	CCONJ
dpc-4595	117	12	both	both	CCONJ
dpc-4595	117	13	clinical	clinical	ADJ
dpc-4595	117	14	manifestations	manifestation	NOUN
dpc-4595	117	15	—	—	PUNCT
dpc-4595	117	16	specifically	specifically	ADV
dpc-4595	117	17	telangiectasia	telangiectasia	VERB
dpc-4595	117	18	—	—	PUNCT
dpc-4595	117	19	along	along	ADP
dpc-4595	117	20	with	with	ADP
dpc-4595	117	21	the	the	DET
dpc-4595	117	22	absence	absence	NOUN
dpc-4595	117	23	of	of	ADP
dpc-4595	117	24	correlation	correlation	NOUN
dpc-4595	117	25	of	of	ADP
dpc-4595	117	26	il-6	il-6	NOUN
dpc-4595	117	27	levels	level	NOUN
dpc-4595	117	28	with	with	ADP
dpc-4595	117	29	hif-1α	hif-1α	NOUN
dpc-4595	117	30	levels	level	NOUN
dpc-4595	117	31	in	in	ADP
dpc-4595	117	32	rosacea	rosacea	NOUN
dpc-4595	117	33	patients	patient	NOUN
dpc-4595	117	34	suggest	suggest	VERB
dpc-4595	117	35	that	that	SCONJ
dpc-4595	117	36	there	there	PRON
dpc-4595	117	37	may	may	AUX
dpc-4595	117	38	be	be	AUX
dpc-4595	117	39	pathways	pathway	NOUN
dpc-4595	117	40	other	other	ADJ
dpc-4595	117	41	than	than	ADP
dpc-4595	117	42	il-6	il-6	NOUN
dpc-4595	117	43	that	that	PRON
dpc-4595	117	44	are	be	AUX
dpc-4595	117	45	influencing	influence	VERB
dpc-4595	117	46	hif-1α	hif-1α	NOUN
dpc-4595	117	47	levels	level	NOUN
dpc-4595	117	48	in	in	ADP
dpc-4595	117	49	rosacea	rosacea	NOUN
dpc-4595	117	50	.	.	PUNCT
dpc-4595	118	1	understanding	understand	VERB
dpc-4595	118	2	this	this	DET
dpc-4595	118	3	mechanism	mechanism	NOUN
dpc-4595	118	4	could	could	AUX
dpc-4595	118	5	lead	lead	VERB
dpc-4595	118	6	to	to	ADP
dpc-4595	118	7	a	a	DET
dpc-4595	118	8	deeper	deep	ADJ
dpc-4595	118	9	comprehension	comprehension	NOUN
dpc-4595	118	10	of	of	ADP
dpc-4595	118	11	rosacea	rosacea	NOUN
dpc-4595	118	12	pathophysiology	pathophysiology	NOUN
dpc-4595	118	13	and	and	CCONJ
dpc-4595	118	14	aid	aid	NOUN
dpc-4595	118	15	in	in	ADP
dpc-4595	118	16	identifying	identify	VERB
dpc-4595	118	17	potential	potential	ADJ
dpc-4595	118	18	therapeutic	therapeutic	ADJ
dpc-4595	118	19	targets	target	NOUN
dpc-4595	118	20	.	.	PUNCT
dpc-4595	119	1	accordingly	accordingly	ADV
dpc-4595	119	2	,	,	PUNCT
dpc-4595	119	3	we	we	PRON
dpc-4595	119	4	anticipate	anticipate	VERB
dpc-4595	119	5	that	that	SCONJ
dpc-4595	119	6	our	our	PRON
dpc-4595	119	7	study	study	NOUN
dpc-4595	119	8	will	will	AUX
dpc-4595	119	9	contribute	contribute	VERB
dpc-4595	119	10	to	to	ADP
dpc-4595	119	11	the	the	DET
dpc-4595	119	12	existing	exist	VERB
dpc-4595	119	13	knowledge	knowledge	NOUN
dpc-4595	119	14	in	in	ADP
dpc-4595	119	15	this	this	DET
dpc-4595	119	16	field	field	NOUN
dpc-4595	119	17	.	.	PUNCT
dpc-4595	120	1	limitations	limitation	NOUN
dpc-4595	120	2	our	our	PRON
dpc-4595	120	3	study	study	NOUN
dpc-4595	120	4	is	be	AUX
dpc-4595	120	5	limited	limit	VERB
dpc-4595	120	6	by	by	ADP
dpc-4595	120	7	the	the	DET
dpc-4595	120	8	fact	fact	NOUN
dpc-4595	120	9	that	that	SCONJ
dpc-4595	120	10	it	it	PRON
dpc-4595	120	11	was	be	AUX
dpc-4595	120	12	conducted	conduct	VERB
dpc-4595	120	13	at	at	ADP
dpc-4595	120	14	a	a	DET
dpc-4595	120	15	single	single	ADJ
dpc-4595	120	16	center	center	NOUN
dpc-4595	120	17	and	and	CCONJ
dpc-4595	120	18	with	with	ADP
dpc-4595	120	19	a	a	DET
dpc-4595	120	20	limited	limited	ADJ
dpc-4595	120	21	patient	patient	NOUN
dpc-4595	120	22	group	group	NOUN
dpc-4595	120	23	;	;	PUNCT
dpc-4595	120	24	furthermore	furthermore	ADV
dpc-4595	120	25	,	,	PUNCT
dpc-4595	120	26	there	there	PRON
dpc-4595	120	27	were	be	VERB
dpc-4595	120	28	no	no	DET
dpc-4595	120	29	patients	patient	NOUN
dpc-4595	120	30	with	with	ADP
dpc-4595	120	31	severe	severe	ADJ
dpc-4595	120	32	rosacea	rosacea	NOUN
dpc-4595	120	33	in	in	ADP
dpc-4595	120	34	our	our	PRON
dpc-4595	120	35	study	study	NOUN
dpc-4595	120	36	.	.	PUNCT
dpc-4595	121	1	in	in	ADP
dpc-4595	121	2	addition	addition	NOUN
dpc-4595	121	3	,	,	PUNCT
dpc-4595	121	4	patients	patient	NOUN
dpc-4595	121	5	were	be	AUX
dpc-4595	121	6	not	not	PART
dpc-4595	121	7	randomly	randomly	ADV
dpc-4595	121	8	selected	select	VERB
dpc-4595	121	9	;	;	PUNCT
dpc-4595	121	10	meeting	meet	VERB
dpc-4595	121	11	the	the	DET
dpc-4595	121	12	inclusion	inclusion	NOUN
dpc-4595	121	13	and	and	CCONJ
dpc-4595	121	14	exclusion	exclusion	NOUN
dpc-4595	121	15	criteria	criterion	NOUN
dpc-4595	121	16	,	,	PUNCT
dpc-4595	121	17	they	they	PRON
dpc-4595	121	18	were	be	AUX
dpc-4595	121	19	included	include	VERB
dpc-4595	121	20	in	in	ADP
dpc-4595	121	21	the	the	DET
dpc-4595	121	22	study	study	NOUN
dpc-4595	121	23	.	.	PUNCT
dpc-4595	122	1	conclusions	conclusion	NOUN
dpc-4595	122	2	levels	level	NOUN
dpc-4595	122	3	of	of	ADP
dpc-4595	122	4	il-6	il-6	NUM
dpc-4595	122	5	and	and	CCONJ
dpc-4595	122	6	hif-1α	hif-1α	NOUN
dpc-4595	122	7	are	be	AUX
dpc-4595	122	8	elevated	elevate	VERB
dpc-4595	122	9	in	in	ADP
dpc-4595	122	10	patients	patient	NOUN
dpc-4595	122	11	with	with	ADP
dpc-4595	122	12	rosacea	rosacea	NOUN
dpc-4595	122	13	compared	compare	VERB
dpc-4595	122	14	to	to	ADP
dpc-4595	122	15	people	people	NOUN
dpc-4595	122	16	without	without	ADP
dpc-4595	122	17	rosacea	rosacea	NOUN
dpc-4595	122	18	.	.	PUNCT
dpc-4595	123	1	in	in	ADP
dpc-4595	123	2	addition	addition	NOUN
dpc-4595	123	3	,	,	PUNCT
dpc-4595	123	4	a	a	DET
dpc-4595	123	5	patient	patient	NOUN
dpc-4595	123	6	’s	’s	NOUN
dpc-4595	123	7	hif-1α	hif-1α	NOUN
dpc-4595	123	8	level	level	NOUN
dpc-4595	123	9	correlates	correlate	VERB
dpc-4595	123	10	with	with	ADP
dpc-4595	123	11	the	the	DET
dpc-4595	123	12	disease	disease	NOUN
dpc-4595	123	13	severity	severity	NOUN
dpc-4595	123	14	.	.	PUNCT
dpc-4595	124	1	the	the	DET
dpc-4595	124	2	higher	high	ADJ
dpc-4595	124	3	level	level	NOUN
dpc-4595	124	4	of	of	ADP
dpc-4595	124	5	hif-1α	hif-1α	NOUN
dpc-4595	124	6	—	—	PUNCT
dpc-4595	124	7	a	a	DET
dpc-4595	124	8	known	know	VERB
dpc-4595	124	9	participant	participant	NOUN
dpc-4595	124	10	in	in	ADP
dpc-4595	124	11	the	the	DET
dpc-4595	124	12	pathogenesis	pathogenesis	NOUN
dpc-4595	124	13	of	of	ADP
dpc-4595	124	14	vascular	vascular	ADJ
dpc-4595	124	15	formation	formation	NOUN
dpc-4595	124	16	—	—	PUNCT
dpc-4595	124	17	in	in	ADP
dpc-4595	124	18	patients	patient	NOUN
dpc-4595	124	19	with	with	ADP
dpc-4595	124	20	telangiectasia	telangiectasia	NOUN
dpc-4595	124	21	suggests	suggest	VERB
dpc-4595	124	22	its	its	PRON
dpc-4595	124	23	potential	potential	ADJ
dpc-4595	124	24	role	role	NOUN
dpc-4595	124	25	in	in	ADP
dpc-4595	124	26	the	the	DET
dpc-4595	124	27	pathogenesis	pathogenesis	NOUN
dpc-4595	124	28	of	of	ADP
dpc-4595	124	29	telangiectasia	telangiectasia	NOUN
dpc-4595	124	30	formation	formation	NOUN
dpc-4595	124	31	in	in	ADP
dpc-4595	124	32	rosacea	rosacea	NOUN
dpc-4595	124	33	patients	patient	NOUN
dpc-4595	124	34	.	.	PUNCT
dpc-4595	125	1	these	these	DET
dpc-4595	125	2	findings	finding	NOUN
dpc-4595	125	3	imply	imply	VERB
dpc-4595	125	4	that	that	SCONJ
dpc-4595	125	5	drugs	drug	NOUN
dpc-4595	125	6	affecting	affect	VERB
dpc-4595	125	7	hif-1α	hif-1α	NOUN
dpc-4595	125	8	could	could	AUX
dpc-4595	125	9	be	be	AUX
dpc-4595	125	10	considered	consider	VERB
dpc-4595	125	11	for	for	ADP
dpc-4595	125	12	the	the	DET
dpc-4595	125	13	treatment	treatment	NOUN
dpc-4595	125	14	of	of	ADP
dpc-4595	125	15	rosacea	rosacea	NOUN
dpc-4595	125	16	.	.	PUNCT
dpc-4595	126	1	nevertheless	nevertheless	ADV
dpc-4595	126	2	,	,	PUNCT
dpc-4595	126	3	further	further	ADJ
dpc-4595	126	4	research	research	NOUN
dpc-4595	126	5	with	with	ADP
dpc-4595	126	6	larger	large	ADJ
dpc-4595	126	7	patient	patient	NOUN
dpc-4595	126	8	cohorts	cohort	NOUN
dpc-4595	126	9	is	be	AUX
dpc-4595	126	10	needed	need	VERB
dpc-4595	126	11	to	to	PART
dpc-4595	126	12	substantiate	substantiate	VERB
dpc-4595	126	13	our	our	PRON
dpc-4595	126	14	findings	finding	NOUN
dpc-4595	126	15	.	.	PUNCT
dpc-4595	127	1	references	reference	NOUN
dpc-4595	127	2	1	1	NUM
dpc-4595	127	3	.	.	PUNCT
dpc-4595	128	1	van	van	PROPN
dpc-4595	128	2	zuuren	zuuren	PROPN
dpc-4595	128	3	ej	ej	PROPN
dpc-4595	128	4	,	,	PUNCT
dpc-4595	128	5	arents	arents	PROPN
dpc-4595	128	6	bwm	bwm	PROPN
dpc-4595	128	7	,	,	PUNCT
dpc-4595	128	8	van	van	PROPN
dpc-4595	128	9	der	der	PROPN
dpc-4595	128	10	linden	linden	PROPN
dpc-4595	128	11	mmd	mmd	PROPN
dpc-4595	128	12	,	,	PUNCT
dpc-4595	128	13	vermeulen	vermeulen	PROPN
dpc-4595	128	14	s	s	PROPN
dpc-4595	128	15	,	,	PUNCT
dpc-4595	128	16	fedorowicz	fedorowicz	PROPN
dpc-4595	128	17	z	z	PROPN
dpc-4595	128	18	,	,	PUNCT
dpc-4595	128	19	tan	tan	PROPN
dpc-4595	128	20	j.	j.	PROPN
dpc-4595	128	21	rosacea	rosacea	PROPN
dpc-4595	128	22	:	:	PUNCT
dpc-4595	128	23	new	new	ADJ
dpc-4595	128	24	concepts	concept	NOUN
dpc-4595	128	25	in	in	ADP
dpc-4595	128	26	classification	classification	NOUN
dpc-4595	128	27	and	and	CCONJ
dpc-4595	128	28	treatment	treatment	NOUN
dpc-4595	128	29	.	.	PUNCT
dpc-4595	128	30	am	be	AUX
dpc-4595	128	31	j	j	PROPN
dpc-4595	128	32	clin	clin	PROPN
dpc-4595	128	33	dermatol	dermatol	NOUN
dpc-4595	128	34	.	.	PUNCT
dpc-4595	129	1	2021;22(4):457	2021;22(4):457	NUM
dpc-4595	129	2	-	-	PUNCT
dpc-4595	129	3	65	65	NUM
dpc-4595	129	4	.	.	PUNCT
dpc-4595	130	1	doi:10.1007	doi:10.1007	VERB
dpc-4595	130	2	/	/	SYM
dpc-4595	130	3	s40257	s40257	NOUN
dpc-4595	130	4	-	-	PUNCT
dpc-4595	130	5	021	021	NUM
dpc-4595	130	6	-	-	PUNCT
dpc-4595	130	7	00595	00595	NUM
dpc-4595	130	8	-	-	PUNCT
dpc-4595	130	9	7	7	NUM
dpc-4595	130	10	.	.	NOUN
dpc-4595	130	11	2	2	NUM
dpc-4595	130	12	.	.	X
dpc-4595	130	13	gether	gether	PROPN
dpc-4595	130	14	l	l	PROPN
dpc-4595	130	15	,	,	PUNCT
dpc-4595	130	16	overgaard	overgaard	ADJ
dpc-4595	130	17	lk	lk	PROPN
dpc-4595	130	18	,	,	PUNCT
dpc-4595	130	19	egeberg	egeberg	PROPN
dpc-4595	130	20	a	a	X
dpc-4595	130	21	,	,	PUNCT
dpc-4595	130	22	thyssen	thyssen	PROPN
dpc-4595	130	23	jp	jp	PROPN
dpc-4595	130	24	.	.	PUNCT
dpc-4595	130	25	incidence	incidence	NOUN
dpc-4595	130	26	and	and	CCONJ
dpc-4595	130	27	prevalence	prevalence	NOUN
dpc-4595	130	28	of	of	ADP
dpc-4595	130	29	rosacea	rosacea	NOUN
dpc-4595	130	30	:	:	PUNCT
dpc-4595	130	31	a	a	DET
dpc-4595	130	32	systematic	systematic	ADJ
dpc-4595	130	33	review	review	NOUN
dpc-4595	130	34	and	and	CCONJ
dpc-4595	130	35	meta	meta	VERB
dpc-4595	130	36	analysis	analysis	NOUN
dpc-4595	130	37	.	.	PUNCT
dpc-4595	131	1	br	br	PROPN
dpc-4595	131	2	j	j	PROPN
dpc-4595	131	3	dermatol	dermatol	NOUN
dpc-4595	131	4	.	.	PUNCT
dpc-4595	132	1	2018;179(2):282	2018;179(2):282	PROPN
dpc-4595	132	2	-	-	SYM
dpc-4595	132	3	9	9	NUM
dpc-4595	132	4	.	.	PUNCT
dpc-4595	132	5	 	 	SPACE
dpc-4595	132	6	doi:10.1111	doi:10.1111	PROPN
dpc-4595	132	7	/	/	SYM
dpc-4595	132	8	bjd	bjd	PROPN
dpc-4595	132	9	.	.	PUNCT
dpc-4595	133	1	16481	16481	NUM
dpc-4595	133	2	.	.	PUNCT
dpc-4595	134	1	3	3	X
dpc-4595	134	2	.	.	X
dpc-4595	134	3	galluccio	galluccio	VERB
dpc-4595	134	4	g	g	NOUN
dpc-4595	134	5	,	,	PUNCT
dpc-4595	134	6	d’onghia	d’onghia	VERB
dpc-4595	134	7	m	m	PROPN
dpc-4595	134	8	,	,	PUNCT
dpc-4595	134	9	malvaso	malvaso	PROPN
dpc-4595	134	10	d	d	NOUN
dpc-4595	134	11	,	,	PUNCT
dpc-4595	134	12	et	et	PROPN
dpc-4595	134	13	al	al	PROPN
dpc-4595	134	14	.	.	PROPN
dpc-4595	134	15	advances	advance	NOUN
dpc-4595	134	16	in	in	ADP
dpc-4595	134	17	the	the	DET
dpc-4595	134	18	pathogenesis	pathogenesis	NOUN
dpc-4595	134	19	and	and	CCONJ
dpc-4595	134	20	treatment	treatment	NOUN
dpc-4595	134	21	of	of	ADP
dpc-4595	134	22	rosacea	rosacea	NOUN
dpc-4595	134	23	:	:	PUNCT
dpc-4595	134	24	a	a	DET
dpc-4595	134	25	phenotype	phenotype	NOUN
dpc-4595	134	26	-	-	PUNCT
dpc-4595	134	27	based	base	VERB
dpc-4595	134	28	therapeutic	therapeutic	ADJ
dpc-4595	134	29	approach	approach	NOUN
dpc-4595	134	30	.	.	PUNCT
dpc-4595	135	1	cosmetics	cosmetic	NOUN
dpc-4595	135	2	.	.	PUNCT
dpc-4595	136	1	2024;11(1):11	2024;11(1):11	X
dpc-4595	136	2	.	.	PUNCT
dpc-4595	136	3	doi:10.3390	doi:10.3390	NOUN
dpc-4595	136	4	/cosmetics11010011	/cosmetics11010011	PUNCT
dpc-4595	136	5	.	.	PROPN
dpc-4595	137	1	4	4	X
dpc-4595	137	2	.	.	X
dpc-4595	137	3	buddenkotte	buddenkotte	PROPN
dpc-4595	137	4	j	j	PROPN
dpc-4595	137	5	,	,	PUNCT
dpc-4595	137	6	steinhoff	steinhoff	PROPN
dpc-4595	137	7	m.	m.	NOUN
dpc-4595	137	8	recent	recent	ADJ
dpc-4595	137	9	advances	advance	NOUN
dpc-4595	137	10	in	in	ADP
dpc-4595	137	11	understanding	understanding	NOUN
dpc-4595	137	12	and	and	CCONJ
dpc-4595	137	13	managing	manage	VERB
dpc-4595	137	14	rosacea	rosacea	NOUN
dpc-4595	137	15	.	.	PUNCT
dpc-4595	138	1	f1000res	f1000res	PROPN
dpc-4595	138	2	.	.	PROPN
dpc-4595	138	3	2018	2018	NUM
dpc-4595	138	4	dec	dec	PROPN
dpc-4595	138	5	3;7	3;7	NUM
dpc-4595	138	6	:	:	PUNCT
dpc-4595	138	7	f1000	f1000	ADJ
dpc-4595	138	8	faculty	faculty	NOUN
dpc-4595	138	9	rev-1885	rev-1885	NOUN
dpc-4595	138	10	.	.	PUNCT
dpc-4595	139	1	doi:10.12688	doi:10.12688	PROPN
dpc-4595	139	2	/	/	SYM
dpc-4595	139	3	f1000research.16537.1	f1000research.16537.1	NOUN
dpc-4595	139	4	.	.	PUNCT
dpc-4595	140	1	5	5	NUM
dpc-4595	140	2	.	.	X
dpc-4595	140	3	zhu	zhu	PROPN
dpc-4595	140	4	wj	wj	PROPN
dpc-4595	140	5	,	,	PUNCT
dpc-4595	140	6	li	li	PROPN
dpc-4595	140	7	p	p	PROPN
dpc-4595	140	8	,	,	PUNCT
dpc-4595	140	9	wang	wang	PROPN
dpc-4595	140	10	l	l	PROPN
dpc-4595	140	11	,	,	PUNCT
dpc-4595	140	12	xu	xu	PROPN
dpc-4595	141	1	yc	yc	PROPN
dpc-4595	141	2	.	.	PUNCT
dpc-4595	141	3	hypoxia	hypoxia	NOUN
dpc-4595	141	4	-	-	PUNCT
dpc-4595	141	5	inducible	inducible	ADJ
dpc-4595	141	6	factor-1	factor-1	PROPN
dpc-4595	141	7	:	:	PUNCT
dpc-4595	141	8	a	a	DET
dpc-4595	141	9	potential	potential	ADJ
dpc-4595	141	10	pharmacological	pharmacological	ADJ
dpc-4595	141	11	target	target	NOUN
dpc-4595	141	12	to	to	PART
dpc-4595	141	13	manage	manage	VERB
dpc-4595	141	14	psoriasis	psoriasis	NOUN
dpc-4595	141	15	.	.	PUNCT
dpc-4595	142	1	int	int	NOUN
dpc-4595	142	2	immunopharmacol	immunopharmacol	PROPN
dpc-4595	142	3	.	.	PUNCT
dpc-4595	142	4	2020;86(june):106689	2020;86(june):106689	NUM
dpc-4595	142	5	.	.	PUNCT
dpc-4595	142	6	doi:10.1016	doi:10.1016	PROPN
dpc-4595	142	7	/	/	SYM
dpc-4595	142	8	j.intimp	j.intimp	PROPN
dpc-4595	142	9	.2020.106689	.2020.106689	PROPN
dpc-4595	142	10	.	.	PUNCT
dpc-4595	143	1	6	6	NUM
dpc-4595	143	2	original	original	ADJ
dpc-4595	143	3	article	article	NOUN
dpc-4595	143	4	|	|	ADV
dpc-4595	143	5	dermatol	dermatol	ADJ
dpc-4595	143	6	pract	pract	NOUN
dpc-4595	143	7	concept	concept	NOUN
dpc-4595	143	8	.	.	PUNCT
dpc-4595	144	1	2024;14(4):e2024267	2024;14(4):e2024267	NUM
dpc-4595	144	2	13	13	NUM
dpc-4595	144	3	.	.	PUNCT
dpc-4595	145	1	shih	shih	PROPN
dpc-4595	145	2	yh	yh	PROPN
dpc-4595	145	3	,	,	PUNCT
dpc-4595	145	4	xu	xu	PROPN
dpc-4595	145	5	j	j	PROPN
dpc-4595	145	6	,	,	PUNCT
dpc-4595	145	7	kumar	kumar	PROPN
dpc-4595	145	8	a	a	PROPN
dpc-4595	145	9	,	,	PUNCT
dpc-4595	145	10	li	li	PROPN
dpc-4595	145	11	r	r	PROPN
dpc-4595	145	12	,	,	PUNCT
dpc-4595	145	13	chang	chang	PROPN
dpc-4595	145	14	als	als	PROPN
dpc-4595	145	15	.	.	PUNCT
dpc-4595	146	1	alterations	alteration	NOUN
dpc-4595	146	2	of	of	ADP
dpc-4595	146	3	immune	immune	ADJ
dpc-4595	146	4	and	and	CCONJ
dpc-4595	146	5	keratinization	keratinization	NOUN
dpc-4595	146	6	gene	gene	NOUN
dpc-4595	146	7	expression	expression	NOUN
dpc-4595	146	8	in	in	ADP
dpc-4595	146	9	papulopustular	papulopustular	ADJ
dpc-4595	146	10	rosacea	rosacea	NOUN
dpc-4595	146	11	by	by	ADP
dpc-4595	146	12	whole	whole	ADJ
dpc-4595	146	13	transcriptome	transcriptome	ADJ
dpc-4595	146	14	analysis	analysis	NOUN
dpc-4595	146	15	.	.	PUNCT
dpc-4595	147	1	j	j	PROPN
dpc-4595	147	2	invest	invest	VERB
dpc-4595	147	3	dermatol	dermatol	NOUN
dpc-4595	147	4	.	.	PUNCT
dpc-4595	148	1	may	may	AUX
dpc-4595	148	2	2020;140(5):1100	2020;140(5):1100	NUM
dpc-4595	148	3	-	-	PUNCT
dpc-4595	148	4	1103.e4	1103.e4	ADJ
dpc-4595	148	5	.	.	PUNCT
dpc-4595	149	1	doi	doi	NOUN
dpc-4595	149	2	:	:	PUNCT
dpc-4595	149	3	10.1016	10.1016	NUM
dpc-4595	149	4	/	/	SYM
dpc-4595	149	5	j.jid.2019	j.jid.2019	PROPN
dpc-4595	149	6	.09.021	.09.021	NOUN
dpc-4595	149	7	.	.	PUNCT
dpc-4595	150	1	14	14	NUM
dpc-4595	150	2	.	.	PUNCT
dpc-4595	151	1	geng	geng	PROPN
dpc-4595	151	2	rsq	rsq	PROPN
dpc-4595	151	3	,	,	PUNCT
dpc-4595	151	4	bourkas	bourkas	PROPN
dpc-4595	151	5	an	an	PROPN
dpc-4595	151	6	,	,	PUNCT
dpc-4595	151	7	sibbald	sibbald	PROPN
dpc-4595	151	8	rg	rg	PROPN
dpc-4595	151	9	,	,	PUNCT
dpc-4595	151	10	sibbald	sibbald	ADJ
dpc-4595	151	11	c.	c.	NOUN
dpc-4595	151	12	biomarkers	biomarker	NOUN
dpc-4595	151	13	in	in	ADP
dpc-4595	151	14	rosacea	rosacea	NOUN
dpc-4595	151	15	:	:	PUNCT
dpc-4595	151	16	a	a	DET
dpc-4595	151	17	systematic	systematic	ADJ
dpc-4595	151	18	review	review	NOUN
dpc-4595	151	19	.	.	PUNCT
dpc-4595	152	1	j	j	PROPN
dpc-4595	152	2	eur	eur	PROPN
dpc-4595	152	3	acad	acad	PROPN
dpc-4595	152	4	dermatol	dermatol	NOUN
dpc-4595	152	5	venereol	venereol	NOUN
dpc-4595	152	6	.	.	PUNCT
dpc-4595	153	1	june	june	PROPN
dpc-4595	153	2	2024;38(6):1048	2024;38(6):1048	NUM
dpc-4595	153	3	-	-	SYM
dpc-4595	153	4	57	57	NUM
dpc-4595	153	5	.	.	PUNCT
dpc-4595	154	1	doi	doi	NOUN
dpc-4595	154	2	:	:	PUNCT
dpc-4595	154	3	10.1111	10.1111	NUM
dpc-4595	154	4	/	/	SYM
dpc-4595	154	5	jdv.19732	jdv.19732	DET
dpc-4595	154	6	15	15	NUM
dpc-4595	154	7	.	.	PUNCT
dpc-4595	155	1	salamon	salamon	PROPN
dpc-4595	155	2	m	m	PROPN
dpc-4595	155	3	,	,	PUNCT
dpc-4595	155	4	sysa	sysa	NOUN
dpc-4595	155	5	-	-	PUNCT
dpc-4595	155	6	jedrzejowska	jedrzejowska	NOUN
dpc-4595	155	7	a	a	PRON
dpc-4595	155	8	,	,	PUNCT
dpc-4595	155	9	lukamowicz	lukamowicz	PROPN
dpc-4595	155	10	j	j	PROPN
dpc-4595	155	11	,	,	PUNCT
dpc-4595	155	12	lukamowicz	lukamowicz	PROPN
dpc-4595	155	13	m	m	PROPN
dpc-4595	155	14	,	,	PUNCT
dpc-4595	155	15	swiatkowska	swiatkowska	PROPN
dpc-4595	155	16	e	e	NOUN
dpc-4595	155	17	,	,	PUNCT
dpc-4595	155	18	wozniacka	wozniacka	VERB
dpc-4595	155	19	a.	a.	NOUN
dpc-4595	155	20	concentration	concentration	NOUN
dpc-4595	155	21	of	of	ADP
dpc-4595	155	22	selected	select	VERB
dpc-4595	155	23	cytokines	cytokine	NOUN
dpc-4595	155	24	in	in	ADP
dpc-4595	155	25	serum	serum	NOUN
dpc-4595	155	26	of	of	ADP
dpc-4595	155	27	patients	patient	NOUN
dpc-4595	155	28	with	with	ADP
dpc-4595	155	29	acne	acne	NOUN
dpc-4595	155	30	rosacea	rosacea	NOUN
dpc-4595	155	31	.	.	PUNCT
dpc-4595	156	1	przegl	przegl	PROPN
dpc-4595	156	2	lek	lek	PROPN
dpc-4595	156	3	.	.	PUNCT
dpc-4595	157	1	2008;65(9):371	2008;65(9):371	PROPN
dpc-4595	157	2	-	-	PUNCT
dpc-4595	157	3	4	4	NUM
dpc-4595	157	4	.	.	NUM
dpc-4595	157	5	16	16	NUM
dpc-4595	157	6	.	.	PUNCT
dpc-4595	158	1	chen	chen	PROPN
dpc-4595	158	2	c	c	PROPN
dpc-4595	158	3	,	,	PUNCT
dpc-4595	158	4	wang	wang	PROPN
dpc-4595	158	5	p	p	PROPN
dpc-4595	158	6	,	,	PUNCT
dpc-4595	158	7	zhang	zhang	PROPN
dpc-4595	158	8	l	l	PROPN
dpc-4595	158	9	,	,	PUNCT
dpc-4595	158	10	et	et	PROPN
dpc-4595	158	11	al	al	PROPN
dpc-4595	158	12	.	.	PUNCT
dpc-4595	158	13	exploring	explore	VERB
dpc-4595	158	14	the	the	DET
dpc-4595	158	15	pathogenesis	pathogenesis	NOUN
dpc-4595	158	16	and	and	CCONJ
dpc-4595	158	17	mechanism	mechanism	NOUN
dpc-4595	158	18	-	-	PUNCT
dpc-4595	158	19	targeted	target	VERB
dpc-4595	158	20	treatments	treatment	NOUN
dpc-4595	158	21	of	of	ADP
dpc-4595	158	22	rosacea	rosacea	NOUN
dpc-4595	158	23	:	:	PUNCT
dpc-4595	158	24	previous	previous	ADJ
dpc-4595	158	25	understanding	understanding	NOUN
dpc-4595	158	26	and	and	CCONJ
dpc-4595	158	27	updates	update	NOUN
dpc-4595	158	28	.	.	PUNCT
dpc-4595	159	1	biomedicines	biomedicine	NOUN
dpc-4595	159	2	.	.	PUNCT
dpc-4595	160	1	2023	2023	NUM
dpc-4595	160	2	jul	jul	NOUN
dpc-4595	160	3	31;11(8):2153	31;11(8):2153	NUM
dpc-4595	160	4	.	.	PUNCT
dpc-4595	161	1	doi	doi	NOUN
dpc-4595	161	2	:	:	PUNCT
dpc-4595	161	3	10.3390	10.3390	NUM
dpc-4595	161	4	/	/	SYM
dpc-4595	161	5	biomedicines11082153	biomedicines11082153	NOUN
dpc-4595	161	6	.	.	PUNCT
dpc-4595	162	1	17	17	NUM
dpc-4595	162	2	.	.	PUNCT
dpc-4595	163	1	hayran	hayran	PROPN
dpc-4595	163	2	y	y	PROPN
dpc-4595	163	3	,	,	PUNCT
dpc-4595	163	4	şen	şen	PROPN
dpc-4595	163	5	o	o	NOUN
dpc-4595	163	6	,	,	PUNCT
dpc-4595	163	7	fırat	fırat	NOUN
dpc-4595	163	8	oğuz	oğuz	PROPN
dpc-4595	163	9	e	e	PROPN
dpc-4595	163	10	,	,	PUNCT
dpc-4595	163	11	et	et	PROPN
dpc-4595	163	12	al	al	PROPN
dpc-4595	163	13	.	.	PROPN
dpc-4595	163	14	serum	serum	PROPN
dpc-4595	163	15	il-17	il-17	NUM
dpc-4595	163	16	levels	level	NOUN
dpc-4595	163	17	in	in	ADP
dpc-4595	163	18	patients	patient	NOUN
dpc-4595	163	19	with	with	ADP
dpc-4595	163	20	rosacea	rosacea	NOUN
dpc-4595	163	21	.	.	PUNCT
dpc-4595	164	1	j	j	PROPN
dpc-4595	164	2	cosmet	cosmet	PROPN
dpc-4595	164	3	dermatol	dermatol	NOUN
dpc-4595	164	4	.	.	PUNCT
dpc-4595	165	1	2022;21(3):1147	2022;21(3):1147	PROPN
dpc-4595	165	2	-	-	PUNCT
dpc-4595	165	3	53	53	NUM
dpc-4595	165	4	.	.	PUNCT
dpc-4595	166	1	doi:10.1111	doi:10.1111	PROPN
dpc-4595	166	2	/	/	SYM
dpc-4595	166	3	jocd.14169	jocd.14169	PROPN
dpc-4595	166	4	.	.	PROPN
dpc-4595	166	5	18	18	NUM
dpc-4595	166	6	.	.	X
dpc-4595	166	7	tang	tang	PROPN
dpc-4595	167	1	yy	yy	PROPN
dpc-4595	167	2	,	,	PUNCT
dpc-4595	167	3	wang	wang	PROPN
dpc-4595	167	4	dc	dc	PROPN
dpc-4595	167	5	,	,	PUNCT
dpc-4595	167	6	wang	wang	PROPN
dpc-4595	167	7	yq	yq	PROPN
dpc-4595	167	8	,	,	PUNCT
dpc-4595	167	9	huang	huang	PROPN
dpc-4595	167	10	af	af	PROPN
dpc-4595	167	11	,	,	PUNCT
dpc-4595	167	12	xu	xu	PROPN
dpc-4595	168	1	wd	wd	PROPN
dpc-4595	168	2	.	.	PUNCT
dpc-4595	168	3	emerging	emerge	VERB
dpc-4595	168	4	role	role	NOUN
dpc-4595	168	5	of	of	ADP
dpc-4595	168	6	hypoxia	hypoxia	NOUN
dpc-4595	168	7	-	-	PUNCT
dpc-4595	168	8	inducible	inducible	ADJ
dpc-4595	168	9	factor-1α	factor-1α	NOUN
dpc-4595	168	10	in	in	ADP
dpc-4595	168	11	inflammatory	inflammatory	ADJ
dpc-4595	168	12	autoimmune	autoimmune	ADJ
dpc-4595	168	13	diseases	disease	NOUN
dpc-4595	168	14	:	:	PUNCT
dpc-4595	168	15	a	a	DET
dpc-4595	168	16	comprehensive	comprehensive	ADJ
dpc-4595	168	17	review	review	NOUN
dpc-4595	168	18	.	.	PUNCT
dpc-4595	169	1	front	front	ADJ
dpc-4595	169	2	immunol	immunol	NOUN
dpc-4595	169	3	.	.	PUNCT
dpc-4595	170	1	2023;13	2023;13	NUM
dpc-4595	170	2	(	(	PUNCT
dpc-4595	170	3	january):1	january):1	NOUN
dpc-4595	170	4	-	-	PUNCT
dpc-4595	170	5	14	14	NUM
dpc-4595	170	6	.	.	PUNCT
dpc-4595	171	1	doi	doi	NOUN
dpc-4595	171	2	:	:	PUNCT
dpc-4595	171	3	10.3389	10.3389	NUM
dpc-4595	171	4	/	/	SYM
dpc-4595	171	5	fimmu.2022.1073971	fimmu.2022.1073971	NOUN
dpc-4595	171	6	.	.	PUNCT
dpc-4595	172	1	19	19	NUM
dpc-4595	172	2	.	.	X
dpc-4595	172	3	gomaa	gomaa	PROPN
dpc-4595	172	4	aha	aha	PROPN
dpc-4595	172	5	,	,	PUNCT
dpc-4595	172	6	yaar	yaar	PROPN
dpc-4595	172	7	m	m	PROPN
dpc-4595	172	8	,	,	PUNCT
dpc-4595	172	9	eyada	eyada	PROPN
dpc-4595	172	10	mmk	mmk	PROPN
dpc-4595	172	11	,	,	PUNCT
dpc-4595	172	12	bhawan	bhawan	PROPN
dpc-4595	172	13	j.	j.	PROPN
dpc-4595	172	14	lymphangiogenesis	lymphangiogenesis	PROPN
dpc-4595	172	15	and	and	CCONJ
dpc-4595	172	16	angiogenesis	angiogenesis	NOUN
dpc-4595	172	17	in	in	ADP
dpc-4595	172	18	non	non	ADJ
dpc-4595	172	19	-	-	ADJ
dpc-4595	172	20	phymatous	phymatous	ADJ
dpc-4595	172	21	rosacea	rosacea	NOUN
dpc-4595	172	22	.	.	PUNCT
dpc-4595	173	1	j	j	PROPN
dpc-4595	173	2	cutan	cutan	PROPN
dpc-4595	173	3	pathol	pathol	NOUN
dpc-4595	173	4	.	.	PUNCT
dpc-4595	174	1	2007;34(10):748	2007;34(10):748	X
dpc-4595	174	2	-	-	SYM
dpc-4595	174	3	53	53	NUM
dpc-4595	174	4	.	.	PUNCT
dpc-4595	174	5	doi	doi	NOUN
dpc-4595	174	6	:	:	PUNCT
dpc-4595	174	7	10.1111	10.1111	NUM
dpc-4595	174	8	/	/	SYM
dpc-4595	174	9	j.1600	j.1600	NOUN
dpc-4595	174	10	-	-	PUNCT
dpc-4595	174	11	0560.2006	0560.2006	NUM
dpc-4595	174	12	.00695.x	.00695.x	NOUN
dpc-4595	174	13	.	.	PUNCT
dpc-4595	175	1	20	20	NUM
dpc-4595	175	2	.	.	PUNCT
dpc-4595	175	3	domingo	domingo	PROPN
dpc-4595	175	4	ds	ds	PROPN
dpc-4595	175	5	,	,	PUNCT
dpc-4595	175	6	camouse	camouse	NOUN
dpc-4595	175	7	mm	mm	PROPN
dpc-4595	175	8	,	,	PUNCT
dpc-4595	175	9	hsia	hsia	PROPN
dpc-4595	175	10	ah	ah	INTJ
dpc-4595	175	11	,	,	PUNCT
dpc-4595	175	12	et	et	PROPN
dpc-4595	175	13	al	al	PROPN
dpc-4595	175	14	.	.	PUNCT
dpc-4595	176	1	anti	anti	ADJ
dpc-4595	176	2	-	-	ADJ
dpc-4595	176	3	angiogenic	angiogenic	ADJ
dpc-4595	176	4	effects	effect	NOUN
dpc-4595	176	5	of	of	ADP
dpc-4595	176	6	epigallocatechin-3	epigallocatechin-3	PROPN
dpc-4595	176	7	-	-	NOUN
dpc-4595	176	8	gallate	gallate	NOUN
dpc-4595	176	9	in	in	ADP
dpc-4595	176	10	human	human	ADJ
dpc-4595	176	11	skin	skin	NOUN
dpc-4595	176	12	.	.	PUNCT
dpc-4595	177	1	int	int	PROPN
dpc-4595	178	1	j	j	PROPN
dpc-4595	178	2	clin	clin	PROPN
dpc-4595	178	3	exp	exp	NOUN
dpc-4595	178	4	pathol	pathol	NOUN
dpc-4595	178	5	.	.	PUNCT
dpc-4595	179	1	2010	2010	NUM
dpc-4595	179	2	aug	aug	PROPN
dpc-4595	179	3	5;3(7):705	5;3(7):705	NUM
dpc-4595	179	4	-	-	SYM
dpc-4595	179	5	9	9	NUM
dpc-4595	179	6	.	.	NOUN
dpc-4595	179	7	6	6	NUM
dpc-4595	179	8	.	.	X
dpc-4595	179	9	torales	torale	NOUN
dpc-4595	179	10	-	-	PUNCT
dpc-4595	179	11	cardeña	cardeña	NOUN
dpc-4595	179	12	a	a	PRON
dpc-4595	179	13	,	,	PUNCT
dpc-4595	179	14	martínez	martínez	NOUN
dpc-4595	179	15	-	-	PUNCT
dpc-4595	179	16	torres	torre	VERB
dpc-4595	179	17	i	i	PRON
dpc-4595	179	18	,	,	PUNCT
dpc-4595	179	19	rodríguez	rodríguez	NOUN
dpc-4595	179	20	-	-	PUNCT
dpc-4595	179	21	martínez	martínez	PROPN
dpc-4595	179	22	s	s	PART
dpc-4595	179	23	,	,	PUNCT
dpc-4595	179	24	et	et	PROPN
dpc-4595	179	25	al	al	PROPN
dpc-4595	179	26	.	.	PROPN
dpc-4595	180	1	cross	cross	PROPN
dpc-4595	180	2	talk	talk	NOUN
dpc-4595	180	3	between	between	ADP
dpc-4595	180	4	proliferative	proliferative	ADJ
dpc-4595	180	5	,	,	PUNCT
dpc-4595	180	6	angiogenic	angiogenic	ADJ
dpc-4595	180	7	,	,	PUNCT
dpc-4595	180	8	and	and	CCONJ
dpc-4595	180	9	cellular	cellular	ADJ
dpc-4595	180	10	mechanisms	mechanism	NOUN
dpc-4595	180	11	orchestred	orchestre	VERB
dpc-4595	180	12	by	by	ADP
dpc-4595	180	13	hif-1	hif-1	PUNCT
dpc-4595	180	14	in	in	ADP
dpc-4595	180	15	psoriasis	psoriasis	NOUN
dpc-4595	180	16	.	.	PUNCT
dpc-4595	181	1	mediators	mediator	NOUN
dpc-4595	181	2	inflamm	inflamm	NOUN
dpc-4595	181	3	.	.	PUNCT
dpc-4595	182	1	2015;2015:607363	2015;2015:607363	NUM
dpc-4595	182	2	.	.	PUNCT
dpc-4595	183	1	doi:10.1155/2015/607363	doi:10.1155/2015/607363	NOUN
dpc-4595	183	2	.	.	PUNCT
dpc-4595	184	1	7	7	X
dpc-4595	184	2	.	.	X
dpc-4595	184	3	shi	shi	PROPN
dpc-4595	184	4	lz	lz	PROPN
dpc-4595	184	5	,	,	PUNCT
dpc-4595	184	6	wang	wang	PROPN
dpc-4595	184	7	r	r	PROPN
dpc-4595	184	8	,	,	PUNCT
dpc-4595	184	9	huang	huang	PROPN
dpc-4595	184	10	g	g	PROPN
dpc-4595	184	11	,	,	PUNCT
dpc-4595	184	12	et	et	PROPN
dpc-4595	184	13	al	al	PROPN
dpc-4595	184	14	.	.	PUNCT
dpc-4595	185	1	hif1α	hif1α	ADJ
dpc-4595	185	2	-	-	PUNCT
dpc-4595	185	3	dependent	dependent	ADJ
dpc-4595	185	4	glycolytic	glycolytic	ADJ
dpc-4595	185	5	pathway	pathway	NOUN
dpc-4595	185	6	orchestrates	orchestrate	VERB
dpc-4595	185	7	a	a	DET
dpc-4595	185	8	metabolic	metabolic	NOUN
dpc-4595	185	9	checkpoint	checkpoint	NOUN
dpc-4595	185	10	for	for	ADP
dpc-4595	185	11	the	the	DET
dpc-4595	185	12	differentiation	differentiation	NOUN
dpc-4595	185	13	of	of	ADP
dpc-4595	185	14	th17	th17	PROPN
dpc-4595	185	15	and	and	CCONJ
dpc-4595	185	16	treg	treg	PROPN
dpc-4595	185	17	cells	cell	NOUN
dpc-4595	185	18	.	.	PUNCT
dpc-4595	186	1	j	j	PROPN
dpc-4595	186	2	exp	exp	NOUN
dpc-4595	186	3	med	med	PROPN
dpc-4595	186	4	.	.	PUNCT
dpc-4595	187	1	2011;208(7):1367	2011;208(7):1367	NUM
dpc-4595	187	2	-	-	SYM
dpc-4595	187	3	76	76	NUM
dpc-4595	187	4	.	.	PUNCT
dpc-4595	188	1	doi	doi	NOUN
dpc-4595	188	2	:	:	PUNCT
dpc-4595	188	3	0.1084	0.1084	NUM
dpc-4595	188	4	/	/	SYM
dpc-4595	188	5	jem.20110278	jem.20110278	NUM
dpc-4595	188	6	.	.	NOUN
dpc-4595	189	1	8	8	NUM
dpc-4595	189	2	.	.	X
dpc-4595	189	3	gallo	gallo	PROPN
dpc-4595	189	4	rl	rl	PROPN
dpc-4595	189	5	,	,	PUNCT
dpc-4595	189	6	granstein	granstein	PROPN
dpc-4595	189	7	rd	rd	PROPN
dpc-4595	189	8	,	,	PUNCT
dpc-4595	189	9	kang	kang	PROPN
dpc-4595	189	10	s	s	PROPN
dpc-4595	189	11	,	,	PUNCT
dpc-4595	189	12	et	et	PROPN
dpc-4595	189	13	al	al	PROPN
dpc-4595	189	14	.	.	PROPN
dpc-4595	190	1	standard	standard	ADJ
dpc-4595	190	2	classification	classification	NOUN
dpc-4595	190	3	and	and	CCONJ
dpc-4595	190	4	pathophysiology	pathophysiology	NOUN
dpc-4595	190	5	of	of	ADP
dpc-4595	190	6	rosacea	rosacea	NOUN
dpc-4595	190	7	:	:	PUNCT
dpc-4595	190	8	the	the	DET
dpc-4595	190	9	2017	2017	NUM
dpc-4595	190	10	update	update	NOUN
dpc-4595	190	11	by	by	ADP
dpc-4595	190	12	the	the	DET
dpc-4595	190	13	national	national	PROPN
dpc-4595	190	14	rosacea	rosacea	PROPN
dpc-4595	190	15	society	society	PROPN
dpc-4595	190	16	expert	expert	PROPN
dpc-4595	190	17	committee	committee	PROPN
dpc-4595	190	18	.	.	PUNCT
dpc-4595	191	1	j	j	PROPN
dpc-4595	191	2	am	be	AUX
dpc-4595	191	3	acad	acad	ADJ
dpc-4595	191	4	dermatol	dermatol	NOUN
dpc-4595	191	5	.	.	PUNCT
dpc-4595	192	1	2018;78(1):148	2018;78(1):148	NUM
dpc-4595	192	2	-	-	SYM
dpc-4595	192	3	55	55	NUM
dpc-4595	192	4	.	.	PUNCT
dpc-4595	193	1	doi:10.1016	doi:10.1016	PROPN
dpc-4595	193	2	/	/	SYM
dpc-4595	193	3	j.jaad.2017.08.037	j.jaad.2017.08.037	PROPN
dpc-4595	193	4	.	.	PROPN
dpc-4595	194	1	9	9	NUM
dpc-4595	194	2	.	.	X
dpc-4595	194	3	ertekin	ertekin	PROPN
dpc-4595	194	4	ss	ss	PROPN
dpc-4595	194	5	,	,	PUNCT
dpc-4595	194	6	koku	koku	PROPN
dpc-4595	194	7	aksu	aksu	PROPN
dpc-4595	194	8	ae	ae	PROPN
dpc-4595	194	9	,	,	PUNCT
dpc-4595	194	10	koçyiğit	koçyiğit	PROPN
dpc-4595	194	11	a	a	PRON
dpc-4595	194	12	,	,	PUNCT
dpc-4595	194	13	güler	güler	VERB
dpc-4595	194	14	em	em	PRON
dpc-4595	194	15	,	,	PUNCT
dpc-4595	194	16	baykara	baykara	PROPN
dpc-4595	194	17	ulusan	ulusan	PROPN
dpc-4595	194	18	m	m	PROPN
dpc-4595	194	19	gm	gm	PROPN
dpc-4595	194	20	.	.	PUNCT
dpc-4595	195	1	carotid	carotid	VERB
dpc-4595	195	2	intima	intima	ADJ
dpc-4595	195	3	-	-	PUNCT
dpc-4595	195	4	media	medium	NOUN
dpc-4595	195	5	thickness	thickness	NOUN
dpc-4595	195	6	and	and	CCONJ
dpc-4595	195	7	serum	serum	VERB
dpc-4595	195	8	proinflammatory	proinflammatory	ADJ
dpc-4595	195	9	cytokine	cytokine	NOUN
dpc-4595	195	10	levels	level	NOUN
dpc-4595	195	11	in	in	ADP
dpc-4595	195	12	rosacea	rosacea	NOUN
dpc-4595	195	13	patients	patient	NOUN
dpc-4595	195	14	without	without	ADP
dpc-4595	195	15	cardiovascular	cardiovascular	ADJ
dpc-4595	195	16	risk	risk	NOUN
dpc-4595	195	17	factors	factor	NOUN
dpc-4595	195	18	.	.	PUNCT
dpc-4595	196	1	dermatol	dermatol	NOUN
dpc-4595	196	2	ther	ther	ADV
dpc-4595	196	3	.	.	PUNCT
dpc-4595	197	1	2021;34	2021;34	NUM
dpc-4595	197	2	:	:	PUNCT
dpc-4595	197	3	e14733	e14733	ADJ
dpc-4595	197	4	.	.	PUNCT
dpc-4595	198	1	doi	doi	NOUN
dpc-4595	198	2	:	:	PUNCT
dpc-4595	198	3	10.1111	10.1111	NUM
dpc-4595	198	4	/	/	SYM
dpc-4595	198	5	dth.14733	dth.14733	NOUN
dpc-4595	198	6	.	.	PROPN
dpc-4595	199	1	10	10	NUM
dpc-4595	199	2	.	.	PUNCT
dpc-4595	200	1	topcu	topcu	ADJ
dpc-4595	200	2	-	-	PUNCT
dpc-4595	200	3	yilmaz	yilmaz	PROPN
dpc-4595	200	4	p	p	X
dpc-4595	200	5	,	,	PUNCT
dpc-4595	200	6	atakan	atakan	ADJ
dpc-4595	200	7	n	n	CCONJ
dpc-4595	200	8	,	,	PUNCT
dpc-4595	200	9	bozkurt	bozkurt	PROPN
dpc-4595	200	10	b	b	PROPN
dpc-4595	200	11	,	,	PUNCT
dpc-4595	200	12	irkec	irkec	NOUN
dpc-4595	200	13	m	m	PRON
dpc-4595	200	14	,	,	PUNCT
dpc-4595	200	15	aban	aban	PROPN
dpc-4595	200	16	d	d	PROPN
dpc-4595	200	17	,	,	PUNCT
dpc-4595	200	18	mesci	mesci	PROPN
dpc-4595	200	19	l	l	NOUN
dpc-4595	200	20	,	,	PUNCT
dpc-4595	200	21	tezcan	tezcan	PROPN
dpc-4595	200	22	i.	i.	NOUN
dpc-4595	200	23	determination	determination	NOUN
dpc-4595	200	24	of	of	ADP
dpc-4595	200	25	tear	tear	NOUN
dpc-4595	200	26	and	and	CCONJ
dpc-4595	200	27	serum	serum	VERB
dpc-4595	200	28	inflammatory	inflammatory	ADJ
dpc-4595	200	29	cytokines	cytokine	NOUN
dpc-4595	200	30	in	in	ADP
dpc-4595	200	31	patients	patient	NOUN
dpc-4595	200	32	with	with	ADP
dpc-4595	200	33	rosacea	rosacea	NOUN
dpc-4595	200	34	using	use	VERB
dpc-4595	200	35	multiplex	multiplex	PROPN
dpc-4595	200	36	bead	bead	PROPN
dpc-4595	200	37	technology	technology	NOUN
dpc-4595	200	38	.	.	PUNCT
dpc-4595	201	1	ocul	ocul	PROPN
dpc-4595	201	2	immunol	immunol	PROPN
dpc-4595	201	3	inflamm	inflamm	PROPN
dpc-4595	201	4	.	.	PUNCT
dpc-4595	202	1	2013	2013	NUM
dpc-4595	202	2	oct;21(5):351	oct;21(5):351	NOUN
dpc-4595	202	3	-	-	SYM
dpc-4595	202	4	9	9	NUM
dpc-4595	202	5	.	.	PUNCT
dpc-4595	203	1	doi:10.3109/09273948.2013.795229	doi:10.3109/09273948.2013.795229	NOUN
dpc-4595	203	2	.	.	PROPN
dpc-4595	203	3	11	11	NUM
dpc-4595	203	4	.	.	PUNCT
dpc-4595	204	1	dajnoki	dajnoki	PROPN
dpc-4595	204	2	z	z	PROPN
dpc-4595	204	3	,	,	PUNCT
dpc-4595	204	4	béke	béke	PROPN
dpc-4595	204	5	g	g	PROPN
dpc-4595	204	6	,	,	PUNCT
dpc-4595	204	7	kapitány	kapitány	PROPN
dpc-4595	204	8	a	a	PROPN
dpc-4595	204	9	,	,	PUNCT
dpc-4595	204	10	et	et	PROPN
dpc-4595	204	11	al	al	PROPN
dpc-4595	204	12	.	.	PROPN
dpc-4595	204	13	sebaceous	sebaceous	ADJ
dpc-4595	204	14	gland	gland	NOUN
dpc-4595	204	15	-	-	PUNCT
dpc-4595	204	16	rich	rich	ADJ
dpc-4595	204	17	skin	skin	NOUN
dpc-4595	204	18	is	be	AUX
dpc-4595	204	19	characterized	characterize	VERB
dpc-4595	204	20	by	by	ADP
dpc-4595	204	21	tslp	tslp	ADJ
dpc-4595	204	22	expression	expression	NOUN
dpc-4595	204	23	and	and	CCONJ
dpc-4595	204	24	distinct	distinct	ADJ
dpc-4595	204	25	immune	immune	ADJ
dpc-4595	204	26	surveillance	surveillance	NOUN
dpc-4595	204	27	which	which	PRON
dpc-4595	204	28	is	be	AUX
dpc-4595	204	29	disturbed	disturb	VERB
dpc-4595	204	30	in	in	ADP
dpc-4595	204	31	rosacea	rosacea	NOUN
dpc-4595	204	32	.	.	PUNCT
dpc-4595	205	1	j	j	PROPN
dpc-4595	205	2	invest	invest	VERB
dpc-4595	205	3	dermatol	dermatol	NOUN
dpc-4595	205	4	.	.	PUNCT
dpc-4595	206	1	2017	2017	NUM
dpc-4595	206	2	may;137(5):1114	may;137(5):1114	NOUN
dpc-4595	206	3	-	-	PUNCT
dpc-4595	206	4	1125	1125	NUM
dpc-4595	206	5	.	.	PUNCT
dpc-4595	207	1	doi	doi	NOUN
dpc-4595	207	2	:	:	PUNCT
dpc-4595	207	3	10.1016	10.1016	NUM
dpc-4595	207	4	/	/	SYM
dpc-4595	207	5	j.jid.2016.12.025	j.jid.2016.12.025	ADJ
dpc-4595	207	6	.	.	PUNCT
dpc-4595	208	1	12	12	NUM
dpc-4595	208	2	.	.	PUNCT
dpc-4595	209	1	buhl	buhl	PROPN
dpc-4595	209	2	t	t	PROPN
dpc-4595	209	3	,	,	PUNCT
dpc-4595	209	4	sulk	sulk	PROPN
dpc-4595	209	5	m	m	PROPN
dpc-4595	209	6	,	,	PUNCT
dpc-4595	209	7	nowak	nowak	PROPN
dpc-4595	209	8	p	p	PROPN
dpc-4595	209	9	,	,	PUNCT
dpc-4595	209	10	et	et	PROPN
dpc-4595	209	11	al	al	PROPN
dpc-4595	209	12	.	.	PROPN
dpc-4595	210	1	molecular	molecular	ADJ
dpc-4595	210	2	and	and	CCONJ
dpc-4595	210	3	morphological	morphological	ADJ
dpc-4595	210	4	characterization	characterization	NOUN
dpc-4595	210	5	of	of	ADP
dpc-4595	210	6	inflammatory	inflammatory	ADJ
dpc-4595	210	7	infiltrate	infiltrate	NOUN
dpc-4595	210	8	in	in	ADP
dpc-4595	210	9	rosacea	rosacea	NOUN
dpc-4595	210	10	reveals	reveal	VERB
dpc-4595	210	11	activation	activation	NOUN
dpc-4595	210	12	of	of	ADP
dpc-4595	210	13	th1	th1	PROPN
dpc-4595	210	14	/	/	SYM
dpc-4595	210	15	th17	th17	PROPN
dpc-4595	210	16	pathways	pathway	NOUN
dpc-4595	210	17	.	.	PUNCT
dpc-4595	211	1	j	j	PROPN
dpc-4595	211	2	invest	invest	VERB
dpc-4595	211	3	dermatol	dermatol	NOUN
dpc-4595	211	4	.	.	PUNCT
dpc-4595	212	1	2015;135(9):2198	2015;135(9):2198	NUM
dpc-4595	212	2	-	-	SYM
dpc-4595	212	3	208	208	NUM
dpc-4595	212	4	.	.	PUNCT
dpc-4595	213	1	doi	doi	NOUN
dpc-4595	213	2	:	:	PUNCT
dpc-4595	213	3	10.1038	10.1038	NUM
dpc-4595	213	4	/	/	SYM
dpc-4595	213	5	jid.2015.141	jid.2015.141	PROPN
dpc-4595	213	6	.	.	PUNCT